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Ulcerative colitis (UC) is an inflammatory bowel disease that has high rates of 
persistent or relapsing symptoms despite available therapies. Many of these therapies 
also have the potential for unacceptable side effects including allergy, intolerance, 
serious infection and malignancy due to long-term immunosuppression. It is for these 
reasons that new therapies for UC are required; particularly therapies that target novel 
pathways and do not suppress the immune system. Faecal microbiota transplantation 
(FMT) has demonstrated efficacy in the treatment of recurrent and refractory 
Clostridium difficile infection (CDI) and has been proposed as a novel therapy for UC. 
Aims 
The aims of this thesis were to: 
1. establish a stool bank of screened donor stool containing viable organisms 
2. assess the efficacy and safety of FMT for the induction of remission of UC 
3. explore the mechanisms by which FMT may alter the disease process of UC. 
Methods 
Methods of stool donor recruitment and screening as well as anaerobic stool processing 
were developed and optimised. The viability of culturable organisms was validated after 
6 months of frozen storage. A double-blind randomised controlled trial of a short 
duration of FMT using anaerobically prepared stool for the induction of remission of 
mild to moderate UC was undertaken with clinical and endoscopic remission assessed at 
8 weeks and 12 months. Exploratory immunological, microbiological and metabolomic 
analyses were undertaken. A systematic review and meta-analysis was undertaken to 
assess the broader evidence for FMT as therapy for the induction of remission of UC. 
Results 
A stool bank of anaerobically prepared donor stool was established; 14 (31%) of 44 
respondents to donor recruitment questionnaires were eligible. Bacterial viability was 
similar to baseline at both 2 and 6 months in specimens stored with saline and 10% 
xii 
glycerol and at 2 months in stool stored only in saline, but was reduced by >1 log at 6 
months for aerobes, coliforms and lactobacilli in saline alone. In patients undergoing 
FMT with stool frozen for 2–10 months in 10% glycerol, the cure rate for rCDI was 
88% after a single FMT.  
In mild to moderate active UC, clinical and endoscopic remission was achieved in 12 of 
the 38 participants (32%) who received pooled donor FMT, compared with 3 of the 35 
(9%) who received autologous FMT (odds ratio [OR] 5.0 [95% CI 1.2–20.1]; P = 0.03). 
A number of bacterial species were associated with the observed donor FMT treatment 
effect. Neither lamina propria mononuclear cell populations nor short-chain fatty acid 
levels were associated with the donor FMT treatment effect.  
Meta-analysis of randomised controlled trials of FMT for UC demonstrated that clinical 
remission was achieved in 39 of 140 (28%) patients in the donor FMT groups, 
compared with 13 of 137 (9%) patients in the placebo groups (OR 3.67 [95% CI 1.82–
7.39]; P < 0.01]. 
Conclusions 
Establishing a bank of anaerobically prepared frozen donor stool facilitates the delivery 
of FMT for clinical and clinical trial purposes. Anaerobic stool processing with normal 
saline and glycerol results in viability of bacteria in frozen storage for 6 months. Donor 
FMT is an effective therapy for the induction of remission of UC. Further research is 
required to assess the efficacy and safety of FMT as maintenance therapy for UC and to 




I certify that this work contains no material which has been accepted for the award of 
any other degree or diploma in my name, in any university or other tertiary institution 
and, to the best of my knowledge and belief, contains no material previously published 
or written by another person, except where due reference has been made in the text. In 
addition, I certify that no part of this work will, in the future, be used in a submission in 
my name, for any other degree or diploma in any university or other tertiary institution 
without the prior approval of the University of Adelaide and, where applicable, any 
partner institution responsible for the joint-award of this degree. 
I acknowledge that copyright of published works contained within this thesis resides 
with the copyright holder(s) of those works. 
I also give permission for the digital version of my thesis to be made available on the 
web, via the University’s digital research repository, the Library Search and also 
through web search engines, unless permission has been granted by the University to 
restrict access for a period of time. 
I acknowledge the support I have received for my research through the provision of an 
Australian Government Research Training Program Scholarship.  




First, I would like to thank my supervisors Professor Jane Andrews, Dr Patrick Hughes, 
Professor Ian Roberts-Thomson and Dr Michael Conlon. At the beginning of this thesis 
I had a meagre research track record, no funding and no experience in conducting a 
clinical trial or a faecal microbiota transplantation, and I will be forever grateful to each 
of you for taking a risk on this project when many supervisors would not have. Without 
your collective experience, support and courage, the project would not have been 
possible. 
Jane, thank you for your support and mentorship throughout my candidature as well as 
during my gastroenterology training. You have taught me so much. I admire your 
dedication and relentless commitment to improving the care that patients with IBD 
receive. I look forward to working and collaborating closely with you in the future. 
Ian, thank you for your guidance and encouragement over the past eight years. I have 
learnt a great deal about gastroenterology, research and service to the community in 
observing your work and in our many conversations. I admire your broad knowledge 
and willingness to explore the boundaries. 
Pat, thank you for taking a big risk on this project. When your livelihood depends on 
research outputs and grants, it was brave of you to take this on. Thank you also for the 
many hours at the flow cytometer; you went above and beyond your supervisor role in 
that capacity. 
Michael, thank you for your support and for allowing me access to the wonderful people 
and facilities at the CSIRO animal, food and health sciences. I had a fantastic time in the 
lab and loved being able to learn new skills and techniques with the support of you and 
your team. 
I would like to thank the patients who selflessly volunteered to receive experimental 
therapy and the stool donors whose 7.3kg contribution made the study possible! I would 
also like to thank Rosa Katsikeos whose organisational skills kept the trial on track and 
the many hospital staff who assisted with this trial in so many ways, in particular, Julie 
McMahon, Kerry Kristaly and Josie Burfield.  I would also like to acknowledge past 
xv 
and present researchers in the fields of inflammatory bowel disease and faecal 
microbiota transplantation The work in this manuscript has been inspired by, and 
benefited from, the work of so many. 
During the course of my candidature, Emily and I welcomed Evie, Matilda and Freya 
into our family. They have enriched our lives immeasurably; however, it would not 
have been possible to complete this thesis without the support of friends and family. To 
the “village” that helped manage our lives—thank you. I would especially like to thank 
Mum, Dad, Mary, Bob and Auntie Leanne for supporting Em and me during this time. 
Rob, thank you for your friendship and advice during this time. To walk the PhD path 
with someone with your verve and passion for life made it fun. Long may we share 
vegetarian vermicelli noodles. 
Dad, thank you for demonstrating to me a love of learning, that new ideas are to be 
explored and risks on that journey are worth taking. Your boundless optimism and 
energy is inspiring. 
Mum, I could not quite finish this in time.  You gave me the tools to approach science 
by finding, and encouraging me to see, the clear light of logic through (and fun to be 
had in tackling) many a difficult problem. Thank you for this and everything that you 
did for me. I miss you terribly. 
Emily, I cannot possibly thank you enough for the unwavering support that you 
provided to me and our family during my PhD candidature. Your encouragement, razor 
sharp advice and editing have kept me on track. At times I was totally consumed by this 
work and you bore a heavy load. Your capacity to manage the chaos of our lives during 
this time has been incredible. 
The thesis was edited by Elite Editing and editing intervention was restricted to 
Standards D and E of the Australian Standards for Editing Practice. 
 
1 
Chapter 1: Overview 
Ulcerative colitis (UC) is an incurable, relapsing–remitting inflammatory bowel disease 
(IBD) characterised by colonic mucosal inflammation that has significant morbidity. 
UC affects approximately 40,000 Australians at a cost to Australia of 1.38 billion 
dollars per year.1,2 Approximately 25% of those affected with UC have onset by 18 
years of age and have life-long disease. Despite available therapies, UC has an 
unacceptably high rate of persistent or relapsing disease activity3 characterised by 
bloody diarrhoea, anaemia, weight loss and abdominal pain. UC is associated with a 
risk of colectomy4 and an increased risk of colorectal cancer relative to the general 
population.5 Current treatments also have the potential for unacceptable side effects 
including allergy, intolerance, serious infection and malignancy due to long-term 
immunosuppression.6 It is for these reasons that new therapies for UC are required, 
particularly therapies that target novel pathways and are not immune suppressing. 
Faecal microbiota transplantation (FMT) involves the transfer of faecal material from a 
healthy individual to a person with disease with the aim of treating that disease. At 
present, FMT is predominantly used to treat Clostridium difficile infection (CDI) where 
its use is supported by society guidelines7,8 and evidence of efficacy from multiple 
randomised controlled trials (RCTs).9-12 There is strong evidence for the involvement of 
gut microbiota in UC pathogenesis13-15 and evidence that manipulating the microbiome 
improves symptoms.16 FMT is proposed to treat UC by modifying the colonic 
ecosystem; however, the potential biochemical and immune mechanisms by which this 
may occur are unknown. Human stool comprises multiple components including food; 
organisms such as bacteria, protozoa, archaea, fungi and viruses including phages, as 
well as metabolic products of these organisms; and abundant human cells and products 
secreted into the gut lumen, such as bile acids.17 Each of these components may play a 
role in a therapeutic effect of FMT. 
At the beginning of this thesis in 2013, there were anecdotal case reports indicating that 
UC may be successfully treated by FMT18-21; however, there were no RCTs evaluating 
this therapy.22 Despite this paucity of data, UC online forums documented that many 
patients with UC were resorting to non-medical (independent) FMT.23 It was also 
known that FMT was offered to people with UC by doctors in Australia.18 Moreover, a 
2 
survey from a respected IBD centre found that those with UC will consider FMT and 
were eager for it to become available.24 Thus, FMT was occurring in an unregulated 
fashion, despite the lack of high-level efficacy data. Thus, a clinical trial was planned to 
test the efficacy and safety of FMT for UC. 
A stool bank of screened donor stool was required to conduct the proposed study of 
FMT in UC. On review of the blood donation literature and in consultation with 
infectious disease specialists, donor screening protocols were devised. Methods of 
donor recruitment as well as anaerobic stool processing were developed to establish a 
stool bank. This study is presented in Chapter 3 (Costello et al., “Establishing a fecal 
microbiota transplant service for the treatment of Clostridium difficile infection”, 
manuscript published in Clinical Infectious Diseases, 2016 [impact factor (IF) 2017 
9.117]). 
The viability of bacteria frozen for the purposes of FMT was not known. A study was 
therefore undertaken to evaluate the viability of culturable organisms from stool 
processed under anaerobic conditions and frozen for up to 6 months, using different 
preparatory methods. The viability of frozen bacteria within the stool bank was 
important to ascertain prior to interpreting the subsequent analysis of microbiome 
samples from donors and recipients in the RCT of FMT for UC in Chapter 5. To gauge 
the clinical efficacy of stool frozen with 10% glycerol, we assessed efficacy of stool 
frozen for more than 6 months in treating patients with CDI, an indication for which the 
efficacy of FMT using fresh or short-term frozen stool was known. This study is 
presented in Chapter 4 (Costello et al., “Faecal microbiota transplant for recurrent 
Clostridium difficile infection using longer-term frozen stool is effective: Clinical 
efficacy and bacterial viability data”, manuscript published in Alimentary 
Pharmacology & Therapeutics, 2015 [IF 2016 7.286]). 
During the first year of the trial, high-level evidence emerged for the use of FMT for the 
treatment of CDI. In this context, the stool bank was used to treat patients with CDI in 
South Australia. A notable case was the first reported treatment of toxic megacolon 
using FMT in the literature. This case demonstrated the utility of having rapid access to 
screened stool for emergency treatment and is presented in Appendix 1 (Costello et al., 
“Fecal microbiota transplant for Clostridium difficile colitis-induced toxic megacolon”, 
3 
manuscript published in American Journal of Gastroenterology, 2015 [IF 2015 
10.383]). 
A multi-centre RCT of FMT for the treatment of mild to moderately active ulcerative 
colitis (FIRST-UC) was undertaken. The aims of the study were to demonstrate efficacy 
and safety of FMT therapy as well as explore the mechanism of action with 
microbiome, metabolomic and mucosal immune analysis. This study is presented in 
Chapter 5 (Costello et al., “Effect of fecal microbiota transplantation on 8-week 
remission in patients with ulcerative colitis: A randomized clinical trial”, manuscript 
published in Journal of American Medical Association, 2019 [IF 2017 47.661]). 
During the course of the thesis, evidence for FMT for the induction of remission of UC 
emerged from other studies; therefore, a systematic review with meta-analysis was 
undertaken to give context to the FIRST-UC study. This study is presented in Chapter 6 
(Costello et al., “Systematic review with meta-analysis: Faecal microbiota 
transplantation for the induction of remission for active ulcerative colitis”, manuscript 
published in Alimentary Pharmacology & Therapeutics, 2017 [IF 2017 7.357]). 
Finally, a discussion is presented summarising and integrating the findings of the thesis 
(Chapter 7). The place of FMT in the management of UC is discussed. Possible 
mechanisms of action of FMT for UC are explored and the relevance of these findings 
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Chapter 2: Introduction 
2.1 Definitions 
Ulcerative colitis is a relapsing and remitting IBD characterised by superficial colonic 
mucosal inflammation that extends proximally from the rectum in a contiguous manner. 
FMT is the transfer of faecal material from a healthy individual to a person with disease 
with the aim of treating that disease. 
2.2 Gut Microbiome: The “Normal” Gut Microbiome 
The gut microbiota consists of all the organisms that live within the human gut and the 
gut microbiome consists of the genes of these microorganisms. The gastrointestinal 
microbiota alone contains approximately 3.9 × 1013 organisms, meaning that there are 
similar numbers of microorganisms in the gut as there are human cells in the human 
body.1 The first gut microbes are acquired in utero2, and thereafter environmental 
exposures shape the development of the gut ecosystem. An infant’s microbiome is 
dependent on mode of birth, breast feeding and weaning, maternal diet, antibiotic 
exposure and interaction with its environment.3,4 There is a large amount of flux in the 
composition of an infant’s microbiome; however, after about 3 years of age, it is 
relatively stable.5 In adult life, the microbiome broadly remains stable, but can be 
altered by persistent changes in diet, lifestyle or environment, the development of 
disease or treatments such as medications or surgery.6 
Bacteria are commonly classified phylogenetically into taxonomic groupings of 
phylum, family, genus, species and strain, where phyla are broad groupings of 
genetically similar bacteria and strains contain genetically and phenotypically identical 
or almost identical organisms.7 The human gut microbiota is dominated by two main 
phyla of bacteria, Firmicutes and Bacteriodetes, which together account for 90% of gut 
bacteria. Viruses (including phages), fungi, protozoa and archaea are also important 
elements of the human gut microbiome.8 Many of these microorganisms have co-
evolved with humans and perform essential functions for their host.8 An important 
example of this is the short-chain fatty acid (SCFA) butyrate, which is derived from 
bacterial metabolism of fibre in the colon and is the primary energy source of 
colonocytes.9 Some gut microbiota live in close association with the epithelium and 
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have a role in regulating local and distant immune function.10 Others regulate gut barrier 
functions and provide protection against pathogenic organisms such as vancomycin-
resistant enterococci by competitive inhibition.11 
There is large variation in the composition of the gut microbiome between individuals 
as measured by phylogenetic beta diversity. There are axial (mucosal to luminal) 
gradients and longitudinal (proximal to distal) gradients in composition within the gut 
of an individual.12 Many of the organisms that reside in the human gut live in a 
symbiotic relationship with their human host and perform important functions for 
health. Although the composition of the organisms in the gut may vary widely between 
individuals, there is remarkable similarity in the functional pathways in the microbiome 
between individuals.13 Many of the critical metabolic pathways have redundancy within 
the microbiota such that a number of organisms can perform the same metabolic 
function.14 The metabolic capacity of the gut microbiome is much greater than that of 
the human host and some metabolic activities such as bile acid metabolism are shared 
between human and microbial cells.15 
2.3 Analysis of the Microbiome and Its Products 
There are a number of techniques that have been deployed to assess the gut microbiome. 
The original method of determining the composition of the microbiome was bacterial 
culture. Many species and strains of bacteria have been identified by this method; 
however, with the advent of molecular methods of profiling bacterial populations, it was 
realised that the majority of bacteria had not been cultured. This was predominantly 
because the majority of the gut microbiota are obligatory anaerobes with very specific 
growth conditions such that they were not able to be grown in vitro. In recent years, 
new bacterial culture techniques have been developed and many previously 
“unculturable” bacteria have now been cultured.16 
Mapping the composition of the microbiome with 16S ribosomal RNA (16S rRNA) 
sequencing is the most common technique used to identify bacterial groups within stool. 
This technique uses a conserved portion of bacterial RNA to determine the relative 
genetic similarity of organisms within a population. This process is dependent on 
having a reference library of the genome of organisms with which to compare. 
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Sequencing with 16S rRNA has the ability to identify phyla or species of bacteria, but 
the resolution is not typically precise enough to identify organisms at the strain level. 
Metagenomic sequencing facilitates sequencing of the entire genomes of the organisms 
within a sample, and organisms can be identified using computational tools. Therefore, 
with metagenomic sequencing, identification of individual strains of bacteria is possible 
and an assessment of the functional potential of the microbiome can be made. However, 
to determine the expressed function of the microbiome, other techniques are required. 
Metatranscriptomics assays the proportion of a microbial metagenome that is being 
expressed at a specific point in time through RNA transcripts.17 Proteomic and 
metabolomic analysis typically use mass spectroscopy or gas chromatography to 
measure the relative abundance of proteins and metabolites, such as SCFAs, produced 
by a microbiome.18 These analyses give the greatest insight into the function of a 
microbiome in a particular environment. 
2.4 Ulcerative Colitis 
2.4.1 Clinical presentation 
UC typically presents with bloody diarrhoea with associated urgency, tenesmus, mucus 
discharge, fatigue and lower abdominal pain.19 Symptoms may vary depending on 
disease severity and disease extent. Fever and weight loss can accompany severe 
disease. Patients with proctitis (disease limited to the rectum) may present with urgency 
and tenesmus, while patients with pancolitis may be more likely to present with bloody 
diarrhoea and abdominal pain. UC is accompanied by extra-intestinal manifestations in 
approximately a third of patients. These include arthritis, venous thromboembolism, 
metabolic bone disease, uveitis, scleritis and skin disease (e.g., pyoderma gangrenosum 
and erythema nodosum).20,21 Primary sclerosing cholangitis is a cholestatic 
hepatobiliary disorder that occurs in approximately 5% of patients with UC and carries 
significant risk of colon cancer as well as cholangiocarcinoma and liver 
transplantation.22 
Approximately 25% of those affected with UC have onset by 18 years and life-long 
persistence, with 15% of patients requiring colectomy.23 UC is associated with a 
significantly increased risk of colorectal cancer.24 
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2.4.2 Diagnosis 
The diagnosis of UC is based on a composite assessment, incorporating clinical, 
endoscopic, histological and radiological factors.25,26 A diagnosis is established using 
colonoscopy, with consistent features including continuous and confluent rectal and 
colonic mucosal friability, spontaneous bleeding and ulceration.25 Mucosal biopsy 
features of UC include changes of chronicity, basal plasmacytosis, cryptitis and crypt 
abscess formation. At colonoscopy, the differential diagnosis includes Crohn’s disease 
or infection. 
2.4.3 Natural history of ulcerative colitis 
The natural history of UC is one of relapsing and remitting disease, although some 
patients experience an unremitting disease course from the outset.27 Proximal extension 
occurs in around 30% of patients with UC, and around 10% will undergo colectomy 
within 10 years of diagnosis.28-30 
2.4.4 Epidemiology 
The peak age of incidence of UC is between 20 and 30 years of age31 and there is no sex 
predominance.31-33 The incidence and prevalence of UC have been increasing over time 
in Australia and elsewhere around the world, particularly in the last 3 decades.34,35 The 
incidence in Australia has been reported at 7.33 per 100,00036, and prevalence rates are 
as high as 505 per 100,000 people in northern Europe.37 There has also been a rapid 
increase in the incidence of IBD in developing countries, where changing 
environmental conditions, urbanisation and the adoption of a Western lifestyle have 
been implicated.36,38 Accordingly, epidemiologic studies have demonstrated that the risk 
of developing UC in migrants from low-incidence areas is dependent on the age at 
which migration to the high-incidence area occurs; a younger age of immigration is 
associated with a higher risk of developing UC after arrival.39 The children of migrants 
from low-incidence to high-incidence countries assume a similar risk of UC to non-
immigrants.40 These observations support the notion that environmental factors are 
prime drivers of disease pathogenesis. 
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2.4.5 Pathogenesis of ulcerative colitis 
The aetiology of UC is complex and many elements are thought to play a role in the 
pathogenesis.41,42 Two intimately related factors thought to contribute include an 
abnormal composition and function of the microbiome and immune dysregulation.43 
Important components of the interaction between the immune system and the intestinal 
microbiota involve epithelial barrier function, microbial handling, and regulation of 
adaptive and innate immunity.41 Host genetics play a role; however, environmental 
factors appear to be a larger determinant of disease risk.41,42 Environmental exposures in 
the first few years of life play an important role in disease susceptibility; these include 
infant formula feeding and antibiotic exposure in utero.44,45 Other environmental 
exposures that influence both susceptibility and the natural history of UC later in life 
include dietary intake, enteric infections, medications and lifestyle factors such as stress 
and smoking.46 
2.4.6 Evidence of microbial involvement in the pathogenesis of ulcerative colitis 
UC is a mucosal disease occurring at the colonic interface between the luminal contents, 
including the microbiota, and the mucosal immune system. Apart from anatomical 
proximity, there are many lines of evidence that the faecal microbiome is pivotal to 
inflammatory activity in UC: Diversion of the faecal stream away from the colon, by 
creating a temporary ileostomy, can improve colonic inflammation47; antibiotics have 
been shown to improve UC48, and many of the genetic risk alleles associated with UC 
are related to microbes and mucosal defence.49 Additionally, UC-like inflammation 
cannot be induced in germ-free animals.50 
However, bacteria are critical for colonic health as their metabolic products, such as the 
SCFA butyrate, are a source of enterocyte nutrition and have anti-inflammatory 
effects.51 Thus, patients with ileostomy and subsequent diversion of luminal contents 
develop “diversion colitis”47 that is ameliorated by the delivery of butyrate. Rather than 
the traditional pathogen model that has successfully described infectious disease since 
Pasteur and Lister52, UC may represent a loss of function within the gut ecosystem. The 
relative paucity of some important colonic bacteria has been associated with UC, 
including Faecalibacterium prausnitzii (a butyrate producer with independent anti-
inflammatory properties); sulphate-reducing bacteria; and mucosa-associated 
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Akkermansia muciniphila, Ruminococcus torques and Ruminococcus gnavus (potential 
roles in mucus barrier integrity).53,54 It has been demonstrated that the microbiome in 
UC, both active and remission, is less diverse than that of healthy subjects.53,55 This loss 
of diversity is predominantly attributable to a decrease in gram-positive Firmicutes, 
especially Clostridium clusters IV and XIV; meanwhile, some species in the 
Proteobacteriae group, particularly E. Coli and Enterobacteriaceae, are relatively 
overabundant.54,56 Increased gram-negative bacteria such as E. coli can be associated 
with increased lipopolysaccharide (LPS), a component of their cell wall, which triggers 
inflammation via the innate immune pathway.55 It is unclear whether these alterations 
initiate or result from the inflammatory process. 
There has also been increasing recognition of altered function of the microbiome in 
patients with UC through the study of metabolomics.57 There is evidence that there is a 
failure of butyrate oxidation in the colonocytes of patients with UC.9,58,59 Butyrate 
oxidation in human colonocytes has been demonstrated to be inhibited by high levels of 
nitric oxide that result from high levels of nitrite and sulphides.60 This leads to an 
energy deficiency state within the colonocyte with an associated loss of critical 
functions such as maintenance of the mucosal barrier by mucus and tight-junction 
production. Barrier loss leads to immune activation and the resultant inflammation and 
hyperaemia can further promote invasive oxygen-tolerant bacteria.61 
Taken together, these observations lead to the hypothesis that “dysbiosis”, or 
perturbation of the faecal microbiota, plays a causal role in UC, and thus modifying the 
microbiome may promote mucosal healing. Little detail is currently understood of the 
presumed bidirectional relationship between the metabolic and immunologic functions 
of the microbiome and its possible role in UC. 
2.4.7 Mucosal immune and barrier functions in ulcerative colitis 
The gastrointestinal tract contains a potent immune system that is separated from the 
luminal microorganisms by barriers of the mucous layer and the epithelium.62 The 
innate immune system provides a further non-specific defence against invading 
organisms and is aided by the adaptive immune cells that provide specific responses to 
antigens. Current evidence from human studies indicates that the mucosal inflammatory 
infiltrate in UC consists of a complex mixture of innate and adaptive immune cells and 
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their products.63 However, little is clearly understood regarding the mechanism of this 
immune response. The hypothesis with the most traction is that UC is characterised by a 
natural killer (NK) T cell-driven, IL-13 and IL-5 dependent, TH2 mediated immune 
response initiated by a loss of immune tolerance to colonic microbiota.63 This is 
proposed to initiate a cascade of cytokine and chemokine secretion, causing an influx of 
granulocytes including eosinophils and neutrophils as well as plasma B cells. However, 
much of these data are derived from animal models and a limited number of human 
studies. Several studies indicate alterations in the immune cell types involved in 
immune tolerance, such as regulatory T cells, where numbers are consistently decreased 
in blood but increased in inflamed colonic mucosa in people with UC.64 The phenotype 
and function of dendritic cells, dedicated antigen-presenting cells that link innate and 
adaptive immunity, are also altered in patients with UC in flare, compared with healthy 
controls, with gut-resident dendritic cells having increased expression of the microbial 
sensors TLR4 and TLR2 in UC.65 The resultant immune cell infiltrate is complex and 
relatively undefined in diseased regions of UC patients, and likely differs according to 
current disease with symptom severity and therefore within and between patients.63 
Longitudinal investigations of immune function in humans with UC in flare or 
remission have not been previously reported. 
2.4.8 Conventional management of ulcerative colitis 
The management of UC involves both induction therapy (to induce remission) and 
maintenance therapy (to prevent further flares).66 The goal of treatment is maintenance 
of remission without steroids.66 Ideally remission should be both clinical (absent 
symptoms, patient feels well and normal quality of life) and endoscopic (absent 
inflammation, thus no ongoing damage or increased risk for colectomy or colorectal 
cancer). Targets for remission include resolution of clinical symptoms, defined as 
cessation of rectal bleeding and diarrhoea, and endoscopic healing, which is commonly 
defined as an endoscopic Mayo score of 0 or 1.67 Mucosal healing at colonoscopy has 
been shown to greatly improve long-term clinical remission, decrease risk of colectomy 
and limit corticosteroid use.68 
Induction therapy is usually high-dose oral 5-aminosalicylic acid compounds (5-ASAs) 
with or without topical 5-ASAs via enema or suppository. More severe flares require 
systemic corticosteroids (tapered over time and discontinued). Prolonged steroids are 
13 
ineffective at preventing flares and are associated with a myriad of complications not 
limited to infection, such as osteoporosis, obesity, diabetes, poor healing, thinning skin, 
mood changes and insomnia. As thiopurines take 8–12 weeks to be effective, they have 
no role as induction agents. Severe flares of UC unresponsive to steroids require 
medical rescue therapy (cyclosporin or infliximab) or urgent colectomy.69 
Maintenance therapy choice in UC is determined by disease extent, severity, frequency 
of flares and past treatment history. The mainstays of maintenance therapy are 5-ASAs 
used orally or topically, and thiopurines for patients with repeated flares despite 5-
ASAs.66 In recent years, new biological agents have demonstrated efficacy and have 
been funded by the Australian Pharmaceutical Benefits Scheme for the maintenance of 
remission in UC. These are the anti-tumour necrosis factor α (anti-TNFα) agents 
infliximab70, adalimumab71 and golimumab72and the anti-integrin agent vedolizumab.73 
However, these newer agents are expensive and have incomplete efficacy, with 
induction of remission gains over placebo ranging from 7% for adalimumab to 20% for 
infliximab in registration studies.70-73 
2.4.9 Current unmet need 
Current treatments are hampered by incomplete efficacy and have the potential for 
unacceptable side effects including allergy, intolerance, serious infection and 
malignancy due to long-term immunosuppression.74 The current treatments for UC are 
inadequate to maintain long-term remission in a significant proportion of patients.66 
Many patients have chronic or relapsing inflammation of the colon, leading to work and 
personal impairment at a cost to the Australian community estimated to be 1.3 billion 
dollars per year75, and up to 10% require colectomy during the course of their disease 
despite current therapies.76,77 A meta-analysis of oral 5-ASA trials found an 
unacceptably high relapse rate of 61.5% by 2 years in patients initially in remission with 
these agents.78 Thiopurines and anti-TNF agents induce systemic immunosuppression, 
reducing the incidence and severity of flares, but at the cost of increased risk of serious 
infections and malignancy, particularly lymphoma.74 Patients in whom mucosal 
inflammation cannot be controlled fully eventually require total colectomy, which 
entails surgical risks, such as infection and wound breakdown, and has a mortality rate 
of approximately 1% in high volume centres.79 Colectomy is considered “curative”, 
especially if patients have an ileostomy created; however, it frequently leads to 
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significant short- and long-term complications. In addition, when an ileal–anal pouch is 
fashioned (to avoid stoma), up to 50% of patients develop pouchitis by 4 years post 
surgery.80 This documented therapeutic gap requires that new therapies are developed, 
particularly those that mediate a clinical benefit via novel pathways ideally without the 
risks of immunosuppression. 
2.4.10 Gut microbial manipulation 
Given the strong evidence for colonic microbial dysbiosis in UC pathogenesis, the 
gastrointestinal administration of microorganisms has been proposed as therapy. 
Probiotics are live microorganisms that indend to provide beneficial health effects when 
administered in adequate amounts.81 While some putative probiotics modulate gut 
metabolic function or gut immune cells in vitro82,83, they are many and varied and do 
not act as a uniform class of agents. For example, studies have indicated that some 
probiotics have modest efficacy in UC, with E. coli Nissle 1917 equally effective as 5-
ASA for maintaining remission84 and VSL#3, a cocktail of eight different bacteria, 
better than placebo in inducing remission at 12 weeks.85 VSL#3 has shown both 
therapeutic and prophylactic efficacy for patients with pouchitis.86 However, there are 
also several negative studies (many never reaching full publication) and the outcomes 
for probiotics are generally regarded to be modest and inconsistent.81 This may be due 
to variable actions of different bacterial species tested and limitations of preparations. 
Probiotics provide a very low number and diversity of species in contrast to the vast 
human gut microbiota. Thus, probiotics may be unable to compete effectively against 
the complex interactions of an established and adapted indigenous gut microbial 
community.87 
2.4.11 Faecal microbiota transplantation 
FMT involves the transfer of stool from a healthy individual to a person with disease 
with the aim of treating the disease. FMT can be described as “the ultimate probiotic” as 
it provides an entire ecosystem, with a much greater number and diversity of strains 
than any available probiotic. FMT is a therapy with a long tradition in human and 
veterinary medicine. FMT for animals is referred to as transfaunation and has been used 
to treat ruminal acidosis in cattle for centuries.88 The first reports of FMT or “yellow 
soup” being used to treat diarrhoea and other human gastrointestinal ailments come 
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from 4th century China.89 The Bedouin people have a long tradition of using camel 
faeces as a treatment for dysentery, and this practice was adopted by German soldiers 
stationed in north Africa during World War 2.90 Human FMT was first reported in the 
Western literature in 1958 for the curative treatment of four critically ill patients with 
pseudomembranous colitis.91 
In the past decade, there has been heightened interest in FMT, predominantly driven by 
increasing rates and virulence of CDI. At present, FMT is predominantly used to treat 
recurrent or refractory CDI (rCDI), where there is evidence of efficacy from multiple 
RCTs92 and its use is supported by society guidelines.93,94 FMT successfully treats rCDI 
in >90% of cases, compared with cure rates of 26–30% with the previous standard of 
care, vancomycin.87,95-97 Cost–benefit analyses have demonstrated FMT to be more cost 
effective than traditional antibiotic therapy for rCDI in the Australian setting with 
savings of over $4,000 per patient treated.98 FMT for the treatment of rCDI also has an 
impressive short-term safety record, with very few side effects directly attributable to 
FMT.92 The long-term safety of FMT has not been well studied as the vast majority of 
FMT reported in the literature has been performed in the last 5–10 years. 
The success of FMT in the treatment of rCDI has inspired research into the use of FMT 
for other disorders associated with dysbiosis. There are case reports of the use of FMT 
to treat a wide range of ailments including autism, Crohn’s disease, irritable bowel 
syndrome and constipation.87,99-101 At the commencement of this thesis, there were case 
reports and small case series of patients with active UC receiving FMT in the medical 
literature. A systematic review in 2012 included 18 reported cases: symptoms resolved 
in 12 subjects, reduced in four and worsened in two; endoscopically, UC resolved in 12 
patients, deteriorated in two and persisted in two.102 
2.5 Research Question 
2.5.1 Rationale 
Current therapies for ulcerative colitis are limited by incomplete efficacy, with most 
having rates of sustained disease remission of 30% or less. Many of these therapies are 
hampered by intolerance as well as side effects of infection and malignancy. 
16 
2.5.2 Aim 
The aims of this thesis were to assess the efficacy and safety of donor FMT to induce 
remission in active UC and develop methodologies to deliver this therapy. 
2.5.3 Research objectives 
The objectives of this research were to: 
1. develop methods to establish a stool bank for the reliable delivery of FMT 
2. optimise stool-processing methods to maximise bacterial viability during storage 
of stool 
3. evaluate the efficacy and safety of FMT as a therapy for active ulcerative colitis 
4. explore the possible mechanisms by which FMT may have a therapeutic effect 
in UC. 
2.5.4 Research process 
Several studies were conducted to address the overarching aim set out for this thesis. 
The research performed may be broadly divided into two inter-related workstreams 
along with a systematic review and meta-analysis: 
• Project 1. The first workstream set out to develop a stool bank capable of 
delivering reliable and safe FMT. 





1. Sender R, Fuchs S, Milo R. Are we really vastly outnumbered? Revisiting the 
ratio of bacterial to host cells in humans. Cell 2016;164:337-40. 
2. Collado MC, Rautava S, Aakko J, Isolauri E, Salminen S. Human gut 
colonisation may be initiated in utero by distinct microbial communities in the 
placenta and amniotic fluid. Sci Rep 2016;6:23129. 
3. Dominguez-Bello MG, Costello EK, Contreras M, et al. Delivery mode shapes 
the acquisition and structure of the initial microbiota across multiple body 
habitats in newborns. Proc Natl Acad Sci U S A 2010;107:11971-5. 
4. Saavedra JM, Dattilo AM. Early development of intestinal microbiota: 
implications for future health. Gastroenterol Clin North Am 2012;41:717-31. 
5. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed 
across age and geography. Nature 2012;486:222-7. 
6. Lax S, Smith DP, Hampton-Marcell J, et al. Longitudinal analysis of microbial 
interaction between humans and the indoor environment. Science 
2014;345:1048-52. 
7. Dijkshoorn L, Ursing BM, Ursing JB. Strain, clone and species: comments on 
three basic concepts of bacteriology. J Med Microbiol 2000;49:397-401. 
8. Young VB. The role of the microbiome in human health and disease: an 
introduction for clinicians. BMJ 2017;356:j831. 
9. Roediger WE. The colonic epithelium in ulcerative colitis: an energy-deficiency 
disease? Lancet 1980;2:712-5. 
10. Kaparakis-Liaskos M, Ferrero RL. Immune modulation by bacterial outer 
membrane vesicles. Nat Rev Immunol 2015;15:375-87. 
11. Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev 
Cancer 2017;17:271-85. 
12. Backhed F, Fraser CM, Ringel Y, et al. Defining a healthy human gut 
microbiome: current concepts, future directions, and clinical applications. Cell 
Host Microbe 2012;12:611-22. 
13. Human Microbiome Project C. Structure, function and diversity of the healthy 
human microbiome. Nature 2012;486:207-14. 
14. Moya A, Ferrer M. Functional redundancy-induced stability of gut microbiota 
subjected to disturbance. Trends Microbiol 2016;24:402-13. 
18 
15. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human 
intestinal bacteria. J Lipid Res 2006;47:241-59. 
16. Browne HP, Forster SC, Anonye BO, et al. Culturing of 'unculturable' human 
microbiota reveals novel taxa and extensive sporulation. Nature 2016;533:543-6. 
17. Di Bella JM, Bao Y, Gloor GB, Burton JP, Reid G. High throughput sequencing 
methods and analysis for microbiome research. J Microbiol Methods 
2013;95:401-14. 
18. Brinkworth GD, Noakes M, Clifton PM, Bird AR. Comparative effects of very 
low-carbohydrate, high-fat and high-carbohydrate, low-fat weight-loss diets on 
bowel habit and faecal short-chain fatty acids and bacterial populations. Br J 
Nutr 2009;101:1493-502. 
19. Hoie O, Wolters F, Riis L, et al. Ulcerative colitis: patient characteristics may 
predict 10-yr disease recurrence in a European-wide population-based cohort. 
Am J Gastroenterol 2007;102:1692-701. 
20. Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for 
extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. 
Am J Gastroenterol 2011;106:110-9. 
21. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. 
Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel 
Dis 2015;21:1982-92. 
22. Dyson JK, Beuers U, Jones DEJ, Lohse AW, Hudson M. Primary sclerosing 
cholangitis. Lancet 2018;391:2547-59. 
23. Magro F, Rodrigues A, Vieira AI, et al. Review of the disease course among 
adult ulcerative colitis population-based longitudinal cohorts. Inflamm Bowel 
Dis 2012;18:573-83. 
24. Castano-Milla C, Chaparro M, Gisbert JP. Systematic review with meta-
analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment 
Pharmacol Ther 2014;39:645-59. 
25. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based 
consensus on the diagnosis and management of ulcerative colitis part 1: 
definitions and diagnosis. J Crohns Colitis 2012;6:965-90. 
26. Van Assche G, Dignass A, Panes J, et al. The second European evidence-based 
consensus on the diagnosis and management of Crohn's disease: definitions and 
diagnosis. J Crohns Colitis 2010;4:7-27. 
19 
27. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 
2009;361:2066-78. 
28. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of 
ulcerative colitis: results from a population-based inception cohort (IBSEN 
Study). Scand J Gastroenterol 2009;44:431-40. 
29. Langholz E, Munkholm P, Davidsen M, Nielsen OH, Binder V. Changes in 
extent of ulcerative colitis: a study on the course and prognostic factors. Scand J 
Gastroenterol 1996;31:260-6. 
30. Torres J, Billioud V, Sachar DB, Peyrin-Biroulet L, Colombel JF. Ulcerative 
colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis 
2012;18:1356-63. 
31. Chouraki V, Savoye G, Dauchet L, et al. The changing pattern of Crohn's 
disease incidence in northern France: a continuing increase in the 10- to 19-year-
old age bracket (1988-2007). Aliment Pharmacol Ther 2011;33:1133-42. 
32. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural 
history of inflammatory bowel diseases. Gastroenterology 2011;140:1785-94. 
33. Bernstein CN, Wajda A, Svenson LW, et al. The epidemiology of inflammatory 
bowel disease in Canada: a population-based study. Am J Gastroenterol 
2006;101:1559-68. 
34. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence 
of the inflammatory bowel diseases with time, based on systematic review. 
Gastroenterology 2012;142:46-54 e42; quiz e30. 
35. The economic costs of Crohn's disease and ulcerative colitis. Access Economics, 
2007.  
36. Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory 
bowel disease based on results from the Asia-pacific Crohn's and colitis 
epidemiology study. Gastroenterology 2013;145:158-65 e2. 
37. Bengtson MB, Solberg C, Aamodt G, et al. Familial aggregation in Crohn's 
disease and ulcerative colitis in a Norwegian population-based cohort followed 
for ten years. J Crohns Colitis 2009;3:92-9. 
38. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of 
inflammatory bowel disease in the 21st century: a systematic review of 
population based studies. The Lancet 2018;390:2769-2778. 
20 
39. Benchimol EI, Mack DR, Guttmann A, et al. Inflammatory bowel disease in 
immigrants to Canada and their children: a population-based cohort study. 
American J Gastroenterol 2015;110:553-63. 
40. Benchimol EI, Manuel DG, To T, et al. Asthma, type 1 and type 2 diabetes 
mellitus, and inflammatory bowel disease amongst South Asian immigrants to 
Canada and their children: a population-based cohort study. PLoS One 
2015;10:e0123599. 
41. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel 
disease. Nature 2011;474:307-17. 
42. Knights D, Lassen KG, Xavier RJ. Advances in inflammatory bowel disease 
pathogenesis: linking host genetics and the microbiome. Gut 2013;62:1505-10. 
43. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel 
disease. Gastroenterology 2011;140:1704-12. 
44. Ortqvist AK, Lundholm C, Halfvarson J, Ludvigsson JF, Almqvist C. Fetal and 
early life antibiotics exposure and very early onset inflammatory bowel disease: 
a population-based study. Gut 2018. 
45. Xu L, Lochhead P, Ko Y, Claggett B, Leong RW, Ananthakrishnan AN. 
Systematic review with meta-analysis: breastfeeding and the risk of Crohn's 
disease and ulcerative colitis. Aliment Pharmacol Ther 2017;46:780-9. 
46. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev 
Gastroenterol Hepatol 2015;12:205-17. 
47. Harig JM, Soergel KH, Komorowski RA, Wood CM. Treatment of diversion 
colitis with short-chain-fatty acid irrigation. N Engl J Med 1989;320:23-8. 
48. Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel 
disease: a systematic review and meta-analysis. Am J Gastroenterol 
2011;106:661-73. 
49. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped 
the genetic architecture of inflammatory bowel disease. Nature 2012;491:119-
24. 
50. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are 
necessary for development of spontaneous colitis and immune system activation 
in interleukin-10-deficient mice. Infect Immun 1998;66:5224-31. 
21 
51. Conlon MA, Kerr CA, McSweeney CS, et al. Resistant starches protect against 
colonic DNA damage and alter microbiota and gene expression in rats fed a 
Western diet. J Nutr 2012;142:832-40. 
52. Lister J. On the antiseptic principle in the practice of surgery. Br Med J 
1867;2:246-8. 
53. Conlon M CC, Roberts-Thomson I. Sa1807 fermentation products and fecal 
microbiota in patients with quiescent ulcerative colitis. Gastroenterology 
2013;AGA abstracts:S310. 
54. Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing 
species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in 
patients with ulcerative colitis. Gut 2014;63:1275-83. 
55. De Cruz P, Prideaux L, Wagner J, et al. Characterization of the gastrointestinal 
microbiota in health and inflammatory bowel disease. Inflamm Bowel Dis 
2012;18:372-90. 
56. Rajilic-Stojanovic M, Shanahan F, Guarner F, de Vos WM. Phylogenetic 
analysis of dysbiosis in ulcerative colitis during remission. Inflamm Bowel Dis 
2013;19:481-8. 
57. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel 
disease: current status and the future ahead. Gastroenterology 2014;146:1489-
99. 
58. Roediger WE, Duncan A, Kapaniris O, Millard S. Sulphide impairment of 
substrate oxidation in rat colonocytes: a biochemical basis for ulcerative colitis? 
Clin Sci (Lond) 1993;85:623-7. 
59. Roediger WE. Nitric oxide damage to colonocytes in colitis-by-association: 
remote transfer of nitric oxide to the colon. Digestion 2002;65:191-5. 
60. Roediger WE. Review article: nitric oxide from dysbiotic bacterial respiration of 
nitrate in the pathogenesis and as a target for therapy of ulcerative colitis. 
Aliment Pharmacol Ther 2008;27:531-41. 
61. Sartor RB, Wu GD. Roles for intestinal bacteria, viruses, and fungi in 
pathogenesis of inflammatory bowel diseases and therapeutic approaches. 
Gastroenterology 2017;152:327-39 e4. 
62. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev 
Immunol 2009;9:799-809. 
22 
63. Roberts-Thomson IC, Fon J, Uylaki W, Cummins AG, Barry S. Cells, cytokines 
and inflammatory bowel disease: a clinical perspective. Expert Rev 
Gastroenterol Hepatol 2011;5:703-16. 
64. Maul J, Loddenkemper C, Mundt P, et al. Peripheral and intestinal regulatory 
CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 
2005;128:1868-78. 
65. Hart AL, Al-Hassi HO, Rigby RJ, et al. Characteristics of intestinal dendritic 
cells in inflammatory bowel diseases. Gastroenterology 2005;129:50-65. 
66. Travis SP, Stange EF, Lemann M, et al. European evidence-based consensus on 
the management of ulcerative colitis: current management. J Crohns Colitis 
2008;2:24-62. 
67. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets 
in Inflammatory Bowel Disease (STRIDE): ddetermining therapeutic goals for 
treat-to-target. Am J Gastroenterol 2015;110:1324-38. 
68. Shah SC, Colombel JF, Sands BE, Narula N. Mucosal healing is associated with 
improved long-term outcomes of patients with ulcerative colitis: a systematic 
review and meta-analysis. Clin Gastroenterol Hepatol 2016;14:1245-55 e8. 
69. Narula N, Marshall JK, Colombel JF, et al. Systematic review and meta-
analysis: infliximab or cyclosporine as rescue therapy in patients with severe 
ulcerative colitis refractory to steroids. American J Gastroenterol 2016;111:477-
91. 
70. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and 
maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. 
71. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and 
maintains clinical remission in patients with moderate-to-severe ulcerative 
colitis. Gastroenterology 2012;142:257-65 e1-3. 
72. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains 
clinical response in patients with moderate-to-severe ulcerative colitis. 
Gastroenterology 2014;146:96-109 e1. 
73. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and 
maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710. 
74. Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy and adverse drug 
reactions in patients with inflammatory bowel disease: impact of thiopurine S-
methyltransferase polymorphism. Pharmacogenetics 2002;12:429-36. 
23 
75. The economic costs of Crohn's disease and ulcerative colitis. Access Economics 
2007. 
76. Parragi L, Fournier N, Zeitz J, et al. Colectomy rates in ulcerative colitis are low 
and decreasing: 10-year follow-up data from the Swiss IBD cohort study. 
Journal of Crohn's and colitis 2018;12:811-8. 
77. Castano-Milla C, Chaparro M, Gisbert JP. Systematic review with meta-
analysis: the declining risk of colorectal cancer in ulcerative colitis. Alimentary 
pharmacology & therapeutics 2014;39:645-59. 
78. Ford AC, Khan KJ, Achkar JP, Moayyedi P. Efficacy of oral vs. topical, or 
combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic 
review and meta-analysis. Am J Gastroenterol 2012;107:167-76; author reply 
77. 
79. Lynch RW, Lowe D, Protheroe A, Driscoll R, Rhodes JM, Arnott IDR. 
Outcomes of rescue therapy in acute severe ulcerative colitis: data from the 
United Kingdom inflammatory bowel disease audit. Aliment Pharmacol Ther 
2013;38:935-45. 
80. Keranen U, Luukkonen P, Jarvinen H. Functional results after restorative 
proctocolectomy complicated by pouchitis. Dis Colon Rectum 1997;40:764-9. 
81. Andrews JM, Tan M. Probiotics in luminal gastroenterology: the current state of 
play. Intern Med J 2012;42:1287-91. 
82. Petrof EO, Claud EC, Sun J, et al. Bacteria-free solution derived from 
Lactobacillus plantarum inhibits multiple NF-kappaB pathways and inhibits 
proteasome function. Inflamm Bowel Dis 2009;15:1537-47. 
83. Russell DA, Ross RP, Fitzgerald GF, Stanton C. Metabolic activities and 
probiotic potential of bifidobacteria. Int J Food Microbiol 2011;149:88-105. 
84. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis 
with the probiotic Escherichia coli Nissle 1917 is as effective as with standard 
mesalazine. Gut 2004;53:1617-23. 
85. Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 
induces remission in patients with mild-to-moderately active ulcerative colitis. 
Clinical Gastroenterol Hepatol 2009;7:1202-9, 9 e1. 
86. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance 
treatment in patients with chronic pouchitis: a double-blind, placebo-controlled 
trial. Gastroenterology 2000;119:305-9. 
24 
87. Landy J, Al-Hassi HO, McLaughlin SD, et al. Review article: faecal 
transplantation therapy for gastrointestinal disease. Aliment Pharmacol Ther 
2011;34:409-15. 
88. Niederwerder MC. Fecal microbiota transplantation as a tool to treat and reduce 
susceptibility to disease in animals. Vet Immunol Immunopathol 2018;206:65-
72. 
89. Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old 
fecal microbiota transplantation? Am J Gastroenterol 2012;107:1755; author 
reply p. 6. 
90. Lewin RA. More on Merde. Perspect Biol Med 2001;44:594-607. 
91. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the 
treatment of pseudomembranous enterocolitis. Surgery 1958;44:854-9. 
92. Quraishi MN, Widlak M, Bhala N, et al. Systematic review with meta-analysis: 
the efficacy of faecal microbiota transplantation for the treatment of recurrent 
and refractory Clostridium difficile infection. Aliment Pharmacol Ther 
2017;46:479-93. 
93. Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal 
microbiota transplantation in clinical practice. Gut 2017;66:569-80. 
94. Trubiano JA, Cheng AC, Korman TM, et al. Australasian Society of Infectious 
Diseases updated guidelines for the management of Clostridium difficile 
infection in adults and children in Australia and New Zealand. Intern Med J 
2016;46:479-93. 
95. Mattila E, Uusitalo-Seppala R, Wuorela M, et al. Fecal transplantation, through 
colonoscopy, is effective therapy for recurrent Clostridium difficile infection. 
Gastroenterology 2012;142:490-6. 
96. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces 
for recurrent Clostridium difficile. N Engl J Med 2013;368:407-15. 
97. Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal 
microbiota transplantation by colonoscopy vs. vancomycin for the treatment of 
recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2015;41:835-
43. 
98. Merlo G, Graves N, Brain D, Connelly LB. Economic evaluation of fecal 
microbiota transplantation for the treatment of recurrent Clostridium difficile 
infection in Australia. J Gastroenterol Hepatol 2016;31:1927-32. 
25 
99. Grehan MJ, Borody TJ, Leis SM, Campbell J, Mitchell H, Wettstein A. Durable 
alteration of the colonic microbiota by the administration of donor fecal flora. J 
Clin Gastroenterol 2010;44:551-61. 
100. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging 
applications. Nat Rev Gastroenterol Hepatol 2012;9:88-96. 
101. Kang DW, Adams JB, Gregory AC, et al. Microbiota transfer therapy alters gut 
ecosystem and improves gastrointestinal and autism symptoms: an open-label 
study. Microbiome 2017;5:10. 
102. Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota 
transplantation in the management of inflammatory bowel disease. Aliment 
Pharmacol Ther 2012;36:503-16. 
 
26 
Chapter 3: Methods for Establishing a Stool Bank 
3.1 Background 
FMT is a proven and potentially life-saving therapy for rCDI. Emerging data have also 
demonstrated efficacy of FMT for other indications including UC. Establishing a stool 
bank is fundamental to delivering safe and reliable FMT. 
Frozen stool banking gives clinicians rapid access to thoroughly screened donor stool 
when needed, without the ethical and logistical problems associated with patient-
selected donors. Frozen stool banking facilitates timely, safe and effective access to 
FMT. Although frozen and fresh stool are equally efficacious for treatment of rCDI, 
frozen stool banking offers a number of advantages. Stool banking allows time for the 
application of rigorous screening protocols, enhancing the safety of FMT and allowing 
FMT to be delivered on demand. Moreover, stool banking allows for cost efficacy in 
manufacture and ensures anonymity for the donor. 
Despite the advantages, a number of technical, logistical and regulatory issues have 
hampered the development of FMT capability at most hospitals. This manuscript 
describes the methods used to establish the first public FMT service in Australia using a 
stool bank of pre-screened donor stool, including details regarding donor recruitment 
and screening, stool preparation and delivery of the FMT. 
Presented in this chapter is the manuscript published in Clinical Infectious Diseases 
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Recurrent or refractory CDI has become an increasing problem in the past decade. FMT 
is a highly efficacious treatment for rCDI; however, a number of technical, logistical 
and regulatory issues have hampered the development of FMT capability at many 
hospitals. The development of a frozen stool bank of screened donor stool is an 
important step in the standardization of the procedure. This gives clinicians rapid access 
to thoroughly screened donor stool when needed, without the ethical and logistical 
problems associated with patient-selected donors. We describe the practicalities of 
establishing such a service using a stool bank of pre-screened donor stool, including 






Clostridium difficile is the most common cause of health care associated diarrhea, and 
its incidence has been increasing in the last decade[1]. The recent emergence of 
hypervirulent strains has also lead to increased morbidity and mortality associated with 
the infection[2]. A major impediment to the successful treatment of patients with C. 
difficile infection CDI has been the 25–30% rate of relapse following antibiotic 
therapy[3]. In those patients who do relapse, further antibiotic treatments give 
diminishing rates of cure, in that after a second recurrence the chance of further 
recurrence increases to 60% and it is even greater for subsequent recurrences[3]. 
The problem of recurrent CDU (rCDI) is thought to result from an underlying 
deficiency of the microbiome as well as, in some patients, defective antibody mediated 
immunity[4]. Patients with CDI usually have a depleted commensal flora with reduced 
diversity of organisms[5]. This is commonly caused by previous exposure to antibiotics 
or is a manifestation of other conditions such as UC[6]. Traditional antibiotic therapy 
for CDI can perpetuate this dysbiosis, thus leaving an ecological void into which C. 
difficile emerges and proliferates[7]. FMT is thought to be effective as it replenishes the 
colonic microbial diversity by providing a new and diverse microbiome that occupies 
the niche into which C. difficile would otherwise multiply[5]. 
FMT is by far the most successful treatment for rCDI, with primary cure rates between 
81% and 94%[8-12]. A randomized control trial of FMT delivered via duodenal 
infusion for rCDI demonstrated symptom resolution in 81% of patients receiving a 
single FMT, compared with only 31% receiving vancomycin and 23% receiving 
vancomycin with bowel lavage. This study was stopped early after an interim analysis 
revealed the clear superiority of FMT over vancomycin therapy[10]. It is therefore now 
incumbent upon hospitals to establish FMT services so that rCDI can be effectively 
managed with this therapy. However, from a large institutional viewpoint, there are 
technical and logistical issues in establishing such a non-standardized, non-drug therapy 
with appropriate safety and governance. 
Establishing an FMT service 
An FMT service should be run in a standardized and efficient manner that allows safe 
and effective treatment to be delivered in a timely fashion. This is important because 
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patients with rCDI are often unwell, elderly patients with co-morbidities that make 
prompt treatment critical. The development of a frozen stool bank is the optimal way to 
standardize the FMT process and allow stool to be available on demand[11]. This is 
particularly important in cases where delayed treatment could result in colectomy[13]. 
A frozen stool bank also allows fecal donors to be recruited and thoroughly screened 
ahead of time, in a methodical manner, without time pressure.  Donor stool banks can 
be established at individual treatment centers or stool can be shipped from a centralized 
stool bank such as the not-for-profit organization “open-biome” in the United 
States[14]. 
Historically, patients undergoing FMT would often select their own stool donor from 
family or friends and this known donor would then undergo screening prior to giving 
their stool donation. This creates delays with therapy, and moreover there are a number 
of potential problems with this approach. These include the possibility of coercion of 
donors and also ethical and confidentiality concerns regarding screening known donors 
in the event that disease is found in a donor or transmitted to the recipient. Stringent 
exclusion criteria can be more easily and dispassionately applied to volunteer donors 
from the community than recipient-directed donors as there are a greater number of 
potential candidates and no perceived personal obligation between recipients and 
donors. There is also evidence from blood transfusion safety analyses that recipient-
directed donors are more likely to test positive for infectious disease than unrelated 
volunteer donors[15]. Depending on stool weight, up to eight treatments can be 
produced from each stool donation, and donors to the frozen stool bank can give 
multiple samples over a short period of time, making the process more economical[16]. 
Lastly, stool contains viable bacteria after 6 months of frozen storage at -80°C[11], and 
in case series, frozen stool appears to be as effective as fresh stool for treating patients 
with rCDI[11, 16, 17]. For these reasons, units such as ours have moved to only using 
pre-screened, unrelated donors who are anonymous to the recipient. 
Common problems associated with establishing an FMT service 
A major difficulty in establishing FMT services around the world has been regulatory 
restriction and uncertainties surrounding the practice[18]. This has, in part, occurred 
because of concern regarding potential risk to patients and the non-standardized nature 
of donor feces. To date, the short-term risk of FMT for rCDI is documented to be very 
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low and there have not been any directly attributable long-term side effects reported, 
although there are currently little long-term data[9, 19]. Despite randomized control trial 
efficacy data, the United States Food and Drug Administration (FDA) have 
implemented a policy of “enforcement discretion” regarding FMT only for rCDI after 
initially imposing a moratorium on the procedure[20]. There has also been difficulty 
classifying FMT as a therapeutic “drug” or tissue[21]. In the authors’ opinion, feces for 
FMT would be better classified as a bodily tissue donation in a similar way that blood 
and blood donation are regarded. Stool is derived from human donors, and is not a 
“standard product” as are manufactured drugs. In Australia[22] and many European 
countries[23], the development of FMT services has been left to local health 
administrations rather than national organizations such as the FDA in the United States. 
Therefore, there remains a need for consensus guidelines to achieve greater 
standardization of the procedure. 
Funding for FMT services can also be problematic with most third-party payers not 
rebating or covering the costs of individual FMT treatments or service establishment 
and delivery. Our FMT service has been established as a linked benefit from a clinical 
trial examining FMT in UC from research funds. However, for long-term sustainability, 
clinical funding from the health service will be needed. 
Recruitment and screening of donors 
Donor screening is expensive and time consuming, and therefore recruiting donors who 
are more likely to pass screening is advantageous. We found young, healthy donors by 
advertising at a nearby university. There is currently no evidence that donor 
characteristics or “enterotypes” predict the success of FMT treatment for CDI and so 
donor screening focuses on risk reduction rather than increasing the therapeutic effect. 
Donor screening has a high exclusion rate with rates of donor eligibility as low as 10% 
in an Australian study where donors were sought by advertisement to the general 
community[24]. We found that even when targeting young, apparently healthy 
university students, only 14 (31%) of 44 respondents were eligible donors after 
completing screening (Figure 3.1). When screening potential stool donors, it is 
advisable to take the medical history and physical examination prior to stool and then 
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blood screening, because the majority of candidates are excluded on history and stool 
testing, thus avoiding the additional costs of blood testing (Table 3.1). 
The risk of infection transmission is minimized with a thorough history for known 
exposures or risk factors as well as stool and blood screening. A number of atopic, 
autoimmune, psychiatric, malignant and neurological diseases are associated with gut 
dysbiosis, and so donors with these conditions are excluded[7]. Transmission of an 
obese phenotype has been demonstrated in animal studies[25], and the possible 
transmission of obesity has been reported in a single human case report [26]. Also, 
increased insulin sensitivity has been demonstrated in obese subjects following 
duodenal infusion of feces from lean donors[27]. Given these findings, elements of the 
metabolic syndrome should also be donor exclusions. Our screening protocol has 
evolved and is adapted from previous guidelines[10, 12, 28] (Table 3.1). Screening 
guidelines should reflect the risk of diseases applicable to the local population as this 
may vary depending on the geographical location of donor recruitment. 
Processing stool (Figure 3.2) 
Once screening is completed, stool should be collected from an individual donor within 
1 month[28]. Alternatively, screening can be undertaken both before and after a period 
of donation to ensure that all stool collected and frozen between the two dates is 
safe[17]. We give donors a clean opaque plastic bag that can be opened over a toilet to 
collect the stool and then sealed with a cable tie and placed in a larger zip-lock bag. 
Donors have the option of donating on site or taking the bag home with a cooler box 
and an ice pack so it can be delivered within 1 hour of defecation. Stool can be stored 
for up to 8 hours at 4°C without significant impact on bacterial survival, but viability 
declines at room temperature or at 4°C for more than 8 hours[29]. 
Approximately 50g of stool is required for each treatment[8]. Fresh stool (25%) should 
be blended with normal saline (65%) and pharmaceutical grade glycerol (10%). This 
ratio maximizes the amount of stool in suspension without being too viscous for 
delivery via the biopsy channel of a colonoscope or nasoduodenal tube. Glycerol is used 
to retain bacterial viability in the frozen stool preparations[11]. The entire donor stool 
can be placed in the blender to make as many 200mL aliquots as possible with a 
minimum of 50g stool content. Once blending is complete, the stool mixture should be 
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aliquoted into individual cryo-tolerant pots and immediately frozen at -80°C. We use 
250mL pots filled with 200mL of stool suspension as the liquid expands on freezing. In 
our experience the number of aliquots obtained from a single stool can vary from 
insufficient for a single preparation to eight aliquots. After 57 individual stool donations 
from 14 donors, we found a wide range in donor stool size from 7g to 436g with a 
median of 105g (IQR 51–220g). The mean stool weight was significantly greater for 
male donors (172g, CI 213–122g) than female donors (92g, CI 118–67g; P = 0.006). 
We conduct the blending in an anaerobic chamber to reduce operator exposure, and 
because it has the theoretical advantage of preventing oxygen exposure to obligate 
anaerobic bacteria during the blending process. However, there is evidence that 
processing and freezing stool under aerobic conditions is also clinically effective[17, 
30] and can be conducted without a fume hood as exposure risk is probably less than for 
colonoscopy (given the rigorous stool screening)[7, 30]. Blending for 1 minute 
produces a suspension with sufficiently small particle size for it to be easily drawn into 
a catheter tip syringe and flushed down the biopsy channel of a colonoscope with the 
cap removed. There is no need to strain the blended suspension for colonoscopic or 
enema delivery. We have conducted more than 80 FMT procedures using colonoscopic 
delivery of blended stool without filtration with no instances of colonoscope channel or 
syringe blockage. Many butyrate-producing colonic bacteria require fiber as a 
substrate[31] and so there are also theoretical reasons for not removing fibrous material 
from the suspension. However, if delivery is via a nasoduodenal or nasogastric tube, 
filtering is required to prevent tube blockage. 
If a blender or an autoclave is not available, the FMT suspension can be prepared by 
combining stool, saline and glycerol in the collection bag and manually agitating the 
contents. Alternatively, stool can be mixed directly in the plastic storage container with 
a spatula[30] or shaken in a bottle of normal saline[32]. Whilst these methods are 
simple, they can result in a suspension with large unsuspended particles that can block 
the syringe and so filtering the suspension is often required. 
Stool donors should be given an identification number that is marked onto each pot of 
stool suspension with the date the sample was produced. This identification number 
should be recorded in a secure donor document along with contact details and screening 
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results so that the donor is de-identified to the recipient but can be traced in the event of 
illness developing in the recipient. 
Cleaning equipment 
Cleaning the equipment between donor stool processing is important to minimize the 
risk of cross contamination. We use a blender that has a stainless steel container 
(Waring SS515) with Teflon seals and a stainless steel lid, both of which can be 
sterilized with an autoclave as this is the best infection control practice[33]. The blender 
container and spoon must be cleaned to remove all residue prior to autoclaving. We use 
an enzymatic wash and then detergent wash followed by a water rinse and then 
autoclave both at 121°C for 20 minutes. The container and spoon are then autoclaved 
again immediately prior to next use. Given donor stool is screened for potential 
pathogens it is likely to be safer than stool encountered during routine colonoscopy. 
Therefore, we believe endoscope cleaning following FMT should follow standard 
protocols. 
The equipment required to establish such a service with a frozen stool bank is listed in 
Table 3.2. 
Patient selection 
The decision to proceed with FMT should be made on an individual patient basis; 
however, there are three main factors that influence the decision: the number of CDI 
recurrences, the severity of the episode and whether the disease is refractory to 
antimicrobial therapy[28]. More than two relapses of CDI following antimicrobial 
therapy gives <35% chance that subsequent antimicrobial therapy alone will be 
successful. In these patients, FMT offers a much higher chance of success[9, 10]. A 
severe infection with CDI resulting in shock or requiring supportive care in hospital in 
which recurrence of CDI could be life threatening is another indication, as is moderate 
disease not responding to antimicrobial therapy for at least 1 week[28]. Gastrointestinal 
perforation is an absolute contraindication and anaphylactic food allergy a relative 
contraindication. Severe immunosuppression has previously been regarded as a 
contraindication; however, FMT in patients with at least moderate immunosuppression 
appears safe[34]. Patients with toxic megacolon should be offered subtotal colectomy in 
the first instance, and FMT via colonoscopy is contraindicated in these patients. In those 
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refusing surgery, FMT via the upper gastrointestinal route can be cautiously considered 
and has resulted in cure[13]. 
Consent 
There have been two deaths directly attributable to FMT, with both of these patients 
developing aspiration pneumonia. The first patient aspirated during sedated endoscopic 
FMT delivery to the duodenum[35], and the other aspirated during the anaesthetic for 
colonoscopic FMT[34]. One other death following FMT occurred because of toxic 
megacolon and sepsis[36]; however, this may have been attributable to the recurrence of 
the underlying CDI or a gastrostomy tube leak and not the FMT. There have been no 
other directly attributable long-term side effects of FMT in over 600 cases in the 
literature[19]. There is a paucity of long-term data[37], and so the possibility of as yet 
unknown long-term risk needs to be factored into any screening protocol and discussed 
with patients when consenting patients for FMT. A cohort study of patients who had 
received FMT for rCDI found 4 of 77 patients developed new autoimmune disease 
during the follow-up period of 3–68 months[37]. This study had no control group and 
thus no association between FMT and the development of autoimmune disease could be 
made. 
Route of delivery of FMT 
FMT can be delivered directly to the colon via colonoscopy or retention enema, or 
alternatively into the upper gastrointestinal tract via nasogastric tube, nasoduodenal tube 
or duodenoscopy. Another potential delivery method of FMT is the use of enteric-
coated or lyophilized capsules that contain stool[38] or synthetic stool made of multiple 
different bacterial strains. These have shown success in small case series and phase I/II 
trials and similar preparations, although not widely available, are under commercial 
development[39]. 
The only randomized control trial comparing methods of delivery had 10 patients 
receive FMT via nasogastric tube and 10 patients receive FMT via colonoscopy for 
rCDI[17]. Resolution of diarrhea was achieved in 6/10 in the nasogastric tube delivery 
group, compared with 8/10 in the colonoscopic delivery group. There was no significant 
difference between groups although the numbers in this study were small. In a 
systematic review of case series, cure rates varied depending on the site of infusion; 
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when FMT was infused into the stomach, duodenum/jejunum, caecum/ascending colon 
and rectum the rates of cure were 81%, 86%, 93% and 84%, respectively[40]. 
Colonoscopy appears to have a higher cure rate than other methods; however, it is 
difficult to compare case series with heterogeneous populations. Colonoscopy does have 
the advantage of assessing the degree of inflammation and assessing other pathology 
that may be present; however, it is resource intensive and costly, and for this reason 
enema delivery is a reasonable alternative[18]. The upper gastrointestinal route carries 
the risk of fever and abdominal cramping[8, 10], whereas colonoscopic delivery carries 
the theoretical but unreported risk of colonic perforation. The FMT is delivered down 
the biopsy channel of the colonoscope into the caecum by removing the cap from the 
biopsy channel and opposing the catheter tip syringe. 
Patient preparation and follow-up (Figure 3.3) 
The standard approach has been to give 5–10 days of oral vancomycin (250mg QID), 
ceasing 36–72 hours prior to the procedure[12]; however, there are no data comparing 
no antimicrobial preparation or various different antimicrobial preparations. FMT via 
the duodenal route does not require bowel lavage, whereas colonoscopic delivery 
usually does[17]. We give the patient 4mg loperamide 3 hours prior to the procedure 
and have them lie on their right side at the point of delivery and for 1 hour following the 
procedure to aid with retention of the FMT. Symptoms of diarrhea and cramping often 
improve quite rapidly, and thus there is no routine need for further stool testing. 
However, if diarrhea persists for longer than 1 week, then repeat C. difficile toxin PCR 
should be done and FMT repeated if positive. 
Conclusion 
FMT is the most efficacious treatment available for the increasing problem of rCDI. 
This necessitates that health care services develop the capability to deliver FMT safely 
and reliably. A stool bank of pre-screened frozen aliquots from healthy volunteers is the 
most practical, ethical and cost-effective approach. The practical steps outlined here 
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Table 3.1: Donor screening criteria 
Medical interview (exclusions) 
Age: <18 or >65 
Antimicrobial therapy or probiotics in the past 3 months 
Active medical illness or symptoms 
Any medications 
International travel in last 6 months to areas at high risk of traveler’s diarrhea 
High-risk sexual activity (unprotected sex in last 1 month outside of a monogamous relationship, men 
who have sex with men, sex for drugs or money) 
Illicit drug use 
Tattoo or body piercing within 6 months 
Known HIV or viral hepatitis exposure in the last 12 months 
Incarceration or a history of incarceration 
Family history of colorectal carcinoma involving two or more first-degree relatives 
Household members with active gastrointestinal infection 
Medical history and examination (exclusions) 
Any gastrointestinal disorder 
Obesity (BMI >30),hypertension, type 2 diabetes and dyslipidaemia 




Infection with HIV, syphilis, hepatitis B or C 
Malignancy 
Chronic pain syndromes, neurologic or neurodevelopmental disorders 
Blood screening 
Full blood count 
Electrolytes, urea and creatinine 
Liver function tests 
Human T cell lymphotropic virus 1 and 2 serology 
Epstein Barr Virus IgM and IgG 
Cytomegalovirus IgM and IgG 
Syphilis (rapid plasma reagin) 
Strongyloides stercoralis, Entamoeba histolytica, Helicobacter pylori serology 
Hepatitis A virus IgM 
Hepatitis B surface antigen, core antibody, hepatitis C virus antibody 
HIV type 1 and 2 antibody and p24 antigen 
Antinuclear antibody 
Fasting lipids and blood sugar level 
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C-reactive protein and erythrocyte sedimentation rate 
Stool screening 
Microscopy and culture 
Rotavirus, norovirus and adenovirus PCR 
Clostridium difficle toxin PCR 
Eggs, cysts and parasites (including Cryptosporidium spp., Giardia spp., Dientamoeba fragilis and 
Entamoeba histolytica PCR) 





Table 3.2: Equipment 
Equipment required 
Opaque plastic bag (to collect stool), cable tie 
Blender with autoclaveable container 
Stainless steel spoon 
Normal saline 
Pharmaceutical grade glycerol 
Safe work bench on which to blend stool (fume hood or anaerobic chamber ideally) 
-80°C freezer 
Cryo-tolerant screw top containers (250 mL) 
Catheter tip syringes (60 mL) 








Figure 3.1: Donor recruitment 
	 	
44 respondents to advertising flyer sent donor information sheet via email 
1/15 excluded on blood testing (positive Strongyloides stercoralis serology and 
anaemia) 
16/38 excluded on history and examination 
2 each of: obesity, returned traveler, recent antimicrobial therapy, depression, high-
risk sexual activity 
1 each of: irritable bowel syndrome, past hepatitis B, age <18, age >65, psoriasis, 
BMI <18 
7/ 22 excluded on stool testing (all had Dientamoeba fragilis detected by 
PCR) 
38/44 responded to 
email 





Figure 3.2: Stool preparation 
  
Donor produces stool directly into bag then 
closes bag with cable tie 
Deliver in cooler box for processing within 1 hour 
Blend with glycerol (10%) and normal saline (65%) for 1 minute 
Divide blend into 200mL aliquots 
  
Label pots with donor number and date and record in 
donor register 






Figure 3.3: Patient preparation and follow-up 
Repeat CDT PCR and consider other 
causes of diarrhea including post-







No further action required 
	 
Resolution of symptoms 
	 
Review at 1 week 
	 
FMT (enema, colonoscopy or nasogastric/duodenal tube) 
Thaw stool at room temperature 3 hours prior to procedure and then draw 
into catheter tip syringes 
Loperamide 4mg 3 hours pre-procedure (lower gastrointestinal 
delivery) 
or 
Proton pump inhibitor 12 hours pre-procedure (upper gastrointestinal 
delivery) 
Bowel lavage 12 hours prior (colonoscopy only) 
Vancomycin 250mg po QID for 5–10 days 
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Chapter 4: Validating Stool Bank Storage Methods 
4.1 Background 
In Chapter 3 of this thesis, the methods detailing the establishment of a stool bank for 
the reliable delivery of FMT were outlined. Critical to the efficient and reliable delivery 
of FMT from a stool bank is the ability to store stool frozen for prolonged time periods. 
The storage methods for stool, including the components of the emulsion, had not been 
validated to ensure viability of the frozen organisms. It had previously been 
demonstrated that FMT using fresh stool and stool frozen for less than 2 months was 
effective treatment for rCDI; however, the efficacy of using stool stored for prolonged 
periods was not known.  
This manuscript therefore had two parts. The first part assessed bacterial viability in 
stool frozen in saline with and without glycerol for up to 6 months. In the second part, a 
retrospective analysis of the treatment efficacy of FMT for the treatment of CDI where 
stool had been frozen for more than 2 months was undertaken. 
Presented in this chapter is the manuscript published in Alimentary Pharmacology & 
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Background: Faecal microbial transplantation (FMT) for recurrent Clostridium difficile 
infection rCDI is greatly facilitated by frozen stool banks. However, the effect of frozen 
storage of stool for more than 2 months on the viability of stool bacteria is unknown and 
the efficacy of FMT is not clear. 
Aim: To evaluate the viability of bacteria in stool frozen for up to 6 months, and the 
clinical efficacy of FMT with stool frozen for 2–10 months, for the treatment of rCDI. 
Methods: Viability of six representative groups of faecal bacteria after 2 and 6 months 
of storage at -80°C, in normal saline or 10% glycerol, was assessed by culture on plate 
media. The clinical outcomes of 16 consecutive patients with rCDI treated with aliquots 
of stool frozen in 10% glycerol and stored for 2–10 months were also examined. 
Results: Viability was similar to baseline at both 2 and 6 months in specimens stored in 
10% glycerol and at 2 months in stool stored in saline, but was reduced by >1 log at 6 
months for aerobes (P < 0.01), total coliforms (P < 0.01) and lactobacilli (P < 0.01) in 
saline. In patients undergoing FMT with stool frozen for 2–10 months in 10% glycerol, 
the cure rate for rCDI was 88% with one FMT and 100% after repeat FMT in those who 
relapsed. 
Conclusions: Stool for FMT to treat rCDI can be safely stored frozen in 10% glycerol 





Clostridium difficile is a spore-forming gram-positive bacillus that is a common cause 
of health care associated diarrhoea, particularly in elderly or debilitated patients1-3. CDI 
is thought to result from a diminished indigenous colonic flora, particularly after the use 
of broad spectrum antibiotics, that allows C. difficile to proliferate into the resultant 
ecological void4-6. rCDI is an increasing problem and hypervirulent strains have 
emerged7-9 resulting in increased morbidity and mortality10. FMT has become the 
standard of care for patients with rCDI as a result of randomized control trial evidence 
of its superiority to traditional antibiotic therapy alone11. It is therefore now incumbent 
upon hospitals to establish FMT services so that rCDI can be effectively managed with 
this new therapy. 
Whilst many facilities use fresh stool from donors known to the recipients, there are a 
number of issues making this practice problematic. First, there are ethical concerns 
regarding coercion as well as confidentiality concerns in screening known donors in the 
event that pre-existing undeclared disease is found in a donor or transmitted to the 
recipient. There is also evidence from blood transfusion safety analyses that recipient-
directed donors are more likely to test positive for infectious disease than unrelated 
volunteer donors12.  Stringent exclusion criteria can be more easily and dispassionately 
applied to volunteer donors from the community than recipient-directed donors as there 
are a greater number of potential candidates and no perceived personal obligation 
between donors, recipients and healthcare workers. Lastly, donor recruitment and 
testing is labor intensive and costly and by using a frozen stool bank with anonymous 
volunteers the process becomes more economical. Up to six treatments can be produced 
from each stool donation and suitable donors can give multiple samples over a short 
period of time. 
Treating FMT donation in a similar way to blood banking, with pre-screened 
anonynmized donors, addresses many of the issues with fresh and/or recipient-directed 
donors. The development of a frozen stool bank is the most efficient and reliable way to 
standardize the donor stool processing and screening and allows stool to be available for 
the clinician to use on demand13. The precise elements of donor stool that determine the 
success of FMT are not known. A determinant of the success of a frozen stool bank may 
be the viability of the bacteria within the frozen stool specimens. There have also been 
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suggestions that success may be attributable to non-toxigenic clostridial spores in the 
donor samples14. There is evidence that FMT using stool frozen for less than 2 months 
is clinically as effective as fresh samples for rCDI15 and the successful use of stool 
frozen for up to 5 months has been reported16, 17. However, the concurrent clinical 
efficacy and bacterial viability of stool frozen for periods substantially greater than 2 
months has not been reported to date. 
Glycerol is commonly used as a cryoprotective agent for frozen faecal samples13, 15; 
however, it is not known for how long stool can be frozen and continue to deliver viable 
bacteria. We therefore examined the viability of six culturable bacterial populations 
within stool stored for 2 and 6 months in two different storage media: normal saline 
(0.9% sodium chloride) and a normal saline and 10% glycerol mix. In addition, we 
reviewed our prospectively maintained FMT for rCDI database for patients who 
received stool that had been in frozen storage in 10% glycerol for >2 months to assess 
its clinical effectiveness. 
Methods 
Volunteer stool donors were sought by advertisement at the University of Adelaide. 
Donors were thoroughly screened with history, examination, and blood and stool testing 
similar to published guidelines18. Stool collected for clinical use and stored in our stool 
bank was processed using a blender under anaerobic conditions where stool, saline and 
glycerol were mixed in a 2:7:1 ratio. 
Stool bacterial viability study 
Stool samples collected from four volunteers were immediately processed aseptically 
under anaerobic conditions in an anaerobic chamber (Bactron IV Work Station, Shel 
Lab, Cornelius, Oregon, USA) in a nitrogen (85%) + hydrogen (10%) + carbon dioxide 
(5%) atmosphere. A normal saline stool suspension and a 10% glycerol stool 
suspension were prepared. To create the normal saline suspensions, 30g of stool from 
each volunteer was mixed and homogenised into suspension with of 120mL normal 
saline and then divided into three 50mL aliquots (ratio stool:saline = 1:4). To create the 
10% glycerol suspensions, 20g of stool was mixed with 70mL normal saline and 10mL 
glycerol and divided into two 50mL aliquots (ratio stool:glycerol:saline = 2:1:7). 
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Two normal saline suspension aliquots and two 10% glycerol suspension aliquots from 
each of the four volunteers were then frozen immediately at -80°C. One sample of each 
storage medium was stored for 2 months and the other for 6 months. 
A single saline suspension aliquot was then used to inoculate the plates at time zero 
within 2 hours of collection. Homogenised samples were serially diluted from 10-2 to 
10-9 with sterile pre-reduced buffered peptone (20g/L buffered peptone water, 0.5% 
cysteine HCL and 0.1% Tween 80), and 100µL aliquots were plated onto the following 
media: chromogenic coliform agar (Oxoid, Basingstoke, UK) for total aerobes, total 
coliforms and Escherichia coli; Columbia blood agar (Oxoid, Basingstoke, UK) with 
5% defibrinated horse blood for total anaerobes; Rogosa agar (Oxoid, Basingstoke, UK) 
for lactobacilli; and bifidus-blood agar (Oxoid, Basingstoke, UK) for bifidobacteria. We 
chose to examine the viability of anaerobes and aerobes as these collectively cover the 
breadth of the bacteria present in stool. We also chose to examine the commonly 
cultured bacteria, E coli and coliforms, that are of relevance to human health19. 
Lactobacilli and bifidobacteria were assessed because these are often used and 
promoted as probiotics and increases in their stool numbers are generally regarded as 
beneficial20, 21. 
The dilutions were inoculated onto agar using the spread plate method and incubated at 
37°C. Plates were incubated for 1–5 days depending on the media, and all plates were 
incubated anaerobically within heat sealed plastic pouches containing Anaerogen 
Compact sachets (Oxoid, Basingstoke, UK), except for the cultures of aerobic bacteria, 
which were incubated aerobically. The numbers of colonies characteristic of each 
bacterial group were visually counted and the concentration calculated as colony 
forming units (cfu) per gram of wet weight. Typical morphology included raised copper 
colonies on bifidus-blood agar, identified as bifidobacteria, and purple and pink 
colonies on chromogenic agar identified as E.coli and coliforms, respectively. All 
colonies were counted for both Rogosa and Columbia agars. 
At 2 months, a normal saline suspension aliquot and a 10% glycerol aliquot from each 
participant were thawed at room temperature for 180 minutes before inoculating and 
incubating the plates as per the technique described above. Identical thawing and 
inoculating techniques were again repeated at 6 months. 
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Clinical use of FMT 
FMT was performed for rCDI at three tertiary referral hospitals in South Australia from 
August 2013 until February 2015. Only stool stored in normal saline with 10% glycerol 
suspension and frozen in a stool bank at -80°C was used for this purpose. FMT was 
delivered by colonoscopy to the caecum in all but one patient, who had FMT instilled 
into the jejunum by push enteroscopy as this patient had toxic megacolon22 and 
colonoscopy was therefore unable to be performed safely. 
Our prospectively collected database of FMT for patients with rCDI was interrogated 
for patients who had received stool that had been in frozen storage for more than 2 
months at the time of use. The database contains patient demographic details, history of 
CDI, and FMT delivery and outcome. Patients were reviewed clinically or contacted via 
telephone to confirm resolution of symptoms and report side effects 3 to 14 months 
after FMT. In those with ongoing or recurrent diarrhoea, a stool sample was 
interrogated for the presence of the C. difficile toxin gene by PCR. Patients with a 
positive PCR test were treated with repeat FMT. Primary cure was defined as resolution 
of diarrhoea and/or absence of C. difficile toxin in stool as measured by PCR after at 
least 3 months follow-up following the first FMT treatment. Secondary cure was 
defined as this outcome being achieved after a second FMT treatment. Failure was 
defined as persistent diarrhoea and/or ongoing C. difficile detected in stools. 
Statistics 
Microbiology 
For each of the four individual stool donors, absolute bacterial counts (cfu/mL) over 
each set of six plates were calculated. These counts were log10 transformed to obtain 
data normality and the four means of the six transformed measurements were used as 
the response variable. The four stool samples were used as the random component of 
the mixed model analyses, and storage and time were the fixed effects. A >1 log 
decrease in cfu/mL over time was considered a relevant decrease in bacterial viability 
for the purposes of FMT. The P-values used for indicating significances between means 
were adjusted using the Bonferroni correction for multiple comparisons. Viability was 
calculated using 10^(baseline mean - mean over time), that is, the log difference 
between the fresh stool culture (baseline) and the frozen sample. The percentage 
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viability represents the log count of the frozen sample/log count of the fresh sample 
multiplied by 100. All statistical analyses were performed using the R statistical 
package. 
Clinical 
Data were expressed as a median with an interquartile range. 
Results 
Microbiological outcomes 
After storage in 10% glycerol, there was no significant effect of time on bifidobacteria, 
E. coli, total coliforms, lactobacilli, total anaerobic bacteria or total aerobes (log10 
counts) and no bacterial group had a mean >1 log reduction in colony forming unit per 
millilitre (cfu/mL) counts after 2 months or 6 months storage with +10% glycerol 
(Table 4.1). 
After storage in normal saline, none of the tested bacteria had a statistically significant 
or mean >1 log reduction in cfu/mL counts at 2 months, compared with baseline. 
However, there was a significant (>1 log) decrease in lactobacilli (P < 0.01), aerobes (P 
< 0.01) and total coliforms(P < 0.01) at 6 months, compared with baseline (Table 4.2). 
At 6 months, there was also a non-significant trend towards a reduction in E. coli but no 
significant reduction in anaerobic bacteria or bifidobacteria. 
After storage in normal saline, all cultures showed at least some decrease in bacteria 
numbers (Figure 4.1), whereas after storage in 10% glycerol, falls were minor and non-
significant or counts showed a minor non-significant rise (anaerobes). Storage of stool 
in normal saline suspension resulted in a reduction in all cultured bacterial species, 
compared with 10% glycerol suspension with only total coliforms (-1.02 log, P < 0.01) 
and lactobacilli (-0.92 log, P < 0.01) species reaching statistical significance at 6 
months. 
Clinical outcomes 
A total of 20 instances of primary FMT were performed in 20 discrete patients, from 
June 2013 to December 2014, and 16 patients received stool aliquots that had been in 
 
60 
storage for >2 months. Four patients received stool that had been in storage for <2 
months. 
The median age of the 16 patients receiving stool frozen for >2 months at the time of 
the FMT was 69 years (IQR 43–77). The median number of rCDI episodes prior to 
FMT was three (IQR 2–4). Fifteen subjects responded clinically to the initial FMT, one 
relapsed after 1 week following new antibiotic exposure and one subject was a primary 
non-responder. Both of these patients were cured with a second FMT treatment (88% 
primary cure and 100% secondary cure). There were no patients in whom more than 2 
FMTs were required and no cases where FMT failed to cure rCDI. 
Stool used for the 16 episodes of primary FMT was stored for a median of 227 days (8 
months; IQR 170–272 days). There were no complications from FMT. Stool used to 
treat both cases of recurrence had been frozen for >2 months. 
There were four patients with rCDI who received FMT with stool that had been in 
storage <2 months; three patients had primary cure and one had recurrence during the 
follow-up period. This recurrence was treated successfully with a second FMT 
procedure using stool also frozen for <2 months. 
Discussion 
Here we show that stool frozen in 10% glycerol for 2 and 6 months at -80°C contains a 
high number of viable and culturable bacteria. Furthermore, stool that has been frozen 
in 10% glycerol for 2–10 months is highly efficacious at treating rCDI. Previous studies 
have demonstrated the effectiveness of frozen stool for the treatment of rCDI15-17; 
however, the use of stool stored for a prolonged period of >2 months has not been 
specifically assessed.	Studies by Satokari et al. and Youngster et al. have included stool 
frozen for up to 16 weeks and 5 months, respectively, to treat rCDI, but these studies 
did not indicate what proportion of their samples were frozen for a prolonged period 
and therefore are difficult to interpret in this context16, 17. The rate of primary cure of 
88% in our cohort is comparable to other studies using fresh stool11, 23 or stool frozen 
for <2 months15. 
These data are important as they inform stool preparation and storage practices and also 
support the proposition that healthy donors can be pre-screened and stool stored for 
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many months, ready for prompt and convenient use, thus avoiding many practical issues 
that make the use of fresh stool difficult. 
Our data indicate that culturable organisms are viable for at least 6 months in frozen 
storage at -80°C using a 10% glycerol suspension. Viable organisms are important as 
donor FMT increases colonic bacterial diversity in the recipient with engraftment of 
donor bacteria24. This may be the mechanism by which resistance to C. difficile 
recurrence is conferred. Moreover, our data show that stool kept in frozen storage for 
over 2 months in 10% glycerol is clinically effective at treating rCDI. This has 
important implications for stool banks, allowing longer storage of stool than has 
previously been recommended15. Longer storage allows for less frequent donor 
recruitment and screening and furthermore enables the use of frozen stool that would 
have otherwise been discarded on the basis of current recommendations. Frequent blood 
and stool testing of donors is a burden on donors and also adds costs to FMT services 
that are not currently covered by most third-party payer schemes. The ability to store 
stool in a frozen stool bank for prolonged periods of time thus makes the development 
of a stool bank less resource intensive and more economical. Donors can therefore 
produce multiple samples at the time of screening and have them stored for a longer 
period of time. 
Storage in various glycerol solutions has been demonstrated to enhance the viability of a 
range of bacteria in frozen storage25-28. Acha et al. found that after 1 year of frozen 
storage of infant and calf stool in 10% glycerol broth at -70°C, E. coli isolates were 
viable and in similar proportion to fresh samples26. Bonten et al. found that bacteria 
recovered from rectal swabs stored in phosphate buffered glycerol saline at -20°C for 4 
weeks had reduced viability of a number of cultured bacteria, compared with fresh 
specimens, but significantly better viability than storage with Cary-Blair media and 
Amies media27. The reduced viability of organisms stored in phosphate buffered 
glycerol saline in that study might have in part been due to the storage temperature of -
20°C rather than -80°C, because it has been demonstrated that lower temperatures 
enhance bacterial survival26. Cryopreserving media, such as Cary-Blair media, skim 
milk and Amies media, have been used to store stool for the purpose of later analysis29-
31; however, some of these media are less effective than 10% glycerol solutions at 
retaining microbial viability and others are unsuitable to be administered into a patient’s 
gastrointestinal tract as they are untested on humans. 
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Most FMT frozen stool banks use normal saline + 10% glycerol as a storage medium at 
-80°C 15-17; however, there are no data on the viability of stool bacteria stored in this 
way for the purpose of FMT. Our study demonstrated a high viability of six culturable 
bacterial groups after 6 months of frozen storage in 10% glycerol solution. At 6 months, 
the viability of many of the cultured organisms was reduced in saline, compared with 
the 10% glycerol solution, with total coliforms (-1.02 log, P < 0.01) and lactobacillus (-
0.92 log, P < 0.01) species reaching statistical significance, indicating that glycerol has 
a cryoprotective effect for these stool bacteria in storage. Anaerobes and lactobacilli 
groups had non-significant rises in their populations after 2 months’ storage in 10% 
glycerol and bifidobacteria had non-significant rises after 2 and 6 months’ storage in 
10% glycerol solution (Table 4.1). This is likely to be artifactual and may partially 
represent statistical variation or possibly a small growth-enhancing effect of glycerol on 
those bacteria. 
Different species of bacteria vary in their susceptibility to damage by freezing and 
thawing. Haines et al. found that a single freeze–thaw cycle killed 98% of 
Saccharomyces cerevisiae, but only 5% of Staphylococcus aureus32. We demonstrated 
that bifidobacteria had better survival in frozen storage at 6 months, compared with total 
coliforms and E. coli, particularly in the saline-only solution (P < 0.01) (Table 4.2). The 
different rates of viability for different bacterial species in frozen storage may have 
clinical implications for long-term FMT storage and warrants further investigation. All 
of the tested species were within 1 log of the baseline levels after 2 months of storage in 
saline alone. This suggests that stool frozen for less than 2 months in saline alone may 
have a sufficiently diverse viable population for use in FMT although this has not been 
confirmed in vivo. 
Limitations 
Few species of colonic flora are readily culturable with conventional techniques and so 
these data represent only a fraction of the bacteria in the samples that we have tested. 
The six groups of bacteria tested, however, represent a diverse range of bacteria and 
each group contains a number of distinct species. Also, these culture studies 
demonstrate that the six bacterial groups that we did culture at baseline remained viable 
after 2 and 6 months of storage with 10% glycerol. PCR-based sequencing techniques 
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are not useful in testing the viability of bacteria after frozen storage as they are unable 
to differentiate between viable and non-viable bacteria. 
Only 16 patients in this study received stool that was frozen for 2 months or more and a 
larger sample size would be necessary to confirm that there is no difference in clinical 
efficacy of stool frozen for prolonged periods, compared with stool <2 months old. The 
success in all 16 patients does, however, suggest that the bacterial viability data that we 
describe are relevant clinically and that any negative effect on clinical efficacy is small. 
Only the 10% glycerol storage media was tested clinically in this study as this is the 
current standard and is highly effective at treating rCDI. Given this, there is not 
sufficient clinical equipoise to justify a trial of less viable FMT storage media such as 
normal saline alone. 
Conclusion 
This study demonstrates that a selected group of culturable bacteria are viable in stool 
stored at -80°C in 10% glycerol for up to 6 months and in normal saline for up to 2 
months. Moreover, stool stored in 10% glycerol for more than 2 months is effective in 
vivo at treating rCDI. Longer storage times for frozen stool will allow greater flexibility 
in the recruitment of donors and the processing of donor stool and reduce the cost of 
frequent screening of donors. This has important practical implications for the 
maintenance and cost effectiveness of frozen stool banks used for FMT as a treatment 
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Figure 4.1: Changes in bacterial culture colony counts relative to baseline (0.0) 
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Chapter 5: Faecal Microbiota Transplantation for the 
Induction of Remission of Ulcerative Colitis 
5.1 Background 
UC is a chronic IBD that occurs at the interface between the colonic microbiota and the 
mucosal immune system. Although there is growing evidence implicating the colonic 
microbiome in UC pathogenesis4,5, most currently available therapies target the immune 
response rather than the luminal microbial environment.6 These therapies are limited by 
incomplete efficacy as well as intolerance and side effects, many of which result from 
immunosuppression. Hence, new therapies are needed for UC and microbiota-based 
therapies offer potential advantages over immunosuppressive medications. 
This RCT (FIRST-UC study) evaluated the use of FMT for the induction of remission 
of mild to moderately active UC. Patients were randomised to receive either 
anaerobically prepared pooled donor stool or autologous FMT via colonoscopy. They 
were then reassessed at 8 weeks for clinical and endoscopic remission of UC. Patients 
underwent exploratory faecal microbiome and metabolome analyses as well as 
peripheral blood and mucosal mononuclear cell population analysis prior to and 
following FMT with the aim of understanding the mechanisms by which FMT may 
have a clinical effect. 
During the course of this trial, the results of three other studies assessing FMT for UC 
emerged. These studies had relatively intensive FMT protocols and used aerobic 
processing methods for donor stool. Most colonic bacteria are obligate anaerobes, and 
are extremely oxygen sensitive; thus, they may be diminished or eliminated when stool 
is processed under aerobic conditions. High-intensity treatment FMT regimes may not 
be suitable for real-world practice. Unique features of this study were the use of 
anaerobic stool processing and a short-duration and low-intensity FMT treatment 
regimen over a 1-week period. 
Presented in this chapter is the manuscript published in the Journal of the American 
Medical Association (2019, Vol. 321, pp. 156–164). 
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Question: Can a short duration of FMT using anaerobically prepared pooled stool 
suspension induce remission in active UC? 
Findings: In this randomized clinical trial that included 73 adults with mild to 
moderately active UC, the proportion achieving steroid-free remission at 8 weeks was 
32% with donor FMT vs 9% with autologous FMT—a significant difference. 
Meaning: Anaerobically prepared fecal microbiota transplantation may be effective in 




Importance: High-intensity, aerobically prepared FMT has demonstrated efficacy in 
treating active UC. FMT protocols involving anaerobic stool processing methods may 
enhance microbial viability and allow efficacy with a lower treatment intensity. 
Objective: To assess the efficacy of a short duration of FMT therapy to induce 
remission in UC using anaerobically prepared stool. 
Design, setting and participants: A total of 73 adults with mild to moderately active 
UC were enrolled in a multicenter, randomized, double-blind clinical trial in three 
Australian tertiary referral centers between June 2013 and June 2016, with 12-month 
follow-up until June 2017. 
Intervention: Patients were randomized to receive either anaerobically prepared pooled 
donor FMT (n = 38) or autologous FMT (n = 35) via colonoscopy followed by two 
enemas over 7 days. Open-label therapy was offered to autologous FMT participants at 
8 weeks and they were followed up for 12 months. 
Main outcome and measures: The primary outcome was steroid-free remission of UC, 
defined as a total Mayo score of ≤2 with an endoscopic Mayo score of 1 or less at week 
8. Total Mayo score ranges from 0 to 12 (0 = no disease and 12 = most severe disease). 
Steroid-free remission of UC was reassessed at 12 months. Secondary clinical outcomes 
included adverse events. 
Results: Among 73 patients who were randomized (mean age, 39 years; women, 33 
[45%]), 69 [95%] completed the trial. The primary outcome was achieved in 12 of the 
38 participants (32%) receiving pooled donor FMT, compared with 3 of the 35 (9%) 
receiving autologous FMT (difference 23% [95% CI 4–42%]; OR 5.0 [95% CI 1.2–
20.1]; P = 0.03). Five of the 12 participants (42%) who achieved the primary endpoint 
at week 8 following donor FMT maintained remission at 12 months. There were three 
serious adverse events in the donor FMT group and two in the autologous FMT group. 
Conclusions and relevance: In this preliminary study of adults with mild to moderate 
UC, 1-week treatment with anaerobically prepared donor FMT, compared with 
autologous FMT, resulted in a higher likelihood of remission at 8 weeks. Further 
research is needed to assess longer-term maintenance of remission and safety.          
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UC is a chronic IBD characterized by colonic mucosal inflammation occurring at the 
interface between the luminal contents and the mucosal immune system. UC is 
increasingly common worldwide and has a high rate of persistent or relapsing 
symptoms1 characterized by bloody diarrhea, anemia, and abdominal pain. UC is 
associated with a risk of colectomy2 and an increased risk of colorectal cancer relative 
to the general population.3 Although there is growing evidence implicating the colonic 
microbiome in UC pathogenesis4,5, most therapies target the immune response rather 
than the luminal microbial environment.6 
In studies conducted since 2013, FMT was an extremely effective treatment for rCDI.7-
10 This has encouraged research examining FMT as a potential therapy for other 
diseases possibly influenced by the microbiome. FMT is proposed to treat UC by 
modifying the colonic ecosystem; however, the potential biochemical and/or immune 
mechanisms by which this may occur are unknown. FMT has demonstrated variable 
efficacy in treating active UC in three randomized clinical trials using aerobically 
prepared stool suspensions with relatively high treatment intensities.11-13 
Most colonic bacteria and archaea are obligate anaerobes, and are extremely oxygen 
sensitive; thus, they may be diminished or eliminated when stool is processed under 
aerobic conditions.14 If oxygen-sensitive organisms or their metabolites contribute to the 
clinical effect of FMT, preserving their viability may enhance the clinical effect. The 
objective of this study was to investigate whether using anaerobically prepared stool 
with a lower treatment burden would be effective at inducing remission in active UC. 
Methods 
Study design, setting, and patients 
A randomized, double-blind clinical trial of FMT that enrolled 73 patients with active 
UC was conducted between June 2013 and June 2016 at three Australian centers. 
Participants were followed for 12 months until June 2017. All participants were 18 
years of age or older and gave written informed consent. The ethics committee at each 
site approved the protocols. The full protocol appears in Appendix 2B. 
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Eligible patients had active UC with a total Mayo score15 of 3 to 10 points and an 
endoscopic subscore of ≥2. The total Mayo score is a composite of clinical and 
endoscopic markers and ranges from 0 to 12 (0 = no disease and 12 = most severe 
disease). Patients were excluded if they had severe disease defined by either a total 
Mayo score of 11 to 12 or Truelove and Witts criteria16 (passing >6 bloody stools/ day 
plus one or more of the following: temperature >37.8°C, pulse >90bpm, hemoglobin 
<10.5g/dL and erythrocyte sedimentation rate >30mm/hour). Other exclusion criteria 
were previous colonic surgery, gastrointestinal infection, pregnancy, anticoagulant 
therapy and current use of antibiotics or probiotics. 
Stable dosing of UC maintenance therapy was required prior to enrollment: 4 weeks for 
5-ASA, 6 weeks for thiopurines and methotrexate, and 8 weeks for biological agents. 
Patients could enroll taking an oral dose of prednisolone ≤25mg, with a mandatory taper 
of 5mg per week. Participants unable to cease oral prednisolone by week 8 were 
considered FMT non-responders. 
Patient screening included total Mayo score comprised of symptom and sigmoidoscopy 
assessment. Stool was collected for autologous FMT, fecal calprotectin, microbiota and 
metabolome analysis, and infective screening (microscopy, culture, and C. difficile 
toxin mRNA). Baseline Simple Clinical Colitis Activity Index score (range, 0–19, 0 = 
no symptoms, and 19 = most severe symptoms),17 medical history, demographic details, 
a survey of patient perception and acceptability of FMT, and a 3-day diet diary 
including a weighed record of all food and fluid consumed for 2 weekdays and 1 
weekend day were recorded. Blood was taken for complete blood examination, 
electrolytes, and liver function; C-reactive protein; and peripheral blood mononuclear 
cell populations.  
Donor selection and stool processing 
Donors were sought by advertisement. Strict criteria applied to potential donors to 
minimize risks of disease transmission as previously described18 (Table S5.1 in 
Supplement 2). Potential stool donors sequentially underwent a screening questionnaire, 
medical interview, and examination followed by blood and stool testing; 76 potential 
donors were screened, with 19 (25%) fulfilling the screening strategy. Stool was pooled 
and blended from three to four donors at 16 collection time points, producing 16 distinct 
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batches. Each stool batch provided treatment for one to seven participants. Treatment 
batches consisted of pooled stool (25%) blended with normal saline (65%) and glycerol 
(10%) under anaerobic conditions, and aliquoted into three containers for each recipient 
and frozen immediately at -80°C. The container for colonoscopic delivery contained 
50g of stool in 200mL and the two containers for enema delivery contained 25g of stool 
in 100mL. Autologous stool containers had identical ratios and volumes of stool, saline, 
and glycerol; however, they were processed under aerobic conditions. 
Randomization 
Accrued participants were randomized 1:1 using a computer-generated simple 
randomization algorithm (http://www.random.org) to receive either pooled donor stool 
FMT (dFMT) or autologous FMT (aFMT). The randomization and blinding procedure 
was conducted by nursing staff who were not present at FMT administration. The 
randomization record was kept in a separate document to the patient record and other 
study data such that participants and clinicians performing the procedures and assessing 
the primary and secondary endpoints were blinded to the therapy received. 
Interventions 
Participants received 3L polyethylene glycol bowel preparation the evening before and 
loperamide, 2mg orally, immediately prior to colonoscopy. At colonoscopy, 200mL of 
fecal suspension of either donor stool or autologous stool was delivered into the right 
colon. Two further 100mL aliquots of the same fecal suspension were administered by 
enema in the following 7 days. The total weight of stool administered over the three 
FMT procedures was 100g. Recipient stool samples were collected at baseline (week 0) 
and weeks 4, 8, and 52 for microbiome, metabolome, and fecal calprotectin assessment. 
Biopsies were taken at colonoscopy at weeks 0 and 8 for lamina propria mononuclear 
cell (LPMC) analysis. 
At the week 8 colonoscopy, following an assessment of the primary and secondary 
endpoints of remission, un-blinding of randomization occurred, and autologous FMT 
participants received open-label donor FMT induction by colonoscopy followed by two 
donor FMT enemas over the following 7 days. The same IBD specialized 
gastroenterologist performed and assessed both colonoscopies for each patient. 
Participants who did not undergo the week 8 assessment, required rescue therapy, or 
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were unable to wean oral steroids were considered to have not achieved the primary 
outcome of steroid-free remission. 
Outcomes 
Primary outcome 
The primary outcome was steroid-free remission of UC as defined as a total Mayo score 
of ≤2 (range, 0–12) with an endoscopic Mayo score of ≤1 (range, 0–3) at week 8. 
Secondary outcomes 
There were several secondary outcome measures. Clinical response (measured by a ≥3 
point reduction in total Mayo score at week 8 and 12 months), clinical remission 
(measured by a Simple Clinical Colitis Activity Index ≤2 at week 8 and 12 months), and 
endoscopic remission (measured by a Mayo score of <1 at week 8 and 12 months) were 
compared for participants receiving donor FMT with those receiving autologous FMT. 
Patients’ perception and acceptability of FMT were assessed using a written 
questionnaire completed by patients prior to enrollment and at 12 months (details 
appear in Supplement 2). Adverse events were assessed at week 8 and 12 months by 
patient survey. 
Changes from baseline in peripheral blood and colonic LPMC populations (assessed by 
flow cytometry) following FMT were evaluated at week 8, stratified by both change in 
total Mayo score following FMT and randomization. LPMCs were isolated 
enzymatically from left colonic biopsies and peripheral blood mononuclear cells 
isolated from blood by density gradient centrifugation as previously described19,20 and 
processed immediately for analysis of immune cell populations by flow cytometry 
(methods are detailed in Supplement 2). 
Changes in fecal-associated microbiota following FMT (at 8 weeks and 12 months) 
were assessed by 16S rRNA sequencing, stratified by both change in total Mayo score 
following FMT and randomization. The durability of engraftment of these species 
acquired following donor FMT was assessed by quantifying these species at 12 months. 
The V4 hypervariable region of the 16S rRNA gene was amplified and raw sequencing 
data processed into operational taxonomic units at 97% similarity in stool samples from 
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individual donors, pooled stool batches, and FMT recipients taken at weeks 0, 4, 8, and 
52 (methods are detailed in Supplement 2). 
Fecal SCFA analyses were not a pre-specified secondary endpoint; however, SCFA 
levels were assessed during microbiome analysis. These were performed via the tube 
filtration method using high-performance gas chromatography as previously 
described.21 
Sample size 
Sample size was calculated using a Z test with pooled variance for the difference of two 
independent proportions. The estimated remission rate in the aFMT group was set at 
26% and the remission rate in the dFMT group at 60% (based on case series22). With 64 
patients, there would be 80% power to detect a 34% difference between groups. Type 1 
error was set at 5% (2-sided). 
Statistical analysis 
Baseline demographic, medication, and dietary factors are presented using means 
(standard deviations) or frequencies (percentages) as appropriate, unless otherwise 
stated. Baseline levels of butyrate and dietary fiber were compared between donors and 
UC participants using non-parametric Mann-Whitney-Wilcox tests. Nutrient intake was 
analyzed using FoodWorks 9 software package (Xyris). 
The primary analysis compared steroid-free remission of UC at week 8 between 
treatment groups using a Fisher’s exact test. Individuals were analyzed in the group to 
which they were allocated (intention to treat). A post hoc linear mixed effects logistic 
regression was performed, estimating the effect of treatment (fixed effect) on remission. 
Non-nested random intercepts were included to account for batch effects (individuals 
receiving the same donor mix) and site effects (treating institution). Secondary 
dichotomous clinical outcomes were also compared using Fisher’s exact tests and 
identical mixed effects logistic regression models. Change in total Mayo score (week 8 
minus week 0) was assessed using linear mixed effects regression with randomization, 
baseline score, and steroid use as fixed effects and non-nested random intercepts per 
batch and site, as above. Individuals missing the week 8 Mayo assessment were 
assumed missing at random, imputed using multiple multivariate fully conditional 
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imputation by chained equations (100 imputations, 20 iterations each). In addition to the 
variables used in the mixed effects regressions (baseline Mayo score, randomized 
allocation, use of steroids, donor mix, and treating institution), patient characteristics 
(sex, age at diagnosis, and age at study entry), disease characteristics (extent of disease 
and baseline endoscopic Mayo score), and medication use (oral 5-ASA, topical 5-ASA, 
immunomodulatory drugs, and biologic drugs) were included in the imputation. 
Assessment of treatment effect on immunological markers was also assessed using 
linear mixed effects regressions with week 8 values as outcome, treatment group and 
baseline values as fixed effects. Random intercepts were included for each group of 
individuals receiving the same donor mix (batch effects), and post hoc non-nested 
random intercepts were included for each treating institution (site effects). Treatment 
effect models on immunological markers were extended to include change in Mayo 
score (week 8 minus week 0) as a fixed effect. The estimate of treatment effect on 
calprotectin and SCFAs, which underwent an extra assessment at week 4, was similarly 
modelled, but with both week 4 and week 8 assessments as outcome. Logistic mixed 
effects regressions were used to assess associations with microbiome diversity and zero-
inflated negative binomial mixed effects regressions used to assess associations with 
microbiome abundance. Organisms defined as being associated with donor FMT were 
those for which the change was statistically significant at both week 4 and week 8 with 
a P value <.01. The details of SCFA and microbiome models are presented in 
Supplement 2. 
Interactions between baseline factors and week 8 Mayo score were assessed by 
including a pairwise interaction between the factor and treatment allocation as a fixed 
effect in the mixed effects regression models with Mayo score as outcome. Similarly, 
associations between week 8 Mayo scores and change in SCFA were assessed by 
including, as fixed effects, the estimated change in SCFAs (see Supplement 2 for 
details). Associations between baseline total Mayo scores and both baseline SCFAs and 
immunological measures were assessed using linear regressions with Mayo scores as 
outcome, adjusting for oral steroid use. In these models, individuals missing week 8 
Mayo score were excluded from the analyses and the calprotectin, SFCA measures, and 
immunological markers were log transformed. Because of the small number of 
individuals missing baseline covariate data (at most n = 6), these missing values were 
imputed using cohort means. 
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For all linear models, visual inspections of residual and (for mixed effects) random 
effect distributions were performed. A two-tailed P value <.05 was considered 
significant. No adjustment for multiple testing was performed as all secondary analyses 
were considered exploratory. Analyses were performed in R version (3.5.0) using lme4, 
mice and glmmTMB packages (R Foundation for Statistical Computing). 
Results 
Between June 2013 and June 2016, 133 patients were assessed for eligibility; 73 were 
randomized, 38 to the dFMT group and 35 to the aFMT group. Three participants 
withdrew from the dFMT group and one from the aFMT group, leaving 69 participants 
who completed the week 8 assessment (Figure 5.1). Baseline patient demographics, 
clinical data, and measures of disease activity and inflammation appeared well balanced 
between the two treatment groups (Table 5.1). 
Primary outcome 
The primary endpoint of steroid-free remission was achieved in more participants who 
received donor compared with autologous FMT (12/38 [32%] vs 3/35 [9%]; difference 
23% [95% CI 4–42%], OR 5.0 [95% CI 1.2–20.1]; P = .03) (Table 5.2). 
The mean total Mayo score decreased in both groups at week 8 (aFMT, -1.2 [95% CI -
1.9 to -0.5] and dFMT, -3.5 [95% CI -4.3 to -2.7]). The change in total Mayo score for 
each participant is represented in Figure 5.2. 
Secondary outcomes 
8 weeks 
Clinical response was also observed in more participants receiving donor FMT than 
autologous FMT (21/38 [55%] vs 8/35 [23%]; difference 32% [95% CI 10–54%], OR 
4.3 [95% CI 1.5–11.9]; P = 0.007), as was clinical remission (18/38 [47%] vs 6/35 
[17%]; difference 30% [95% CI 7–51%], OR 4.5 [95% CI 1.5–13.5]; P = 0.01) (Table 
5.2). Steroid-free endoscopic remission occurred in 4 of the 38 participants (11%) 
receiving donor FMT vs 0 out of 35 (0%) receiving autologous FMT (difference 11% 
[95% CI -1% to 27%]; P = 0.12) (Table 5.2). At 8 weeks, 34 of 35 participants (97%) in 




At 12 months, 72 of 73 participants had received donor FMT, 69 of 73 (95%) were 
contactable, and 9 of 69 (13%) had undergone colectomy. Flexible sigmoidoscopy was 
performed on 26 of 38 patient (68%) randomized to the dFMT group, and 11 of 26 
(42%) were in clinical and endoscopic remission. Five of the 12 participants (42%) who 
achieved the primary endpoint of steroid-free remission at week 8 following donor FMT 
maintained remission at 12 months (Table S5.2 in Supplement 2). 
Patient acceptability 
Prior to FMT, 65 of 69 participants (94%) thought that 1-week induction therapy with 
donor FMT would be acceptable to patients with UC, compared with 57 of 60 (95%) 12 
months following FMT (Tables S5.3 and S5.4 in Supplement 2). 
Immune analysis 
Lamina propria B cell (β = 0.46 [95% CI 0.06–0.87]; P = 0.03) and dendritic cell (β = 
0.43 [95% CI0, 0.04–0.82]; P = 0.03) populations were positively associated with total 
Mayo score at baseline. Conversely, NK cells (β = -0.50 [95% CI -0.91 to -0.09]; P = 
0.02) were negatively associated with total Mayo score at baseline. However, donor 
FMT and donor FMT adjusted for total Mayo score were not significantly associated 
with change in any lamina propria cell populations at week 8 (Table S5.5 in Supplement 
2). 
Microbial diversity, abundance, and durability 
At baseline, blended donor stool showed the most microbial diversity (measured by 
operational taxonomic units), followed by individual donor stool and UC stool of 
patients with UC. Diversity increased following donor FMT, compared with autologous 
FMT, at weeks 4 and 8 (Figure 5.3 and Table S5.6 in Supplement 2). There was no 
significant association between change in total Mayo score following donor FMT and 
baseline diversity (β = 0.6 [95% CI -4.8 to 5.9]; P = 0.84) nor change in diversity at 
week 8 (β = -20.3 [95% CI -50.7 to 11.2]; P = 0.23). 
The 10 bacteria and the archaea Methanobrevibacter smithii, the increased abundance 
of which were most strongly associated with donor FMT at weeks 4 and 8, were all 
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anaerobic (Table S5.7 in Supplement 2). The abundance of these organisms remained 
relatively stable from week 4 to week 8; however, by 12 months there was variability in 
abundance of many of these organisms (Table S5.8 in Supplement 2). Increased 
abundance of Anaerofilum pentosovorans and Bacteroides coprophilus species was 




Change from baseline in-stool concentrations of butyrate and other SCFAs was not 
significantly different between treatment groups at week 4 or 8 (Table S5.10 in 
Supplement 2). Stool SCFA concentrations were not associated with any observed 
donor FMT treatment effect (Table S5.11 in Supplement 2). 
Post hoc outcomes 
We did not detect any interactions of age at diagnosis or randomization, disease 
duration, disease distribution, sex, medication use (other than oral steroid), and 
macronutrient intake with the change in total Mayo score following donor FMT (Table 
S5.12 in Supplement 2). 
Adverse events 
Week 8 
There were three serious adverse events in the dFMT group (worsening colitis, C. 
difficile colitis requiring colectomy, and pneumonia) and two serious adverse events in 
the aFMT group (both worsening colitis). 
Three participants developed new anemia (aFMT, 2; dFMT, 1), two mild elevation in 
alkaline phosphatase (aFMT, 0; dFMT, 2), and four mild elevations of alanine 
aminotransferase (aFMT, 3; dFMT, 1). Overall, there were no significant differences 
from baseline in serum creatinine, alanine aminotransferase, alkaline phosphatase, 
bilirubin, and hemoglobin at week 8 between donor and autologous FMT groups (Table 




At least one adverse event was reported by 31 of 61 (51%) of participants who 
completed the questionnaire; 13 reported worsening colitis and nine of these underwent 
colectomy. There were eight reported infections and five immune-related diseases (two 
new cases of psoriatic arthritis and one each of enteropathic arthritis, Crohn’s disease, 
and allergy to infliximab) that developed in the 12-month follow-up period. During this 
time, 13 participants reported weight gain, 8 weight loss, and 40 weight unchanged 
(Table S5.14 in Supplement 2). 
Discussion 
The main finding of this study was that a three-dose, 1-week induction course of donor 
FMT was more likely to induce clinical and endoscopic remission in participants with 
active UC at week 8 compared with autologous FMT. The study also showed a 
significant difference in favor of donor FMT for the secondary endpoints of clinical 
remission and clinical response. 
Important differences between this study and previous trials of FMT for UC are the 
short duration and low intensity of the induction regime. Paramsothy et al.13 
demonstrated efficacy of donor FMT over placebo with an intensive regime that 
involved a single colonoscopic delivery of FMT to the right colon followed by enemas 
5 days per week for 8 weeks. This is a high treatment burden that would likely limit 
applicability to practice. The other studies did not use colonoscopic delivery; Moayyedi 
et al.12 demonstrated efficacy of donor FMT over placebo using a weekly FMT enema 
for 7 weeks and Rossen et al.11 reported no significant difference between donor FMT 
and autologous FMT using a nasoduodenal infusion of FMT at weeks 0 and 6. In 
addition to being efficacious, the low-intensity regime was also considered acceptable 
to most participants; of the surveyed participants who received the short induction 
course of FMT over 1 week in this study, 95% found it to be acceptable therapy for UC. 
A unique feature of this study was the use of anaerobic stool processing, a method that 
has been previously demonstrated to preserve viable anaerobes.23 Previous FMT 
studies11-13 used aerobic stool processing methods; however, it has been demonstrated 
that many obligate anaerobes such as F. prausnitzi are lost with aerobic stool processing 
but are preserved with anaerobic stool processing.14 All of the organisms positively 
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associated with the observed treatment response in this study were anaerobes (mostly 
obligate anaerobes). Preservation of donor-derived anaerobes may explain the similar 
clinical effect seen with this low-intensity treatment study when compared with other 
protocols with more intensive regimes.12,13 The use of pooled stool increased the 
diversity of microbes in each aliquot and this may also have increased the chance that 
donor FMT contained organisms with the potential to correct a functional deficit in the 
microbiome of people with active UC. Sequencing analysis indicated that the 
abundance of organisms, that changed significantly from baseline to week 4, remained 
stable to week 8; however, abundances varied by 12 months. This pattern paralleled the 
observed treatment effect. 
To our knowledge, this is the first study to assess bacterial metabolites as well as 
mucosal and blood immune cell populations following FMT in UC. These are 
exploratory (hypothesis-generating) analyses conducted to explore potential mechanistic 
effects of FMT. There was no correlation between stool butyrate concentrations and 
either donor FMT effect or disease activity of UC. There was a significant association 
between mucosal immune populations and disease activity; however, there was no 
significant correlation between mucosal immune populations and donor FMT. It is 
plausible that the treatment effect of donor FMT resulted from the acquisition of 
metabolic functional capacity from donor microorganisms and was not driven by a 
primary immunological effect; however, further dedicated studies are required to 
validate these findings. 
Limitations 
This study has several limitations. First, the 12-month data are limited by the crossover 
design, being open-label, and incomplete ascertainment, and therefore are observational 
only. Second, there was a significant loss of follow-up at 12 months compared with 8 
weeks. Third, because of both power limitations and the risk of type 1 error, secondary 
outcome and subgroup analyses should be considered exploratory. Fourth, central video 
reading of colonoscopy was not undertaken; however, autologous stool is a more 
effective blind to the endoscopist and preferable to water-based placebo stool used in 
previous trials.12,13 Fifth, there was not a pre-specified antibiotic “washout period” prior 
to study entry. It is therefore possible that some participants took antibiotics prior to the 
trial and this might have biased the initial microbiome assessment. Sixth, stool handling 
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was not under completely anaerobic conditions outside of the anaerobic chamber. 
However, the processing methods used in this study have been demonstrated to preserve 
the viability of anaerobic organisms.23 Seventh, the study was not powered to assess 
safety and thus further larger studies are required to assess this. 
Conclusions 
In this preliminary study of adults with mild to moderate ulcerative colitis, 1-week 
treatment with anaerobically prepared donor FMT, compared with autologous FMT, 
resulted in a higher likelihood of remission at 8 weeks. Further research is needed to 
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Figure 5.1: Flow of patients in randomized clinical trial of FMT for UC 
Abbreviations: SCCAI, Simple Clinical Colitis Activity Index. 
  
133 Patients assessed for eligibility 
60 Excluded 
19 Not ulcerative colitis 
11 Endoscopic Mayo score <2 
2 Stool infection 
9 Not meeting other criteria 
9 Declined to participate 
10 Other reasons 
73 Randomized 
  
38 Allocated to donor FMT 
 38 Received allocated intervention 
  
35 Allocated to autologous FMT 
 35 Received allocated intervention 
  
1 Withdrew 
 1 Worsening colitis (rescue 
therapy) 
3 Withdrew 
 1 Clostridium difficile colitis 
(colectomy) 
 1 Worsening colitis (rescue therapy) 
 1 Declined colonoscopy at 8 weeks 
35 Assessed at week 8 
  
34 Assessed at week 8 
  
12-month assessment 
17 Underwent sigmoidoscopy 
20 Completed SCCAI diary 
38 Included in primary analysis at week 8 




26 Underwent sigmoidoscopy 




Figure 5.2: Parallel line plot depicting change in total Mayo score for individual 
patients 
For each participant a line starts at their baseline total Mayo score and finishes at their 
week 8 Mayo score. Boxplots of baseline (pre) and week 8 (post) Mayo scores per 
treatment group present the median and interquartile range (IQR = 25th to 75th 
percentiles) with whisker length equal to 1.5 IQR. 






Figure 5.3: Colonic bacterial diversity in UC patients 
Data are shown at baseline, 4 and 8 weeks after either donor or autologous FMT; 
combined groups at 12 months; donors and donor stool mixes. Diversity was assessed 
as the percentage of the total number of identified species. 





Table 5.1: Baseline characteristics of the study groups 
 Donor FMT 
(n = 38) 
Autologous FMT 
(n = 35) 
Female participants 18 (47) 15 (43) 
Male participants 20 (53) 20 (57) 
Age at diagnosis, median (IQR) 30.5 (22–48) 29 (21–39) 
Age at randomization, median (IQR) 38.5 (28–52) 35 (25–46) 
Duration of disease (years), median (IQR) 4.9 (1.6–9.6) 5.8 (2.4–11) 
Left-sided disease extenta 23 (61) 22 (63) 
Total Mayo scoreb, mean (SD) 7.2 (1.7) 7.4 (1.9) 
Medication, no. (%)   
Oral steroids 8 (21) 11 (31) 
5-ASA oral 33 (87) 24 (69) 
5-ASA topical 11 (29) 7 (20) 
Immunomodulatorc 14 (37) 15 (43) 
Biologicsd 3 (8) 4 (11) 
Inflammatory markers, median (IQR)   
CRP (mg/L) 2.8 (1.3–7.2) 2.3 (0.8–10) 
WBC count (×109/L) 6.2 (5.3–7.3) 7.9 (6.1–8.9) 
Fecal calprotectin (mg/kg) 566.5 (372.5–2687.5) 774 (221–1768) 
Diete, mean (SD)   
Protein (g) 97 (38) 109 (42) 
Carbohydrate (g) 230 (70) 221 (102) 
Total fat (g) 76 (33) 86 (34) 
Saturated fat (g) 29 (16) 32 (15) 
Sugars (g) 90 (36) 103 (74) 
Starch (g) 139 (56) 115 (54) 
Fiber (g) 19 (8) 21 (8) 
Calcium (mg) 700 (467) 718 (447) 
Iron (g) 11.1 (6.5) 10.8 (4.4) 
Energy (kj) 8742 (2574) 9049 (3111) 
Sulphate (mg) 1768 (2110) 2073 (3191) 
Abbreviations: IQR, interquartile range; SD, standard deviation; 5-ASA, 5-aminosalicylate; CRP, C-
reactive protein; WBC, white blood cell; g, grams; mg, milligrams; kg, kilograms; kj, kilojoules; L, litres. 
N (%) unless otherwise specified. 
a Left-sided disease extent defined as disease not extending proximal to the splenic flexure. 
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b Total Mayo score is a composite of clinical and endoscopic parameters. It ranges from 0 to 12; clinical 
remission £2; mild disease 3–6, moderate disease 7–10, severe disease 11–12. 
c Immunomodulators were either azathioprine or 6-mercaptopurine. 
d Biologics were either infliximab or vedolizumab. 





Table 5.2: Outcome measures comparing donor FMT with autologous FMT at week 8 
a Absolute percentage gain refers to donor FMT over autologous FMT. 
b P value applies to odds ratio. 
c The primary and secondary outcomes at week 8 between treatment groups were assessed on an intention to treat basis using a Fisher’s exact test. A post hoc logistic 
mixed effects analysis was performed estimating the effect of treatment (fixed effect) on remission. Non-nested random intercepts were included to account for batch 
effects (individuals receiving the same donor mix) and site effects (treating institution). 
dSteroid-free remission was defined as a total Mayo score of ≤2 (range 0–12) with an endoscopic Mayo score of ≤1 (range 0–3). 
 Donor FMT 
(n = 38) 
Autologous FMT 
(n = 35) 
Absolute percentage gain 
over autologous FMTa 
(%) [95% CI] 
Mixed effects odds 
ratio [95% CI] 
P valueb 
 No. (%)    
Primary outcomec 
Steroid-free remission of UC at 
week 8d 
12/38 (32) 3 /35 (9) 23 [4 to 42] 5.0 [1.2–20.1] .03 
Secondary outcomesc	
Clinical responsee 21/38 (55) 8/35 (23) 32 [10 to 54] 4.3 [1.5–11.9] .007 
Clinical remissionf 18/38 (47) 6/35 (17) 30 [7 to 51] 4.5 [1.5–13.5] .01 
Endoscopic remissiong 4/38 (11) 0/35 (0) 11 [-1 to 27] h .12 
Other outcomes	
Mean change in total Mayo score 
from week 0 to week 8 (SD) 
-1.2 (2.1) -3.5 (2.5) -33 [-48 to -17] -2.4 [-3.5 to -1.2] <.001 
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eClinical response was measured by a ≥3 point reduction in total Mayo score at week 8. 
fClinical remission was measured by a Simple Clinical Colitis Activity Index score ≤2 at week 8. 
gEndoscopic remission was measured by a Mayo score of < 1 at week 8. 
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Table S5.1: Donor screening criteria 
Medical interview (exclusions) 
Age: <18 or >65 
Antimicrobial therapy or probiotics in the past 6 months  
Active medical illness or symptoms 
Any medications (other than oral contraceptive pill) 
International travel in last 1 months to areas at high risk of traveler’s diarrhea 
High-risk sexual activity (unprotected sex in last 1 month outside of a monogamous relationship) 
Illicit drug use 
Known HIV or viral hepatitis exposure in the last 12 months 
Incarceration or a history of incarceration 
Medical history and examination (exclusions) 
Any gastrointestinal disorder 
Obesity (BMI >30), hypertension, type 2 diabetes and dyslipidaemia 




Infection with HIV, syphilis, hepatitis B or C 
Malignancy 
Chronic pain syndromes, neurologic or neurodevelopmental disorders 
Blood screening 
Full blood count 
Electrolytes, urea and creatinine 
Liver function tests 
Human T cell lymphotropic virus 1 and 2 serology  
Epstein Barr virus IgM and IgG 
Cytomegalovirus IgM and IgG 
Syphilis (rapid plasma reagin) 
Strongyloides stercoralis, Entamoeba histolytica, Helicobacter pylori serology 
Hepatitis A virus IgM 
Hepatitis B surface antigen and core antibody, hepatitis C virus antibody 
HIV PCR  
Fasting lipids and blood sugar level 
C-reactive protein and erythrocyte sedimentation rate 
Stool screening 
Microscopy and culture 
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Clostridium difficle toxin PCR 
Egg, cysts and parasites (including Cryptosporidium spp., Giardia spp., Dientamoeba fragilis and 




Table S5.2: Twelve-month clinical follow-up of UC patients 




Remission and no UC 
symptoms since donor 
FMT 
  Number (%) 
Clinical and endoscopic 
remissiona  
dFMT 11/26 (42) 4/26 (7) 
aFMTb 10/17 (58) 5/17 (29) 
Combined 21/43 (49) 9/43 (21) 
Clinical remissionc  dFMT 18/29 (62) 5/29 (17) 
aFMTb 9/20 (45) 4/20 (20) 
Combined 27/49 (55) 9/49 (18) 
Endoscopic remissiond  dFMT 4/26 (15) 1/26 (4) 
aFMTb 4/17 (23) 3/17 (18) 
Combined 8/43 (19) 4/43 (9) 
Clinical and endoscopic 
remission at week 8 in 
dFMT group (n = 12)a 
 5/12 (42) 3/12 (25) 
a Clinical and endoscopic remission was defined as a total Mayo score ≤2 and endoscopic Mayo score ≤1. 
b Because of FMT patients crossing over at 8 weeks, 72 of 73 study patients received donor FMT after the 
8-week time point. 
c Clinical remission was defined as a Simple Clinical Colitis Activity Index score ≤2. 
d Endoscopic remission was defined as an endoscopic Mayo score equal to 0.	 	
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Table S5.3: Patient survey of perception and acceptability of FMT prior to 
undergoing FMT 








Do you believe that FMT is 
likely to help with your 
symptoms? 
(n = 69) 
0 (0) 0(0) 25 (36) 36 (52) 8 (12) 4 
Do you consider that FMT 
is likely to be safe? 
(n = 69) 
0(0) 0(0) 10 (14) 45 (65) 14 (20) 4 
Do you consider that 5-ASA 
medication (e.g. 
sulfasalazine, mesalazine) is 
likely to be safe? 
(n = 69) 
6 (9) 7 (10) 18 (26) 26 (38) 12 (17) 4 
Do you consider that steroid 
medication (e.g. 
prednisolone) is likely to be 
safe? 
(n = 69) 
9 (13) 33 (48) 13 (19) 12 (17) 2 (3) 4 
Do you consider that 
thiopurine medication (e.g. 
azathioprine/ 6-
mercaptopurine) is likely to 
be safe? 
(n = 68) 
3 (4) 31 (46) 22 (32) 10 (15) 2 (3) 5 
Do you consider that 
methotrexate medication is 
likely to be safe? 
(n = 67) 
3 (4) 20 (30) 41 (61) 3 (4) 0(0) 6 
Do you consider that anti-
TNF medication (e.g. 
infliximab/adalimumab) is 
likely to be safe? 
(n = 68) 
6 (9) 12 (18) 45 (66) 5 (7) 0(0) 5 
Do you consider that 
surgical removal of the 
colon is likely to be safe? 
(n = 69) 




Table S5.3: Patient survey of perception and acceptability of FMT prior to 
undergoing FMT (continued) 
Question Number (% of responders) No response 
Yes No Unsure 
Do you believe FMT as carried out 
in this study would be seen as 
acceptable by the general 
Australian population? 
(n = 66) 
29 (44) 9 (14) 28 (42) 7 
Do you believe FMT as carried out 
in this study would be seen as 
acceptable by patients with 
ulcerative colitis? 
(n = 68) 
65 (96) 0 (0) 3 (4) 5 
Do you have any cultural or 
religious concerns about receiving 
fecal material from another 
person? 
(n = 68) 
0 (0) 65 (96) 3 (4) 5 
Do you have any concerns about 
discussion FMT with friends or 
family? 
(n = 63) 




Table S5.4: Patient survey of perception and acceptability of FMT 12 months after 
donor FMT (continued) 
Question Number (% of responders) No 
response 
Not at all Yes (at all) Yes a 
little 
Yes a lot Unsure 
Do you believe that 
FMT helped with 
your symptoms at 
least temporarily? 
(n = 61) 
17 (28) 38 (62) 17 (28) 21 (34) 6 (10) 12 






Has your medication 
requirement 
decreased or 
increased in the 12 
months since FMT?  
(n = 60) 
10 (17) 18 (30) 30 (50) 2 (3) 0(0) 13 
Has the amount of 
steroid medication 
changed in the 12 
months post FMT 
compared to the 12 
months prior? 
(n = 60) 
7 (12) 25 (42) 12 (20) 2 (3) 14 (23) 13 
 Impossible Not likely Unsure Quite 
likely 
Very likely No 
response 
Do you consider that 
FMT is likely to be 
safe? 
(n = 60) 




Table S5.4: Patient survey of perception and acceptability of FMT 12-months after 
donor FMT (continued) 
Question Number (% of responders) No response 
Yes No Unsure 
Do you believe FMT as carried out in 
this study would be seen as acceptable by 
the general Australian population? 
(n = 59) 
30 (52) 8 (14) 21 (36) 14 
Do you believe FMT as carried out in 
this study would be acceptable to 
patients with ulcerative colitis? 
(n = 60) 
57 (95) 0 3 (5) 13 
Do you have any cultural or religious 
concerns about receiving fecal material 
from another person? If yes, what are 
your concerns? 
(n = 57) 
1 (2) 56 (98)  16 
Do you have any concerns about 
discussing FMT with friends or family? 
(n = 60) 
5 (8) 55 (92)  13 
Have you required hospitalization in the 
12 months after FMT? 
(n = 61) 
18 (30) 43 (70)  12 
Did you require surgery (colectomy) for 
your ulcerative colitis since your FMT? 
(n = 69) 










Baseline total Mayo Score Mayo change from baseline to 
week 8 
Donor FMT treatment Donor FMT adjusted for 
total Mayo score 
Est [95% CI] P value Est [95% CI] P value Est [95% CI] P value Est [95% CI] P value 
Lamina propria mononuclear cells 
γδ T cell CD3+ gamma 
delta T+ 
-0.17 
[-0.65 to 0.31] 
.48 -0.3 
[-1 to 0.41] 
.42 -0.51 
[-1.2 to 0.19] 
.16 -0.49 







[-0.91 to -0.099] 
.02 -0.39 
[-0.84 to 0.05] 
.11 0.022 
[-0.74 to 0.78] 
.95 -0.25 




CD3+ NKT+ -0.21 
[-0.66 to 0.25] 
.36 -0.43 
[-1 to 0.15] 
.18 -0.43 
[-1.1 to 0.23] 
.2 -0.47 
[-1.2 to 0.26] 
.21 
Memory T cell CD3+ve 
CD45RO+ve 
0.34 
[-0.16 to 0.83] 
.18 0.18 
[-0.61 to 0.97] 
.66 -0.21 
[-0.65 to 0.23] 
.35 0.05 
[-0.4 to 0.5] 
.83 
B cells CD19+/CD20+ 
CD45RO- 
0.46 
[0.057 to 0.87] 
.03 0.67 
[0.13 to 1.2] 
.03 -0.053 
[-0.82 to 0.71] 
.89 0.37 






[-0.26 to 0.77] 
.33 -0.00032 
[-0.61 to 0.61] 
1 -0.36 
[-0.9 to 0.19] 
.20 -0.22 






[0.042 to 0.82] 
.03 0.36 
[-0.08 to 0.81] 





Helper T cell cd4 scc+ 0.11 
[-0.34 to 0.57] 
.62 -0.8 
[-1.4 to -0.19] 
.03 -0.17 
[-0.63 to 0.29] 
.47 -0.31 




cd8 scc+ -0.28 
[-0.75 to 0.19] 
.24 -0.62 
[-1.2 to -0.026] 
.08 -0.32 
[-1.2 to 0.54] 
.46 -0.37 








Baseline total Mayo Score Mayo change from baseline to 
week 8 
Donor FMT treatment Donor FMT adjusted for 
total Mayo score 






[-0.13 to 1] 
.13 1.1 
[0.27 to 2] 
.03 -0.21 
[-0.73 to 0.3] 
.41 -0.056 
[-0.59 to 0.48] 
.84 







[-0.45 to 0.34] 
.78 0.01 
[-0.57 to 0.59] 
.97 0.47 
[0.053 to 0.88] 
.03 0.45 









[-0.7 to 0.76] 
.94 0.41 
[-0.58 to 1.4] 
.44 -0.12 
[-0.6 to 0.36] 
.61 -0.056 





Table S5.6: Microbial diversity comparisons 
Comparison of diversity (number of operational taxonomic units) Odds ratio (95% CI) P value 
Baseline UC patients vs individual stool donors 0.65 (0.53 to 0.80) <.001 
Pooled donor stool vs individual donor stool 1.89 (1.44 to 2.48) <.001 
UC patients week 4 dFMT vs aFMT 1.35 (1.11 to 1.64) .002 
UC patients week 8 dFMT vs aFMT 1.31 (1.08 to 1.60) .006 
UC patients at 12 months following open-label donor FMT vs baseline  1.17 (1.10 to 1.24) <.001 
UC patients at 4 weeks following aFMT vs baseline 0.92 (0.89 to 0.96) <.001 
UC patients at 8 weeks following aFMT vs baseline 0.94 (0.90 to 0.98) .001 




Table S5.7: Organisms associated with a change in abundance following donor FMT as compared to autologous FMT at weeks 4 
and 8 (cut off P £ .01 at weeks 4 and 8) 
Species Family Phylum 
Week 4 log change 
abundance b [95% CI] 
Week 4 P 
value 
Week 8 log change 
abundance b [95% CI] 
Week 8 P 
value 
Association with increased abundance following donor FMT    
Peptococcus niger Peptococcaceae 1 Firmicutes 4.95 [3.18 to 6.73] <.001 4.6 [2.86 to 6.34] <.001 
Faecalicoccus 
pleomorphus Erysipelotrichaceae Firmicutes 3.77 [2.17 to 5.37] <.001 3.07 [1.47 to 4.68] <.001 
Olsenella sp. Coriobacteriaceae Actinobacteria 3.07 [1.96 to 4.17] <.001 2.41 [1.33 to 3.49] <.001 
Acidaminococcus intestini Acidaminococcaceae Firmicutes 1.76 [0.73 to 2.8] <.001 2.27 [1.23 to 3.31] <.001 
Senegalimassilia 
anaerobia Coriobacteriaceae Actinobacteria 1.9 [0.88 to 2.92] <.001 2.03 [1.02 to 3.04] <.001 
Prevotella copri Prevotellaceae Bacteroidetes 2.16 [1.01 to 3.32] <.001 2.03 [0.86 to 3.2] <.001 
Methanobrevibacter 
smithii Methanobacteriaceae Euryarchaeota 1.78 [0.57 to 3] .004 1.65 [0.44 to 2.86] .008 
Clostridium 
methylpentosum Ruminococcaceae Firmicutes 2.03 [0.95 to 3.11] <.001 1.57 [0.49 to 2.66] .004 
Alistipes indistinctus Rikenellaceae Bacteroidetes 1.58 [0.67 to 2.5] <.001 1.49 [0.58 to 2.4] .001 
Slackia 
isoflavoniconvertens Coriobacteriaceae Actinobacteria 1.44 [0.55 to 2.32] .002 1.44 [0.54 to 2.33] .002 
Odoribacter splanchnicus 
strain Porphyromonadaceae Bacteroidetes 1.18 [0.38 to 1.97] .004 1.07 [0.26 to 1.87] .009 
Association with reduced abundance following donor FMT    
Anaerostipes caccae Lachnospiraceae Firmicutes -2.78 [-4.36 to -1.21] <.001 -2.53 [-4.23 to -0.84] .003 
Gordonibacter pamelaeae Coriobacteriaceae Actinobacteria -1.46 [-2.37 to-0.54] .002 -1.7 [-2.65 to -0.76] <.001 
Clostridium aldenense Lachnospiraceae Firmicutes -1.38 [-2.31 to-0.45] .004 -1.4 [-2.36 to -0.44] .004 
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Table S5.8: Log change from baseline abundance following donor FMT at weeks 4, 8 and 12 months in the species listed in Table 
S5.7 



















Positive associations (increase in species following donor FMT) 
Peptococcus niger Peptococcaceae Firmicutes 4.05 [2.76 to 
5.34] 
<.001 3.79 [2.57 to 
5] 
<0.001 4.05 [2.49 to 
5.6] 
<.001 
Faecalicoccus pleomorphus Erysipelotrichaceae Firmicutes 3.22 [2.07 to 
4.38] 
<.001 2.37 [1.23 to 
3.5] 
<0.001 1.93 [0.48 to 
3.39] 
.009 
Olsenella sp. Coriobacteriaceae Actinobacteria 2.17 [1.38 to 
2.96] 
<.001 1.59 [0.81 to 
2.36] 
<0.001 1.22 [0.24 to 
2.19] 
.01 
Acidaminococcus intestini Acidaminococcaceae Firmicutes 1.06 [0.34 to 
1.79] 
.004 1.1 [0.38 to 
1.83] 
0.003 1.19 [0.24 to 
2.15] 
.01 
Senegalimassilia anaerobia Coriobacteriaceae Actinobacteria 1.62 [0.9 to 
2.34] 
<.001 1.69 [0.95 to 
2.42] 
<0.001 0.71  
[-0.21 to 1.64] 
.13 
Prevotella copri Prevotellaceae Bacteroidetes 1.69 [0.88 to 
2.51] 
<.001 2.08 [1.26 to 
2.91] 
<0.001 1.99 [0.89 to 
3.1] 
<.001 
Methanobrevibacter smithii Methanobacteriaceae Euryarchaeota 1.32 [0.46 to 
2.17] 
.002 1.03 [0.18 to 
1.88] 
0.02 0.46  
[-0.67 to 1.58] 
.43 
Clostridium methylpentosum Ruminococcaceae Firmicutes 0.87 [0.1 to 
1.64] 
.03 0.83 [0.05 to 
1.61] 
0.04 1.14 [0.15 to 
2.12] 
.02 
Alistipes indistinctus Rikenellaceae Bacteroidetes 0.93 [0.29 to 
1.58] 
.004 0.68 [0.04 to 
1.31] 
0.04 1.29 [0.45 to 
2.12] 
.002 
Slackia isoflavoniconvertens Coriobacteriaceae Actinobacteria 0.8 [0.17 to 
1.42] 
.01 0.79 [0.15 to 
1.43] 
























Odoribacter splanchnicus Porphyromonadaceae Bacteroidetes 0.29 [-0.27 to 
0.85] 
.31 0.52 [-0.04 to 
1.08] 
0.07 0.91 [0.19 to 
1.63] 
.01 
Negative associations (decrease in species following donor FMT) 
Anaerostipes caccae Lachnospiraceae Firmicutes -2.24 [-3.47 to 
-1.01] 
<.001 -2.43 [-3.74 
to -1.11] 
<0.001 1.98 [0.69 to 
3.26] 
.003 
Gordonibacter pamelaeae Coriobacteriaceae Actinobacteria -0.99 [-1.65 to 
-0.33] 
.003 -1.39 [-2.08 
to -0.7] 
<0.001 -0.28 [-1.18 to 
0.62] 
.54 
Clostridium aldenense Lachnospiraceae Firmicutes -0.9 [-1.59 to -
0.21] 
.01 -1.15 [-1.86 
to -0.44] 






Table S5.9: Organisms whose change in abundance (a) was associated with change in total Mayo score and (b) differed by 
treatment 
Species Family Phylum 












Species associated with Mayo score decrease (disease improvement) 
   
Anaerofilum pentosovorans Ruminococcaceae Firmicutes -1.08 [-1.51 to -0.64] <.001 1.41 [0.51 to 2.32] .002 
Bacteroides coprophilus Bacteroidaceae 
Bacteroidete
s -0.89 [-1.23 to -0.55] <.001 2.84 [0.14 to 5.53] .04 
Clostridium methylpentosum Ruminococcaceae Firmicutes -0.63 [-1.1 to -0.15] .01 1.84 [0.97 to 2.72] <.001 
Acidaminococcus intestini 
Acidaminococcace
ae Firmicutes -0.55 [-1.01 to -0.08] .03 1.93 [1.14 to 2.73] <.001 
Senegalimassilia anaerobia Coriobacteriaceae 
Actinobacteri
a -0.51 [-1.01 to -0.01] .05 1.84 [0.97 to 2.72] <.001 




saccharivoransc Lachnospiraceae Firmicutes 0.58 [0.07 to 1.09] .03 -0.67 [-1.11 to -0.23] .003 
Paraprevotella xylaniphilad Prevotellaceae 
Bacteroidete
s 0.5 [0.11 to 0.89] .02 0.83 [0.04 to 1.63] .04 
a 
Total Mayo change was defined as the change in total Mayo score per standard deviation in log abundance of organism (cut off p £ .05). 
b 
Treatment difference log change was defined as organisms associated with a change in abundance following donor FMT as compared to autologous FMT at weeks 4 
and 8 (cut off p £ 0.05). 
c 
Treatment caused Fusicatenibacter saccharivorans to decrease and thereby was associated with a higher Mayo score. 
d 
Only Paraprevotella xylaniphila was associated in the incorrect direction, i.e., it increased after treatment and was positively associated with Mayo score change. 
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Table S5.10: Change in SCFA levels from baseline at weeks 4 and 8 in donor and 
autologous FMT groups 
Short chain 
fatty acid 
Autologous FMT Donor FMT Treatment 
effect P value 
Week 4 vs 0 
% baseline 
[95% CI] 
Week 8 vs 0 
% baseline 
[95% CI] 
Week 4 vs 0 
% baseline 
[95% CI] 




[89.6 to 145.1] 
88.8 
[70.0 to 112.5] 
98.5 
[77.7 to 124.8] 
107.4 
[85.3 to 135.0] 
.75 
Propionate 126.7 
[96.6 to 166.0] 
104.2 
[79.8 to 136.1] 
130.1 
[98.4 to 171.9] 
147.8 
[112.5 to 194.2] 
.34 
Butyrate 134.1 
[99.3 to 181.0] 
99.0 
[73.7 to 132.9] 
86.4 
[64.3 to 116.1] 
97.8 
[73.5 to 130.2] 
.47 
Iso-butyrate 142.3 [108.2 to 
187.1] 
107.7 
[82.2 to 140.9] 
93.7 
[70.9 to 123.9] 
115.0 
[87.6 to 150.9] 
.11 
Valerate 90.3 
[64.3 to 126.9] 
81.6 
[58.4 to 114.2] 
119.3 
[85.5 to 166.6] 
142.9 
[103.2 to 197.8] 
.41 
Iso-valerate 136.8 
[102.2 to 182.9] 
95.8 
[72.0 to 127.6] 
93.7 
[69.5 to 126.3] 
113.1 
[84.5 to 151.3] 
.46 
Caproate 108.7 
[79.8 to 148.1] 
89.3 
[65.9 to 121.1] 
125.9 







Table S5.11: Associations between total Mayo score at baseline and change in 
Mayo score with SCFA levels (at baseline and change respectively) 
  Baseline Mayo Mayo change 
  Est [95% CI] P value Est [95% CI] P value 
Acetate -0.015 [-0.45 to 0.42] .95 -0.23 [-1.3 to 0.83] .67 
Propionate -0.0092 [-0.36 to 0.35] .96 -0.19 [-0.98 to 0.6] .64 
Butyrate -0.036 [-0.38 to 0.3] .83 -0.14 [-1 to 0.75] .75 
Iso-butyrate 0.024 [-0.35 to 0.39] .90 -0.42 [-1.3 to 0.5] .38 
Valerate -0.078 [-0.42 to 0.26] .65 -0.39 [-1.3 to 0.55] .42 
Iso-valerate 0.027 [-0.34 to 0.4] .88 -0.48 [-1.3 to 0.37] .27 




Table S5.12: The mean change in Mayo score for the two treatment groups for 
each baseline factor, and the linear mixed effects regression estimated P value for 
the pairwise interactiona 
  
Mayo score change Interaction   
Autologous FMT Donor FMT LME P value 
Sex Male -1.2 (2.0) -3.4 (2.6) .79  
Female -1.2 (2.4) -3.7 (2.4) 
 
Age at diagnosis (years) Younger -1.4 (2.1) -3.6 (2.5) .77  
Older -1.1 (2.3) -3.4 (2.6) 
 
Age at randomization (years) Younger -1.9 (2.0) -3.8 (2.4) .12  
Older -0.5 (2.1) -3.3 (2.7) 
 
Duration of disease (years) Shorter -1.6 (1.7) -3.2 (2.9) .1  
Longer -0.9 (2.5) -3.8 (2.1) 
 
Disease extent Pancolitis -0.8 (2.0) -3.7 (2.5) .34  
Left-sided -1.5 (2.2) -3.4 (2.6) 
 
Oral steroids No -1.6 (1.9) -3.1 (2.3) .01  
Yes -0.5 (2.5) -5.7 (2.5) 
 
5-ASA oral No -1.3 (2.4) -2.2 (1.7) .34  
Yes -1.2 (2.1) -3.7 (2.6) 
 
5-ASA topical No -1.2 (2.2) -3.5 (2.5) .99  
Yes -1.4 (1.8) -3.7 (2.7) 
 
Immunomodulator No -1.5 (2.1) -3.5 (2.9) .61  
Yes -0.9 (2.2) -3.5 (1.9) 
 
Biologics No -1.1 (2.0) -3.5 (2.6) .97  
Yes -2.0 (3.2) -4.0 (1.0) 
 
CRP (mg/L) Low -1.5 (1.9) -3.4 (2.1) .35 
 High -0.9 (2.4) -3.6 (2.9)  
WBC (×109/L) Low -1.7 (2.0) -3.6 (2.2) .97 
 High -1.0 (2.2) -3.3 (3.1)  
Calprotectin (mg kg) Low -1.4 (1.9) -3.2 (2.4) .23 
 High -1.1 (2.3) -3.9 (2.7)  
Protein (g) Low -1.0 (1.9) -3.5 (2.8) .25 
 High -1.4 (2.4) -3.6 (2.2)  
Carbohydrate (g) Low -1.2 (2.3) -3.4 (3.0) .49 
 High -1.3 (1.9) -3.6 (2.0)  
Total fat (g) Low -1.1 (2.4) -3.5 (2.8) .43 
 High -1.3 (1.9) -3.6 (2.2)  




Mayo score change Interaction   
Autologous FMT Donor FMT LME P value 
 High -1.1 (1.7) -3.4 (2.2)  
Sugars (g) Low -1.4 (2.4) -3.8 (3.1) .91 
 High -1.1 (1.8) -3.2 (1.9)  
Starch (g) Low -0.7 (1.9) -3.9 (3.0) .47 
 High -1.9 (2.2) -3.2 (2.1)  
Fiber (g) Low -1.1 (1.8) -3.5 (2.8) .63 
 High -1.3 (2.4) -3.6 (2.2)  
Calcium (mg) Low -1.1 (1.7) -3.3 (2.7) .16 
 High -1.4 (2.6) -3.7 (2.4)  
Iron (g) Low -0.9 (1.4) -3.3 (2.8) .87 
 High -1.5 (2.7) -3.7 (2.2)  
Energy (kj) Low -1.4 (2.2) -3.2 (3.1) .25 
 High -1.1 (2.1) -3.8 (1.9)  
Emulsifier Low -0.8 (1.9) -3.7 (3.0) .45 
 High -1.9 (2.3) -3.3 (1.9)  
Sulphate Low -1.4 (2.2) -4.1 (3.0) .38 
 High -1.0 (2.1) -2.9 (1.8)  
Abbreviations: LME, linear mixed effects; CRP, C-reactive protein; WBC, white blood cell. 




Table S5.13: Mean blood measures at baseline and week 8 and the comparison in 
the change over time between treatment groups 
  
Mean (%)  
Autologous FMT Donor FMT   
  Week 0 Week 8 Week 0 Week 8 P value 
Haemoglobin (g/L) 142.1 (17.6) 141 (21.6) 137.2 (16.9) 138.1 (15.7) .55 
Creatinine (umol/L) 74.9 (18.1) 75.9 (18.2) 74.2 (14.5) 75.3 (14.9) .52 
Bilirubin (umol/L) 14.7 (9.3) 13.4 (8) 13.9 (7.2) 13.9 (6) .43 
Alkaline phosphatase (U/L) 76.8 (29.2) 80.7 (59.3) 80.8 (26.3) 84.8 (35.7) .72 
Alanine aminotransferase (U/L) 23.7 (9) 30 (19.7) 25.1 (13.3) 32.6 (43.5) .73 
White blood cells (×10*9/L) 7.7 (2.4) 7.2 (2.6) 6.6 (2.3) 6.2 (1.9) .42 
Neutrophils (×10*9/L) 6.5 (8.7) 6.5 (10.9) 4.2 (1.8) 3.9 (1.7) .54 




Table S5.14: Twelve-month adverse events 
Adverse effects 
Number (%) 
(n  =  61) 
Worsening colitis  13 (21) 
Colectomy 9 (15) 
No colectomy 4 (7) 
Weight gain 13 (21) 
Weight loss 8 (13) 
Fecal incontinence 2 (3) 
Infections  
Influenza  2 (3) 
Clostridium difficile infection 2 (3) 
Sinusitis 1 (2) 
Pneumonia 1 (2) 
Wisdom tooth infection 1 (2) 
Respiratory virus 1 (2) 
Immune related  
Psoriatic arthritis 2 (3) 
Crohn’s disease 1 (2) 
Enteropathic arthritis 1 (2) 
Allergic reaction to infliximab 1 (2) 
Dermatitis 1 (2) 
Back pain 1 (2) 
Skin petechiae 1 (2) 
Urinary hesitancy 1 (2) 
Asthma 1 (2) 
Diverticulitis 1 (2) 
Oesophageal dysmotility 1 (2) 
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Table S5.15: Fecal calprotectin level relative to baseline at week 4 and week 8 (log transformed) 
  % of baseline fecal calprotectin [95% CI] P value 
Donor FMT Week 4 47.0 [23.3, 94.6] .03 
Week 8 44.1 [22.4, 87.2] .02 
Placebo FMT Week 4 81.8 [41.2, 162.2] .56 




Table S5.16: Baseline and week 8 data for patients randomized to autologous FMT 































by week 8 
1 Male Pancolitis 2 6 2 7 No No No No Prednisolone, 
mesalazine 
No 
4 Female Pancolitis 2 9 2 9 No No No No Prednisolone, 6-
mercaptopurine 
No 
6 Female Pancolitis 3 8 3 8 No No No No Mesalazine, 
azathioprine 
No 
7 Male Left-sided 2 7 2 7 No No No No Prednisolone, 
mesalazine 
No 




10 Female Left-sided 2 5 2 5 No No No No Budesonide No 
11 Male Pancolitis 2 7 2 7 No No No No Sulfasalazine No 





19 Male Left-sided 2 4 1 3 No No No No Azathioprine No 









































by week 8 
23 Male Pancolitis 2 8 2 7 No No No No Mesalazine No 









28 Male Left-sided 3 10 2 9 No No No No Azathioprine No 




35 Male Left-sided 2 6 2 7 No No No No Budesonide, 
topical steroid 
No 
37 Male Pancolitis 2 7 2 4 No Yes Yes No Mesalazine No 
38 Female Pancolitis 2 9 n/a 9 No No No No Azathioprine No 
39 Female Left-sided 2 8 1 3 No No No No Prednisolone, 
mesalazine 
No 
43 Female Pancolitis 3 10 2 4 No Yes Yes No Azathioprine, 
infliximab 
No 
44 Male Left-sided 3 10 3 9 No No No No Prednisolone, 6-
mercaptopurine 
No 
45 Male Left-sided 3 8 2 4 No No Yes No Mesalazine No 
46 Male Pancolitis 2 5 2 3 No Yes No No Mesalazine No 
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by week 8 




51 Male Pancolitis 2 5 2 4 No Yes No No Prednisolone No 









57 Female Left-sided 3 10 3 10 No No No No Mesalazine No 
59 Female Pancolitis 2 6 3 7 No No No No Prednisolone No 
61 Male Left-sided 2 7 1 2 Yes Yes Yes No Nil No 
62 Male Left-sided 2 4 1 3 No No No No Mesalazine No 





70 Male Left-sided 2 8 1 3 No No Yes No Prednisolone 
mesalazine 
No 







Table S5.17: Baseline and week 8 data for patients randomized to donor FMT 





























by week 8 
2 Male Left-sided 2 7 1 4 No Yes Yes Yes Sulfasalzine, 
azathioprine 
No 





5 Female Left-sided 3 8 1 4 No Yes Yes Yes Mesalazine, 
azathioprine 
No 
8 Male Left-sided 2 7 1 3 No Yes Yes Yes Sulfasalazine No 






13 Male Pancolitis 2 8 1 3 No Yes Yes Yes Mesalazine, 
azathioprine 
No 














18 Male Pancolitis 2 7 0 0 Yes Yes Yes Yes Mesalazine No 
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by week 8 
20 Female Left-sided 2 5 1 4 No No No No Mesalazine No 
24 Male Pancolitis 2 8 0 0 Yes Yes Yes Yes Mesalazine No 
26 Female Left-sided 3 9 1 2 Yes Yes Yes No Prednisolone, 
sulfasalazine 
No 
29 Male Pancolitis 2 6 2 6 No No No No Nil No 




32 Male Left-sided 2 6 2 9 No No No No Sulfasalazine No 




34 Female Pancolitis 2 7 2 6 No No No No Mesalazine No 
36 Male Left-sided 2 8 2 7 No No No No Mesalazine, 6-
mercaptopurine 
No 





41 Male Pancolitis 2 4 1 2 Yes No No No Mesalazine No 




47 Male Left-sided 2 4 0 0 Yes Yes Yes Yes Sulfasalazine No 


































by week 8 
Azathioprine 
50 Male Left-sided 1 4 0 0 Yes Yes Yes Yes Mesalazine, 
azathioprine 
No 





54 Female Left-sided 2 6 1 4 No No No No Mesalazine, 
azathioprine 
No 
56 Male Pancolitis 2 7 2 6 No No No No Mesalazine, 
azathioprine 
No 
58 Female Left-sided 3 9 2 6 No No Yes No Nil No 








65 Male Pancolitis 3 10 2 6 No Yes Yes No Mesalazine No 








68 Female Left-sided 3 8 2 4 No Yes Yes No Infliximab No 
69 Female Left-sided 3 10 n/a 10 No No No No Prednisolone No 
 
135 





























by week 8 


































1 Male n/a n/a n/a n/a n/a Unknown Unknown No No 
4 Female n/a n/a n/a n/a n/a Nil 0 No Yes 
6 Female 0 1 Yes Yes Yes Azathioprine 0 Yes No 
7 Male 2 9 No No No Prednisolone, 
mesalazine 
11 No No 
9 Female n/a n/a n/a No n/a Prednisolone, 
mesalazine 
12 No No 
10 Female 1 1 Yes Yes No Mesalazine 0 Yes No 
11 Male n/a n/a n/a n/a n/a Infliximab, 
methotrexate 
2 No Yes 
14 Female n/a n/a n/a n/a n/a Unknown Unknown Yes No 
19 Male 1 2 Yes Yes No Azathioprine 3 No No 
21 Female 3 7 No No No Prednisolone, 
mesalazine, 
azathioprine 
6 No No 
22 Male n/a n/a n/a No n/a Mesalazine, 
mesalazine 
(topical) 
0 Yes No 
23 Male n/a n/a n/a n/a n/a Unknown Unknown No Yes 
25 Female 1 2 Yes Yes No Mesalazine 0 No No 
27 Male 1 2 Yes Yes No Mesalazine, 6-
mercapropurine 
3 No No 




























30 Male 2 5 No Yes No Mesalazine, 
mesalazine 
(topical) 
0 No No 
35 Male 1 2 Yes Yes No Budesonide 0 Yes No 
37 Male n/a n/a n/a n/a n/a Unknown Unknown No No 
38 Female n/a n/a n/a n/a n/a Unknown Unknown No No 
39 Female 1 2 Yes Yes No Azathioprine 3 No No 
43 Female 2 7 No No No Azathioprine 
(100mg) 
0 No No 
44 Male n/a n/a n/a n/a n/a Nil 0 No Yes 
45 Male 0 0 Yes Yes Yes Azathioprine 0 Yes No 
46 Male 2 7 No No No Mesalazine, 
vedolizumab 
3 No No 
49 Female 0 2 Yes n/a Yes Unknown Unknown No No 
51 Male 2 7 No No No Infliximab 0 No No 
52 Male n/a n/a n/a No n/a mesalazine 
(topical) 
0 No No 
55 Female n/a n/a n/a No n/a Mesalazine, 
infliximab 
0 No No 
57 Female 3 9 No No No Mesalazine 2 No No 
59 Female n/a n/a n/a n/a n/a Unknown Unknown No Yes 
61 Male n/a n/a n/a n/a n/a Unknown Unknown No No 
































64 64 n/a n/a n/a n/a n/a Nil 0 No Yes 
70 70 0 0 Yes n/a Yes Nil 0 Yes No 
72 72 n/a n/a n/a n/a n/a Mesalazine, 
azathioprine, 
infliximab 































2 Male 0 0 Yes Yes Yes Azathioprine 0 Yes No 
3 Male n/a n/a n/a n/a n/a Mesalazine, 
Infliximab 
3 No No 




2 No No 
8 Male 2 4 No No No Sulfasalazine, 
Infliximab 
4 No No 




10 No Yes 
13 Male n/a n/a n/a Yes n/a Mesalazine, 
Azathioprine 
0 No No 
15 Female n/a n/a n/a No n/a Mesalazine 0 No No 
16 Male 3 10 No No No Unknown Unknown No No 
17 Female n/a n/a n/a n/a n/a Mesalazine 
(topical) 
8 No Yes 
18 Male 1 2 Yes Yes No Mesalazine 0 Yes No 
20 Female 0 0 Yes Yes Yes Mesalazine 
(topical) 
0 No No 
24 Male 2 5 No No No Mesalazine 0 Yes No 
26 Female 1 3 No No No Prednisolone, 
Mesalazine 
10 No No 





























31 Female 2 4 No Yes No Mesalazine 
(topical), 
methotrexate 
0 Yes No 
32 Male 1 6 No No No Sulfasalazine, 
vedolizumab 
Unknown No No 
33 Male n/a n/a n/a n/a n/a Mesalazine, 
mesalazine 
(topical) 
1 No No 
34 Female 2 3 No Yes No Mesalazine Unknown No No 




12 No No 
40 Female n/a n/a n/a Yes n/a Sulfasalazine  2 No No 
41 Male 1 2 Yes Yes No Mesalazine 0 Yes No 
42 Female 3 7 No Yes No Sulfasalazine 0 No No 
47 Male 1 2 Yes Yes No Sulfasalazine 0 No No 
48 Male 1 1 Yes Yes No Azathioprine 6 No No 
50 Male n/a n/a n/a Yes n/a Unknown Unknown No No 
53 Female n/a n/a n/a n/a n/a Nil 0 No Yes 
54 Female 0 0 Yes Yes Yes Mesalazine, 
azathioprine 
2 No No 
56 Male 1 3 No No No Unknown Unknown No No 
58 Female 1 4 No Yes No Unknown Unknown No No 
60 Female 0 0 Yes No Yes Mesalazine, 
azathioprine 





























63 Female 1 1 Yes No No Mesalazine, 
mesalazine 
(topical) 
Unknown No No 
65 Male 2 6 No Yes No Mesalazine 0 No No 
66 Male 1 3 No No No Mesalazine, 6-
mercaptopurine 
0 No No 
67 Male 2 7 No No No Mesalazine, 
adalimumab 
2 No No 
68 Female 1 2 Yes Yes No Infliximab 0 No No 
69 Female n/a n/a n/a Yes n/a Vedolizumab 4 No No 
71 Female 1 2 Yes Yes No Infliximab 0 Yes No 




Table S5.20: Change due to treatment in butyrate-producing species and genera 
Species Family Phylum Treatment difference log 
change abundance week 4 
[95% CI] 
Week 4 P value Treatment difference log change 
abundance week 8 [95% CI] 
Week 8 
P value 
Anaerostipes caccae Lachnospiraceae Firmicutes -2.78 [-4.36 to -1.21] .0005 -2.53 [-4.23 to -0.84] .003 
Butyricicoccus 
pullicaecorum 
Ruminococcaceae Firmicutes 0.95 [-0.13 to 2.03] .09 -0.45 [-1.55 to 0.65] .42 
Roseburia inulinivorans Lachnospiraceae Firmicutes 0.54 [-0.41 to 1.48] .27 -0.36 [-1.3 to 0.59] .46 
Anaerostipes butyraticus Lachnospiraceae Firmicutes -1.26 [-4 to 1.47] .37 -5.11 [-8.12 to -2.1] <.001 
Roseburia. intestinalis Lachnospiraceae Firmicutes -0.3 [-1.02 to 0.41] .4 -0.27 [-0.98 to 0.44] .46 
Faecalibacterium prausnitzii Ruminococcaceae Firmicutes 0.16 [-0.22 to 0.54] .41 -0.06 [-0.45 to 0.32] .74 





Figure S5.1: Butyrate-producing bacteria prevalence in donors (individual and 





Bacterial analysis methods 
There were 228 fecal samples available from 72 patients enrolled in the study and 72 
fecal samples available from donors (53 individual donor and 19 pooled batches). Stool 
from patients and individual donors was frozen without additive at -80°C. Stool swabs 
were stored for up to 8 weeks at -20°C prior to transfer to -80°C. Stool from the donor 
batches was frozen at -80°C with 65% saline and 10% glycerol. 
We extracted bacterial DNA from the samples using the MoBio PowerMag Microbial 
DNA Isolation kit (MoBio Laboratories, Carlsbad, CA, USA) following the 
manufacturer’s protocol. All stool samples were extracted and processed in duplicate. 
Amplicon library preparation was performed using a modified dual-index PCR 
approach.1 The first-step primers (515F, 806R), which were modified by the inclusion 
of a phaser to increase heterogeneity in the sequencing run,2 amplified the V4-V5 
hypervariable region of the 16S rRNA gene and the second set (i5, i7) added the 
indexed barcodes to enable multiplexing of our large number of samples.1 The library 
was pooled at equi-molar concentrations and run on an Illumina HiSeq2500 Rapid 
instrument using 2 × 250 bp paired-end chemistry (Ramaciotti Centre for Genomics, 
University of New South Wales). The median number of reads per sample was 143k 
(thousand) (IQR, 111k-196k). Samples with total read count <10k were excluded. 
Bioinformatics 
Raw sequencing data were processed using a combination of both in-house and open-
source software. The bioinformatic pipeline utilised USEARCH algorithms,3 which 
included merging, quality-filtering, partitioning/de-replicating and clustering into 
operational taxonomic units (OTUs) at 97% similarity. Representative sequences from 
each OTU were classified in two ways: via the RDP Naïve Bayesian Classifier and by 
finding the closest match in a set of curated reference sequences (RDP 16S Training Set 
+ RefSeq 16S).4 The use of two independent classification techniques improves 




LPMC isolation: Colonic mucosal biopsies were incubated twice in Hepes buffered 
HBSS supplemented with 1mM EDTA and 1mM DTT (Sigma) for 10 minutes at 37°C 
under slow rotation, with the suspension strained (100µM) between incubations. 
Residual tissue was incubated in Hepes buffered Ca2+/Mg2+ free HBSS for 10 minutes 
at 37°C under slow rotation and strained (100µM). Residual tissue was minced and 
incubated in complete media (RPMI 1640 [Gibco, Germany] supplemented with fetal 
calf serum, glutamax and penicillin/streptomycin, Collagenase D [1mg/mL, Roche], 
DNAse1 [0.5mg/mL, Sigma] and Dispase [3mg/mL, Roche]) 20 minutes twice, with 
supernatant removal from centrifugation (300g, 5 minutes) after each incubation. 
Residual suspensions were sequentially strained (100µM followed by 40µM), with the 
supernatant centrifuged (300g, 5min), resuspended, and stained with trypan blue to 
determine viability and cell number as previously described.5-7 
Cell staining: 0.5 × 106 Fc blocked cells (BD Biosciences, NSW, Australia) were 
stained for viability (FVD eFlour450, eBioscience) and the following anti-human 
monoclonal antibody panels (BD Bioscience unless otherwise stated): (a) HLADR-
APC, CD11C-FITC, Lin (CD3, CD14, CD16, CD19, CD34, CD56 all APC-Cy7, 
CD33-PerCP Cy5.5); (b) CD3-APC, CD45RO-PerCP Cy5.5, CD19-APC Cy7, CD20-
APC Cy7, CD16-PE, CD56-PE, Vα24jα-FITC (eBioscience); and (c) CD3-APC, CD8-
FITC, CD45RO-PerCP Cy5.5, γδT-PE (eBioscience). For TREG, cells were stained with 
CD4-APC Cy7, CD8-PE, CD45RO PerCP Cy5.5, CD25 PE Cy7, β7-FITC, followed by 
fixation and permeabilization (Transcription buffer staining set, eBioscience) and 
staining with FOXP3-APC (eBioscience). The following gating strategy was used to 
identify cell populations: macrophages (lin-ve/HLADR/CD33+ve), dendritic cells (lin –
ve HLADR+/CD33+/CD11c+), THELPER (CD4+ CD8-), TCYTOTOXIC (CD8+ CD4-), 
TREGULATORY (CD4+/CD8-/CD25+/FOXP3+), B (CD3-, CD19+ CD20+), natural killer 
(CD3-/CD16+/CD56+/CD45RO-), natural killer T (CD3+/NKT+), γδ T (CD3+/γδT+) 
in LPMCs; and gut-homing THELPER (CD4+/CD8-/CD45RO+/β7+) and gut-homing 
TREGULATORY (CD4+/CD8-/CD45RO+/β7+/CD25+/FOXP3+) in PBMCs. Twenty 
thousand events/tube were analyzed on a FACSCanto II (BD Biosciences) and 






Microbiome diversity was defined as the fraction of unique species present at an 
assessment out of all species present at any analysis in any sample. Logistic mixed 
effects regressions were used to compare between treatment groups with donor stool 
and stool mix samples. Outcome was the presence of a species in a particular sample. 
Fixed effects included sample origin (donor vs mix vs treated patient vs untreated 
patient) and total sample count (log transformed). Three non-nested random effects 
were included: patient identifier, donor batch, and the microbiome species identifier. To 
assess the effect of treatment, a separate model was contrasted with only post-baseline 
samples included as outcome. This model was identical to the previous except that the 
fixed effects were baseline prevalence (logit transformed), treatment allocation, 
assessment time (week 4 vs week 8), the pairwise treatment–assessment time 
interaction, and total sample count (log transformed). 
Associations between both baseline diversity and change in diversity, and change in 
Mayo score were assessed as before (re-associations with baseline factors). A two-stage 
approach was taken. First, the mean diversity was estimated using the logistic mixed 
effects models previously described in this section. These diversity estimates were then 
included in the models of total Mayo score as fixed effects.  
Microbiome abundance  
Associations between changes in biome species abundance with total Mayo score were 
modelled in a similar manner. For each sample, the mean proportion of total counts was 
calculated, and subsequently for individuals with samples at both week 4 and 8 
averaged to estimate baseline and post randomization prevalence estimates. The change 
in prevalence was then included in linear mixed effects models of total Mayo score. A 
false discovery rate (FDR) analysis was performed to provide evidence of associations 
beyond what would be expected because of multiple testing, with the FDR being 
compared with the same analysis repeated, but with outcome (total Mayo score) 
permuted between individuals. 
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The change in abundance by treatment group and assessment time were assessed using a 
negative binomial mixed effects regression for each microbiome species. Fixed effects 
included treatment allocation, assessment time (baseline, week 4, week 8, and 12-
months) and their pairwise interaction. Nested random intercepts per patient and 
assessment were included in the model, with total sample count (log transformed) 
included as an offset. Due to the large variation in abundance across species, from 
highly abundant to mostly absent, a zero-inflation term was included in the model and 
Akaike’s information criteria was used to determine whether this improved model fit 
per species.  
Fecal short chain fatty acids and calprotectin 
The estimate of treatment effect on calprotectin and SCFAs, which had an extra 
assessment at week 4, was similarly modelled but with both week 4 and week 8 
assessments as outcome. Baseline values, treatment group, assessment time (week 4 vs 
week 8), and the pairwise interaction between time and treatment were included as fixed 
effects. In addition to the batch and site random intercepts, within-individual random 
intercepts were included nested within site. After inspection of the distribution of the 
residuals, these analyses were performed on log-transformed calprotectin, SFCA 
measures, and immunological markers, with results converted back to the original scale.  
Associations between estimated change in SCFAs and week 8 Mayo score were 
assessed by including the estimated change in SCFAs as a fixed effect in the mixed 
effects regression models with week 8 Mayo score as outcome. Individual level SCFA 
change scores were estimated using linear mixed effects regressions, adjusting for 
baseline levels and treatment, with random intercepts per batch, individual, and site, 





Name:     DOB:     Date: 
Patient perception of faecal transplantation for ulcerative colitis questionnaire 
Prior to faecal transplantation 
Please circle the most appropriate answer 
1. Do you believe that faecal transplantation is likely to help with your symptoms? 
Impossible Not likely Unsure  Quite likely Very likely 
2. Have you considered faecal transplantation for ulcerative colitis previously? 
Yes I have considered it I have heard of it, but not considered it I have never 
heard of it before 
3.1 Do you consider that faecal transplantation is likely to be safe? 
Impossible Not likely Unsure  Quite likely Very likely 
Please explain why 
3.2 Do you consider that 5-ASA medication (e.g. sulphasalazine, mesalazine) is likely 
to be safe? 
Impossible Not likely Unsure  Quite likely Very likely 
3.3 Do you consider that steroid medication (e.g., prednisolone) is likely to be safe? 
Impossible Not likely Unsure  Quite likely Very likely 
3.4 Do you consider that thiopurine medication (e.g. azathioprine/ 6-MP) is likely to be 
safe? 
Impossible Not likely Unsure  Quite likely Very likely 
3.5 Do you consider that methotrexate medication is likely to be safe? 
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Impossible Not likely Unsure  Quite likely Very likely 
3.6 Do you consider that anti-TNF medication (e.g., infliximab (Remicade)/adalimumab 
(Humira)) is likely to be safe? 
Impossible Not likely Unsure  Quite likely Very likely 
3.7 Do you consider that surgical removal of the colon is likely to be safe? 
Impossible Not likely Unsure  Quite likely Very likely 
4. Do you believe faecal transplantation as carried out in this study would be seen as 
acceptable by 
1. The general Australian population?  Yes No Unsure 
2. Patients with ulcerative colitis? Yes No Unsure 
5. Do you have any cultural or religious concerns about receiving faecal material from 
another person?  
Yes No Unsure 
If yes, what are your concerns? 
6. How would you compare faecal transplantation to traditional medical treatments of 
ulcerative colitis? 
• How do you compare the acceptability of these treatments? 
7. How would you compare faecal transplantation to other treatments such as 
probiotics? 
• How do you compare the acceptability of these treatments 
8. Do you have any concerns about discussing faecal transplant with friends or family? 





Name:     DOB:     Date: 
Patient perception of faecal transplantation for ulcerative colitis questionnaire 
12 months post faecal transplantation 
Please circle the most appropriate answer 
1. Do you believe that faecal transplantation helped with your symptoms at least 
temporarily? 
Not at all Yes a little Yes a lot Unsure  
If you had symptom improvement how long did this last? 
2. Has your medication requirement decreased or increased in the 12 months since 
faecal transplant? 
Decreased Increased The same 
What are you now taking? 
For how many months were you taking steroid (eg prednisolone) in the 12 months 
after faecal transplant? 
Has the amount of steroid medication changed in the 12 months post faecal transplant 
compared to the 12 months prior? 
Increased Decreased Stayed the same 
3. How many flares of disease did you have in the 12 months after faecal transplant? 
If you had flares of disease, for how many months were you symptomatic in the 12 
months after faecal transplant? 
Have you required hospitalisation in the 12 months after faecal transplant? 
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Yes (how many times:  ) No 
4. Did you require surgery (colectomy) for your ulcerative colitis since your faecal 
transplant 
Yes (date: ) No 
4. Do you consider that faecal transplantation is likely to be safe? 
Impossible Not likely Unsure  Quite likely Very likely 
5. How would you compare faecal transplantation to traditional medical treatments of 
ulcerative colitis? 
• How do you compare the acceptability of these treatments? 
• How do you compare the effectiveness of these treatments? 
6. How would you compare faecal transplantation to other treatments such as 
probiotics? 
• How do you compare the acceptability of these treatments? 
• How do you compare the effectiveness of these treatments? 
7. Do you believe faecal transplantation as carried out in this study would be seen as 
acceptable by: 
• the general Australian population  Yes No Unsure 
• patients with ulcerative colitis?  Yes No Unsure 
8. Do you have any cultural or religious concerns about receiving faecal material from 
another person? If yes, what are your concerns? 
9 . Do you have any concerns about discussing faecal transplant with friends or family? 
If so why? 
10. If you had your time in the study again would you like any aspects of the faecal 
transplant process to be done differently? 
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Chapter 6: Systematic Review and Meta-Analysis: Faecal 
Microbiota Transplantation for the Induction of Remission of 
Ulcerative Colitis 
6.1 Background 
During the course of the FIRST-UC study (detailed in Chapter 5), evidence emerged 
from a number of other studies assessing FMT for the induction of remission for active 
UC. Each of these trials used different stool processing as well as FMT timing and 
delivery methods. A systematic review with meta-analysis was undertaken to give 
context to the FIRST-UC study 
This systematic review of the literature assessed cohort studies as well as RCTs of FMT 
for the induction of remission of UC. The meta-analysis was restricted to the RCTs 
only. 
Presented in this chapter is the manuscript published in Alimentary Pharmacology & 
Therapeutics (2017, Vol. 46, pp. 213–224). 
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Background: FMT is emerging as a novel therapy for UC. Interpretation of efficacy of 
FMT for UC is complicated by differences among studies in blinding, FMT 
administration procedures, intensity of therapy and donor stool processing methods. 
Aim: To determine whether FMT is effective and safe for the induction of remission in 
active UC. 
Methods: Medline (Ovid), Embase and the Cochrane Library were searched from 
inception through February 2017. Original studies reporting remission rates following 
FMT for active UC were included. All study designs were included in the systematic 
review and a meta-analysis performed including only RCTs. 
Results: There were 14 cohort studies and four RCTs, which used markedly different 
protocols. In the meta-analysis of RCTs, clinical remission was achieved in 39 of 140 
(28%) patients in the donor FMT groups, compared with 13 of 137 (9%) patients in the 
placebo groups (OR 3.67 [95% CI 1.82–7.39]; P < 0.01). Clinical response was 
achieved in 69 of 140 (49%) donor FMT patients, compared with 38 of 137 (28%) 
placebo patients (OR 2.48 [95% CI 1.18–5.21]; P = 0.02). In cohort studies, 39 of 168 
(24%; 95% CI 11–40%) achieved clinical remission. 
Conclusions: Despite variation in processes, FMT appears to be effective for induction 
of remission in UC, with no major short-term safety signals. Further studies are needed 
to better define dose frequency and preparation methods and explore its feasibility, 




UC is a chronic, relapsing and remitting, inflammatory disease of the colon occurring at 
the interface between the luminal contents and the mucosal immune system. There is 
increasing evidence implicating the colonic microbiome in the pathogenesis of UC with 
luminal bacterial antigens contributing to immune cell activation1. Many of the genetic 
risk alleles associated with UC relate to immunological handling of microbes and 
mucosal defence2. The microbiome in UC, both active and remission, is less diverse 
than that of healthy subjects3. This loss of diversity is predominantly attributable to a 
decrease in gram-positive Firmicutes, especially Clostridium clusters IV and XIV, 
whereas some species in the Proteobacteriae group, particularly E. Coli and 
Enterobacteriaceae are relatively overabundant4. However, the relative paucity of many 
other bacteria has also been implicated in IBD, including Faecalibacterium prausnitzii 
(a butyrate producer with independent anti-inflammatory properties); sulphate-reducing 
bacteria; and mucosal-associated Akkermansia muciniphila, Ruminococcus torques and 
Ruminococcus gnavus, which have possible roles in mucus barrier integrity3, 5. Colonic 
enterocyte health is also fundamentally dependent on microbial metabolites with 
butyrate, a product of anaerobic bacterial fermentation of undigested dietary 
carbohydrates, being a primary source of enterocyte nutrition with anti-inflammatory 
effects6. 
Despite evidence implicating microbial factors in the pathogenesis of UC, most medical 
therapies target the immune response without modifying the luminal microbial 
environment. Whilst effective, these “immunocentric” therapies have incomplete 
efficacy and are sometimes limited by side effects including allergy, intolerance, serious 
infection, increased risk of malignancy, drug antibody formation and cost7. 
In recent years, FMT has been proven to be extremely effective for treatment of 
recurrent Clostridium difficile infection (rCDI)8-14. This has encouraged research in FMT 
as a potential therapy for other microbial-related diseases such as UC. FMT is proposed 
as a means of altering the disease process by modifying the colonic ecosystem and thus 
the potential biochemical and antigenic drivers of the disease. 
Since the first case of FMT for the treatment of UC was described by Justin Bennet in 
198915, there have been a number of case reports, case series and, more recently, RCTs. 
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In order to assimilate these data, we conducted a systematic review and meta-analysis to 
assess the efficacy and safety of FMT for induction of remission in active UC. 
Methods 
Search strategy 
A systematic search and retrieval of records was performed in accordance with the 
MOOSE, PRISMA and Cochrane guidelines16-18. 
We searched Medline (1948–February 2017), EMBASE (1948–February 2017) and the 
Cochrane Inflammatory Bowel Disease/Functional Bowel Disorders review group 
specialist trials register without language restriction from inception through February 
2017. Abstracts from major meetings in gastroenterology and IBD were searched 
manually and assessed for relevance. These included the Digestive Disease Week 
(2010–2016), Congress of the European Crohn’s and Colitis Organisation (2006–2017) 
and United European Gastroenterology Week (2010–2016). Bibliographies of review 
articles and meta-analyses19-21 were searched in order to identify additional studies. 
Searching was limited to publications with human subjects. Articles in English and 
Mandarin were reviewed and other languages excluded. 
An initial database search using the key words “fecal”, “faecal”, “microbiota”, 
“microflora”, “feces”, “faeces”, “stool”, “fecal flora” and “faecal flora” was performed. 
Subsequently, each key word was combined with each of the following variations on 
transplant: “transplant”, “enema”, “donor”, “infusion”, “transfusion”, “implant” 
“implantation” and “instillation”. These terms were searched in combination and 
“bacteriotherapy” searched for individually. The results were combined with terms for 
UC by using the Boolean term “AND” “ulcerative colitis” “inflammatory bowel 
disease”, “colitis”, “IBD” or “UC”. This strategy was used both as Medical Subject 
Headings (MeSH) terms if available and as free text. Variations of root word were also 
searched alone or in combination. Two authors independently reviewed all articles other 
than articles in Mandarin, which were reviewed by WS alone, and then discussed 




Eligible studies were RCTs and cohort studies that investigated FMT as induction of 
remission for active UC in both paediatric and adult patients with clearly described 
measures of remission. 
Studies were excluded if enrolled patients did not have clearly defined active disease, 
there was no definition of remission, clinical endpoints were not reported, or the study 
included only patients with comorbid infections such as CDI. Studies that included 
patients with concomitant infections were considered only if the data from patients with 
UC and without infection could be clearly delineated from those with infection. 
The Cochrane risk of bias tool18 was used to assess for bias in RCTs (Supplementary 
Table 6.1. Data were extracted into Microsoft Excel for Mac 2011 (Microsoft, 
Redmont, USA). Risk of bias of the cohort studies was assessed using a modified 
Newcastle–Ottawa scale for cohort studies. The scale was adjusted for use in cohort 
studies without a control group. This was adjusted to a 6-point scale after questions that 
assessed for control groups were removed (Supplementary Table 6.2). 
Two investigators (SPC and WS) independently completed the Cochrane risk of bias 
tool for RCTs and the inter-investigator agreement was 100% (Cohen’s kappa = 1.0). 
The inter- investigator agreement on meeting the inclusion criteria for the observational 
studies was 88% (Cohen’s kappa = 0.75). Consensus was reached by combined review 
of any studies (n = 4) where there had been initial discrepancy. Only RCTs were 
included in the meta-analysis to provide a pooled remission and response rate for FMT 
for induction of remission in UC. 
Data extraction 
Full-text articles and conference abstracts that met inclusion criteria were reviewed by 
SPC and WS to identify study characteristics such as study type, patient characteristics 
(Table 6.1), FMT processing methods and delivery protocols (Table 6.4), as well as 




For RCTs, a random effects model was used to assess the pooled estimate of remission, 
clinical response and endoscopic remission in the meta-analysis using Review Manager 
5.4. (Nordic Cochrane Centre, Copenhagen, Denmark 2014). A random effects model 
was used because of the heterogeneous study designs. Statistical heterogeneity for each 
meta-analysis was assessed using the Cochran Q test (×2) and I2 method. The I2 method 
was used to assess the degree of heterogeneity with scores of 0–39, 40–59 and 60–100 
representing low, moderate and substantial heterogeneity, respectively. 
Results 
Search results 
Figure 6.1 (PRISMA flow diagram) shows the selection methodology of the included 
articles. 
The initial search revealed 2072 potential articles. After screening titles and abstracts, 
44 studies remained after duplicates were removed. After review of full-text articles and 
abstracts, 18/44 were eligible for inclusion, consisting of four RCTs and 14 cohort 
studies. 
Cohort studies 
There were 14 cohort studies22-35, which included a total of 168 patients (Tables 6.1 and 
6.2). The studies were reported from 2013 until 2017. Three of 14 studies included both 
UC and Crohn’s disease patients30, 31, 36, with only the data for UC patients included 
here. Both paediatric and adult patients were included in the analysis (age range 4.6 to 
70 years); follow-up varied between 1 and 72 months. All patients had active UC; 
however, the severity of disease varied from mild to severe among studies. 
Of 168 patients, FMT was administered via the upper gastrointestinal tract 
(nasogastric/nasojejunal tube or endoscopic duodenal infusion) in 22 (13%), via the 
lower gastrointestinal tract (enema, colonoscopy or rectal tube) in 125 (74%) and via 
both routes in 21 (12%). The stool weight used in each dose was reported in 10/14 
cohort studies, ranging from 8 to 250g. The number of faecal infusions given ranged 
from one to six. Seven studies (50%) used fresh donor stool, and four (29%) used a 
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frozen stool protocol; in the remaining three (21%) studies, it was unclear whether fresh 
or frozen FMT was administered (Table 6.1). There were no cohort studies that reported 
the use of anaerobic stool processing techniques. 
In all cohort studies, patients remained on their regular IBD medications during FMT 
therapy, except for a single study where medications other than 5-ASA were ceased22; 
5/14 (36%) cohort studies used pre-treatment with antibiotics prior to FMT. In a single 
study, half of the patients had a prebiotic (pectin) administered with the FMT34. 
Of the 168 patients, 93 (55%; 95% CI 36.7–71.7%) achieved a clinical response, of 
whom 39 (24%; 95% CI 11–40%) achieved clinical remission (both outcomes variably 
defined as per Table 6.2). Six (4%) patients deteriorated and there was no clinical 
change in 68 (40%). Endoscopic remission was only assessed in 7/14 (50%) studies and 
was achieved in 16/56 patients (29%) (Table 6.2). 
Treatment success was numerically higher in the five studies reporting antibiotic pre-
treatment22, 29, 30, 34, 37, with 39/58 patients (67%) demonstrating clinical response and 
19/58 (32%) clinical remission. Clinical remission was achieved in 24/107 (22%) 
patients using fresh stool, compared with 12/40 (30%) using frozen stool. Clinical 
response rates were 12/19 (63%) for upper gastrointestinal delivery, compared with 
64/121 (53%) for lower gastrointestinal delivery. Clinical remission rates were 4/19 
(21%) for upper gastrointestinal delivery and 25/121 (19%) for lower gastrointestinal 
delivery. 
Randomised controlled trials 
Four placebo-controlled RCTs were identified, reporting on a total of 277 patients with 
UC enrolled between 2011 and 2016, of whom 140 (51%) received donor FMT and 137 
(49%) received placebo38-41. Two RCTs used autologous stool as placebo39, 41 and two 
used water (with and without discolourant)38, 40. The RCTs ranged in size from 50 to 81 
patients. All were randomised in a 1:1 ratio of FMT:placebo. 
The studies were heterogeneous in design with inclusion criteria, route of FMT 
administration and follow-up periods varying among studies. Each of the four RCTs 
included patients with active UC, and the majority of enrolled patients had mild to 
moderate disease. Rossen et al.39 included patients with SCCAI values of 4–11. 
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Moayyedi et al. included patients with a total Mayo score >4, which also included 
patients with severe disease38. Paramsothy et al. and Costello et al.40, 41 enrolled patients 
with total Mayo scores of 4–10. All studies required endoscopic evidence of active 
disease for inclusion; three studies required an endoscopic Mayo score ³1, with the 
study of Costello et al. requiring an endoscopic Mayo score ³241. FMT was delivered 
via colonoscopy in the two Australian studies40, 41 and via enema38 and nasoduodenal 
tube39 in one each of the other studies. Patient follow-up periods varied from 7 to 12 
weeks. 
Pooled remission and response rates 
The endpoints reported in each RCT varied. Definitions used in each study are shown in 
Table 6.3. 
Overall, remission was achieved in 39/140 patients (28%) in donor FMT recipients, 
compared with 13/137 (9%) in placebo groups (OR 3.67, 95% CI 1.82–7.39; P < 0.01) 
(Figure 6.2), with no statistically significant heterogeneity between studies (I2 = 0%). 
There were no clinical features consistently associated with remission in the donor FMT 
groups. Moayyedi et al. found that patients who had UC for less than 1 year were more 
likely to enter remission following donor FMT than those with UC for longer38. 
However, UC duration prior to FMT was not associated with remission in two other 
studies40,41. 
The Rossen et al. study was terminated early because of an interim futility analysis as it 
was powered to detect a treatment effect of 70%. This study showed no significant 
difference between donor and placebo groups on intention to treat analysis (30.4% v. 
20%; P = 0.51). The other three studies each demonstrated statistically significant 
benefit of donor FMT over placebo for induction of remission in UC. 
Clinical response was achieved in 69/140 patients (49%) who received donor FMT, 
compared with 38/137 (28%) who received placebo (OR 2.48, 95% CI 1.18–5.21; P = 
0.02) (Figure 6.3) with moderate heterogeneity between studies (I2 = 52%). Endoscopic 
remission, defined as an endoscopic Mayo = 0, was achieved in 20/140 (14%) who 
received donor FMT, compared with 7/137 (5%) who received placebo (OR 2.69, 95% 
CI 1.07–6.74; P = 0.04) (Figure 6.4), with no statistically significant heterogeneity 
between studies (I2 = 0%). 
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Stool weight and delivery 
The weight of stool per treatment and the method of delivery varied between trials. All 
RCTs used a polyethylene glycol-based bowel preparation prior to colonoscopic or 
nasoduodenal delivery, but not prior to enema delivery. The Costello et al. and 
Paramsothy et al. studies used colonoscopic delivery of 50g and 37.5g stool per 
treatment, respectively, and then followed this with two further 25g enemas and 39 
further 37.5g enemas, respectively40, 41. Rossen et al. used nasoduodenal delivery at 
weeks 0 and 3 (median 120g stool per treatment) and Moayyedi et al. used a weekly 
enema for 6 weeks (8.3g per treatment). 
Stool processing 
The method of stool processing varied between trials (Table 6.4). Paramsothy et al. and 
Costello et al. used pooled (3–7 and 3–4 donors, respectively) frozen donor stool from 
de-identified, unrelated healthy volunteers40, 41. Rossen et al. used fresh stool from 
single known or de-identified donors and Moayyedi et al. used fresh and frozen stool 
from single anonymous donors38, 39. Costello et al. processed donor stool anaerobically 
and the other three studies processed stool aerobically. Paramosthy et al. and Costello et 
al. used 10% glycerol as a cryoprotective agent during freezing; Moayyedi et al. used 
water alone. 
Safety 
Adverse events were monitored and reported in each study. Overall, FMT was well 
tolerated. The most common serious adverse event reported was worsening colitis, 
which occurred in 3/140 patients in donor arms (with one colectomy) and 4/137 patients 
in placebo arms. There were three cases of small bowel Crohn’s disease subsequently 
reported and two cases of C. difficile colitis, with one requiring colectomy, in donor 
arms. In placebo arms, there was one case each of Crohn’s disease, primary 
cytomegalovirus infection and cervical cancer (unrelated). Two studies reported adverse 
events more extensively, with 50/63 (79%) in donor arms and 49/65 (75%) in placebo 
arms having at least one adverse event39, 40. The most common adverse events were self-
limiting gastrointestinal complaints. There were no significant differences between 




Rossen et al. showed that compared with donors, pre-FMT UC patients had 
significantly lower abundance of members of Clostridium clusters IV, XIVa and XVIII 
and higher abundance of Bacteroidetes, bacilli, Proteobacteria and Clostridium clusters 
IX and XI39. The stool microbial diversity of UC patients and donors did not differ at 
baseline; however, the Shannon diversity index for responders increased significantly 
following FMT. Redundancy analysis showed that the microbiota composition of 
responders in the donor FMT group shifted from overlap with non-responders at 
baseline to healthy donors at week 12. This shift was mainly explained by regain of 
Clostridium clusters IV, XIVa and XVIII and reduction in Bacteroidetes39. Moayyedi et 
al. found an enrichment for the family Lachnospiraceae and the genus Ruminococcus in 
a particular donor who was associated with most cases (7/9, 78%) of remission38. When 
similarity was compared between the active cohort after FMT and their respective 
donors, there was a statistically significant effect of the active therapy group being more 
similar to their donor than to a control faecal sample. 
Paramsothy et al. found that those patients who went on to achieve remission had a 
greater diversity at both baseline and following FMT. In their study, achieving 
remission following FMT was associated with gains in Ruminococcus, Clostridium 
clusters IV and XVIII, Barnesiella spp., Blautia spp., Dorea spp. and Parabacteroides 
spp. Conversely, the presence of Fusobacterium spp and Sutterella spp following FMT 
was associated with no remission (Table 6.5). 
Discussion 
In the meta-analysis of four published RCTs performed to date, FMT was significantly 
more effective than placebo for induction of remission of active UC, achieving clinical 
remission in 28% of patients with mild to moderate UC (OR 3.67, 95% CI 1.82–7.39; P 
< 0.01) (Figure 6.2)38-41. This effect appears to be robust as it is seen despite variation in 
stool processing and delivery methods between the trials. In addition, no major short-
term safety signals were observed. 
Each trial used different stool delivery protocols and donor stool processing methods, 
which makes it difficult to recommend a particular protocol or technique over the other. 
This also makes interpretation of the pooled results of the studies more difficult. There 
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are likely to be aspects of stool processing and delivery that influence the efficacy of 
FMT, and further research is required to optimise the methods and treatment protocols 
of FMT in UC. Paramsothy et al. and Costello et al. used pooled donor stool. This 
provided an increased diversity of microorganisms in the stool suspension than that of a 
single donor40. Pooling stool may result in a greater chance that an important element of 
stool will be transmitted to the recipient. However, it is not clear whether this 
theoretical benefit translates to improved efficacy, and using pooled stool requires 
blending and does add some logistical complexity to the manufacturing process42. 
The four RCTs had different intensities of FMT delivery, and this has implications for 
the real-world feasibility of use of FMT for UC (Table 6.4). Paramsothy et al. used the 
most intensive protocol of 40 FMT treatments, delivering 187.5g of stool per week over 
the 8-week period40. This study achieved similar remission rates to the Moayyedi et al. 
and Costello et al. studies that used much lower treatment intensities, which may be 
more practical outside of the trial setting38, 41. Moayyedi et al. delivered only 8.3g of 
stool per week via enema and Costello et al. delivered 100g of stool in three treatments 
in the first week and then no further stool for the remaining 7 weeks. Rossen et al. used 
a low-intensity protocol of two large stool weight (median 120g) FMT deliveries via 
nasoduodenal tube; however, they did not demonstrate a significant difference in 
remission rates over placebo39. It appears that a short duration of therapy may be 
sufficient for remission induction in some patients. These studies do not however 
provide data on the longevity of the treatment response, long-term safety or possible 
ability to maintain remission with interval dosing. 
In cohorts of patients who have undergone FMT to treat CDI, the choice of donor does 
not have an important impact on the efficacy of therapy43. Similarly, it seems that 
neither anaerobic or aerobic stool preparation, nor fresh or frozen stool, significantly 
influences the efficacy of FMT for CDI10, 44. It seems that stool from any healthy person 
processed under many different conditions is likely to be effective in treating CDI. 
However, the same may not be true for UC. C. difficile is an oxygen-tolerant spore-
forming clostridial species, and its important ecological competitors may be similarly 
hardy species or other components in the stool, such as bile acids, viruses and prebiotic 
substrates, which may contribute to the treatment effect45. It is unclear which elements 
of faeces are important to its therapeutic effect in UC; however, they may be different to 
those that are important in treating CDI. The benefit, if any, of anaerobic preparation of 
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faeces for FMT in UC is uncertain; however, it may be hypothesised that bacterial 
susceptibility to oxygen exposure may influence bacterial viability and therefore 
bacterial engraftment into the colonic ecosystem46. For example, Faecalibacterium 
prausnitzii, a bacterium frequently associated with colonic health, is an extremely 
oxygen-sensitive bacterium47. 
The choice of placebo agent in FMT studies may have an influence on trial results. A 
water placebo is likely to be hypotonic and recognizably different to faeces to both the 
administrator and recipient of FMT, and therefore has the capacity to bias results 
(Supplementary Table 6.2). To attempt to mitigate this issue, Moayyedi et al. had a 
person not involved in the assessment of patients deliver the FMT enemas38 and 
Paramsothsy et al. used a fluid discolourant and odorant40. Autologous stool is likely to 
represent a better placebo than water; however, through the process of faecal processing 
and freezing, the recipient’s own stool composition will also be altered. A recent FMT 
study for the treatment of CDI had a high placebo response and there is the possibility 
that processing and storage of the autologous stool could have influenced the placebo 
response11. The Rossen and Paramsothy studies had central reading of the colonoscopy 
images, which minimises bias in the blinding of outcome; the other RCT did not use 
central reading of colonoscopy images38-41. 
The optimal route of FMT delivery in UC, whether via the upper or lower 
gastrointestinal tract, is uncertain, although it is likely to influence the success of the 
procedure. In favour of lower gastrointestinal delivery of FMT in UC, the three positive 
RCTs to date employed lower gastrointestinal delivery techniques, and upper 
gastrointestinal delivery was used in the only negative RCT identified. Further, 
systematic review of FMT for the treatment of CDI demonstrated that colonoscopic 
delivery has higher rates of success than other delivery methods for this indication48. 
However, the rate of clinical remission in the UC cohort and RCT studies combined is 
similar between upper gastrointestinal delivery (11/42 [26%]) and lower gastrointestinal 
delivery (63/252 [25%]). This may include the delivery of FMT or rationally designed 
microbial therapeutics via capsule as research and development into these technologies 
is already underway49-51. In addition to efficacy, patient acceptability of any delivery 
method is important to the success of FMT therapy. Clearly, further research is needed 
to elucidate the optimal route of FMT administration. 
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Stool is a non-standardized product with stool composition differing between individual 
donors and even from sample to sample from the same donor52. It is possible that 
certain donors may provide stool that is more or less efficacious than others and this 
could affect individual trial results. For instance, Moayyedi et al. found that the majority 
of the treatment effect observed related to one particular “super donor”38. This particular 
donor had a relative enrichment of the genera Lachnospiraceae and Ruminococcus. 
There are observable changes in bacterial phyla following FMT (Table 6.5); however, 
the 16S rRNA-based analysis is limited as it does not provide strain level detail or 
functional information. Despite these limitations, there are patterns to the microbial 
changes associated with response to FMT that seem to be common among the studies. 
Increases in Clostridium clusters IV and XVIII were observed in those who responded 
in two RCTs39, 40, and Bacteroidetes including Sutterela and Fusobacterium spp. have 
been associated with non-response to FMT40. Paramsothy et al. found significant 
changes in the microbiota at both week 4 and week 8 following FMT, with phylogenic 
diversity increased from UC patient baseline and similar to individual donors. This 
raises the possibility that the FMT infusions prior to week 4 were sufficient to induce 
remission40. In support of this proposition, Costello el al. demonstrated similar efficacy 
of FMT with a shorter duration and intensity of treatment41. 
Prolonged frozen storage will increase the Firmicutes to Bacteroidetes ratio as some of 
the gram-negative species are more fragile and deplete during frozen storage53. There 
may therefore be a theoretical benefit to frozen over fresh stool if elements of the 
Firmicutes phyla are relatively beneficial, compared with elements of the Bacteroidetes. 
Patients in the Rossen et al. study that did not demonstrate efficacy were treated with 
fresh stool39 and the majority of the patients who achieved remission in the other RCTs 
were treated with frozen stool38, 40, 41. There was also a higher rate of remission reported 
in the cohort studies using frozen stool (30%), compared with. fresh stool (22%). 
Given the success of FMT as an agent to induce remission in UC, there is now a need to 
investigate the mechanisms by which this effect is achieved. There are shifts in the 
microbial composition following FMT with increased diversity as well as more specific 
changes in bacterial phyla, particularly in responders40. These changes in microbial 
composition could result in functional alterations in luminal and epithelial metabolic 
and biochemical processes as well as mucosal immune responses to the microbiota. 
Butyrate production and oxidation are dependent on luminal bacterial metabolic 
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processes as are sulphate and nitrogen metabolic pathways54, 55. One small open-label 
study has attempted to potentiate this effect by combining the prebiotic pectin with 
FMT in half of their cohort, demonstrating an improvement in Mayo scores in the group 
receiving pectin34. There may be other elements of the stool, such as phages, fungi, bile 
acids, proteins and other bacterial products, that convey some of the observed 
therapeutic effect. Research into the mechanisms that lead to FMT effecting remission 
in UC should aid the development of rationally designed microbial therapies. In the 
interim, there is a need for studies to further investigate the different methods of FMT 
preparation and delivery as well as the role of FMT in the maintenance of remission in 
UC. There is also a need to develop infrastructure to deliver this therapy to patients 
efficiently. 
Conclusion 
FMT is an effective and safe therapy for the induction of remission of UC, compared 
with placebo. However, there are insufficient data on the long-term efficacy and safety 
of FMT for UC at present. There is a need for further research to refine the techniques 
of stool preparation and delivery for FMT, and to understand the microbial and 
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(n = 14) 
Articles excluded   (n = 26) 
 Incomplete RCT    1 
 Case reports    8 
 Case series    2 
 Clinical endpoints inadequately reported 5 
 No definition of active UC  3 
 No definition of remission  3 
 Inactive UC at enrolment   2 
 Concurrent infection   2 
Full-text articles and 
abstracts assessed for 
eligibility (n = 69) 
Duplicates removed 
(n = 25) 
Records screened 
(n = 2072) 
Records excluded 
(n = 2003) 
Records identified 
through database 
searches (n = 1965) 
Additional records 
through other 








Figure 6.2: Forest plot for remission in RCTs of FMT for UC 





Figure 6.3: Forest plot for clinical response in RCTs of FMT for UC 





Figure 6.4: Forest plot for endoscopic remission (endoscopic Mayo = 0) in RCTs of 
FMT for UC 
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Table 6.1: Cohort studies of FMT for UC: Protocol descriptions 
Author n Disease 
severity 
UC medication Bowel 
preparation 









et al. (2013) 
5 Mayo 
8–11 



































Cui et al. 
(2015) 
15 Montreal 
S2 and S3 
Mesalamine. Thiopurine, 
Steroid 



















(others ceased 1 week 
prior) 















Not specified – stable for 
≥2 weeks 










PEG Rifaximin Omeprazole Nasogastric 1 8g in 30mL 
infused 
NR 










500mg bd 3 
days 
None Colonoscopy 1 44g in 300mL 
infused 
Frozen 




NR NR NR NR Duodenoscopy, 
colonoscopy 
NR NR NR 
Vermeire et 
al. (2016) 
8 Mayo 3 5-ASA, azathioprine, 
steroid, Infliximab 
PEG None None 3 Nasojejunal, 











PEG None None Colonoscopy 1 150–200g Fresh 




NR PEG Vancomycin 
500mg bd 3 
days 






















None Colonoscopy 1 150-250g Fresh 
Legend: FMT = faecal microbiota transplantation; UC = ulcerative colitis; n = number of patients; NR = not reported; PEG = polyethylene glycol; 5-ASA = 5-




Table 6.2: Cohort studies of FMT for UC: Efficacy measures 
Author Follow-up 
(months) 
Def of response Def of clinical remission Clinical 
response 





et al. (2013) 




Mayo ≤2 1 2 2 0 0 
Kump et al. 
(2013) 
12 Mayo score 
reduced ≥3 
Mayo ≤2 2 1 3 0 0 
Kunde et al. 
(2013) 
6 PUCAI 
decrease by >15 
PUCAI <10 6 0 3 3 NR 
Cui et al. 
(2015) 




decrease by ≥3 
(week 4) 
UCDAI ≤2 with no 
individual subscore ≥1 
1  0 6 1 1 
Ren et al. 
(2015) 
1 to 7 Reduction in 
Mayo score 
more than 30% 
or ≥3 
Mayo ≤2, no subscore >1 7 0 0 7 7 
Scaldaferri 
et al. (2015) 
3 Mayo reduced 
by ≥2 
Mayo ≤ 2, no subscore > 1 6 2 0 2 2 
Suskind et 
al. (2015) 
3 NR PUCAI < 10 0 0 4 0 NR 
Wei et al. 
(2015) 
1 IBDQ increase 
>16 
IBDQ >170, Mayo <2 11 0 0 6 NR 
Goyal et al. 
(2016) 
6 PUCAI reduce 
by >15 
PCDAI <10 or 
normalisation of 
calprotectin/lactoferrin 
7 (1 month) 0 2 1 NR 
Vermeire et 
al. (2016) 
24 NR Mayo endoscopic subscore 
0/1 





2 Mayo score 
reduce by ≥3 
Mayo ≤2 11 0 30 0 NR 
Wei et al. 
(2016) 
3 30% reduction 
in Mayo or >16 
point IBDQ 
improvement 
Mayo ≤2 13 0 7 7 NR 
Ishikawa et 
al. (2017) 
1 Reduction in 
CAI ≥3 and 
CAI <10 
CAI <+3 14 1 3 6 NR 
Legend: Total Mayo score (0–12) with endoscopic Mayo score (0–3); PUCAI = Paediatric Ulcerative Colitis Activity Index (score 0–85); UCDAI = Ulcerative Colitis 
Disease Activitiy Index (score 0–12); IBDQ = Inflammatory Bowel Disease Questionnaire (score 32–224); CAI = Lichtiger’s Colitis Activity Index (range 0–16); NR 




Table 6.3: Study characteristics of RCTs of FMT for UC 




50 (23/25) 75 (38/37) 81 (41/40) 73 (38/35) 
Completed primary 
endpoint 
37 70  69 
Placebo Autologous stool Water Discoloured and 
odoured water 
Autologous 
stool in saline 
Endpoint (weeks) 12 weeks 6 weeks 8 weeks 8 weeks 
Disease severity SCCAI 4–11 + 
endoscopic 
subscore ≥1 
Mayo ≥4 with 
endoscopic subscore 
≥1 







NR 8.24 vs 7.86 8 vs 8 (median) 7.40 vs 7.24 
Mean Mayo at 
endpoint (donor vs 
placebo) 





























Mayo score of 
sigmoid and 
rectum 
Total Mayo <3  
with endoscopic 
Mayo = 0 
Total Mayo ≤2 with 
subscores of ≤1 for 
rectal bleeding, stool 
frequency and 
endoscopic 
appearance; and a ≥1 
point reduction in 
endoscopic subscore 
Total Mayo ≤ 
2 with 
endoscopic 
Mayo  ≤ 1 
Definition clinical 
remission 
SCCAI ≤2 NR Combined Mayo 
score of ≤1 for both 








≥3 point reduction 
in Mayo score 
≥3 point reduction in 
Mayo score or ≥50% 
reduction from 
baseline in combined 
























P = 0.51 P = 0.03 P = 0.02 P < 0.01 
Clinical remission 
induction 





P = 1.0 
NR 18/41 (44%) 
vs 
8/40 (20%) 




P < 0.01 
Clinical response 




13/25 (52%)  








P < 0.01 
21/38 (55%)  
vs 
7/35 (20%) 
P < 0.01 
Adverse events 
Worsening colitis 
Nil 1 placebo arm 1 placebo, 2 donor 
including one 
colectomy (3 in open-
label phase) 




2 placebo arm, 2 
donor arm: small 
bowel Crohn’s, 
abdominal pain 
2 placebo arm, 
3 donor arm: 2 
Crohn’s, 1 C. 
difficile 





Legend: Total Mayo score (0-12) with endoscopic Mayo score (0-3); FMT = faecal microbiota 





Table 6.4: Summary of donor stool delivery and processing methods in RCTs of 
FMT for UC 
 Rossen et al. 
201539 




Costello et al. 
201740 
FMT route Nasoduodenal Enema weekly Colonoscopy 
(×1) and enema 
(×39) 
Colonoscopy 
(×1) and enema 
(×2) 
FMT treatments during 
trial 
2 6 40 3 
Preparation 
fresh/frozen 
Fresh Fresh + Frozen Frozen Frozen 
Stool processing oxygen 
exposure 
Aerobic Aerobic Aerobic Anaerobic 
FMT stool weight (g) Median 120g 
(85–g 208g) 
8.3g  37.5g Colon 50g, 
Enema 25g 
Stool weight week 1 120g 8.3g 187.5g 100g 
Average stool weight per 
week of trial  
30g/w 8.3g/w 187.5g/w 12.5g/w 
Dilutant Saline (500mL) Water (50mL) Saline 97.5mL 
(65%) 
Saline (65%) 
Stool additive during 
preparation 
Nil Nil Glycerol 15mL 
(10%) 
Glycerol (10%) 
Stool donor relationship to 
recipient 
Anonymous Anonymous Anonymous Anonymous 








Table 6.5: Summary of microbiome analysis of RCTs of FMT for UC 
Study and sequencing 
type 
Bacterial changes in 
UC patients relative 
to donors 
Bacterial changes 














IX and XI 
↓Clostridium 
clusters IV, XIVa 
and XVIII 
No difference in 
diversity 
↑Diversity in responders 
post FMT 
↑Clostridial clusters IV, 
XIVa and XVIII 
↓Bacteroidetes 
No change in diversity 
post FMT 
Moayyedi et al. 201538 
 
16S ribosomal RNA 
sequencing 
 Change in microbiota 




Paramsothy et al. 201740 
 
16S ribosomal RNA 
sequencing 
 Clostridium cluster IV, 
XVIII, Ruminococcus, 
Barnesiella spp., Blautia 
spp., Dorea spp., 
Parabacteroides spp.  
Fusobacterium spp. and 
Sutterella spp. 




Supplementary Table 6.1: Cochrane collaboration’s tool for assessing the risk of 
bias: RCTs of FMT for UC 
 Rossen et al.39 Moayyedi et al.38 Paramsothy et al.40 Costello et al.41 
Random sequence 
generation 
+ + + + 
Allocation 
concealment 




+ ? ? + 
Blinding of 
outcome assessment 
+ ? + ? 
Incomplete outcome 
data 
+ + + + 
Selective reporting + + + + 
Other bias + + + + 







































































0 0 1 0 0 0 0 0 0 0 0 1 0 1 
Ascertainm












at the start 


























At least 6 
weeks 








1 1 1 0 1 0 0 1 1 1 1 1 1 1 
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Chapter 7: Discussion 
The body of work presented in this thesis explores FMT as a therapy for UC. During the 
course of this thesis, FMT has emerged from being a speculative proposition to an 
evidence-based therapy for the induction of remission of UC. FMT is now ready for 
large scale (phase 3) registration studies and evaluation as an agent for the maintenance 
of remission of UC.  
7.1 Key Outcomes, Significance and Limitations 
7.1.1 Frozen stool banking is critical to the reliable and timely delivery of faecal 
microbiota transplantation 
The stool bank established in Chapters 3 and 4 successfully facilitated the FMT in UC 
study conducted in Chapter 5. We were able to conduct three FMT procedures in a 
week using the same mixture of multi-donor stool in 73 patients. The banking of frozen 
stool allowed screening and stool donation to occur prior to a patient enrolling in the 
study. The stool bank also had a linked benefit of providing screened donor stool to 
treat South Australian patients with rCDI. This has resulted in the successful treatment 
of over 90 patients to date, many of whom would have otherwise required colectomy to 
cure their persistent infection. We were able to perform the first reported case 
worldwide of FMT for C. difficile induced toxic megacolon in a woman who, having 
declined surgery, would have otherwise succumbed to her infection (Appendix 1).1 This 
case demonstrated one of the major advantages that a frozen stool bank offers over ad 
hoc or patient-directed fresh stool donation—the rapid availability of thoroughly 
screened donor stool on demand. This patient deteriorated rapidly on Christmas eve, 
and finding and successfully screening a donor in time would not have been possible 
without access to pre-screened frozen stool aliquots. 
7.1.2 Anaerobic stool processing and glycerol storage media preserve bacterial 
viability 
The anaerobic stool processing methods developed and described in Chapters 3 and 4 
added an important dimension to the FMT study conducted in Chapter 5. It is known 
that the majority of the bacteria and archaea that inhabit the colon are obligate 
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anaerobes, and it has been demonstrated that important species such as 
Faecalibacterium prausnitzii are lost with aerobic stool processing and preserved with 
anaerobic stool processing.2 The culture studies in Chapter 4 demonstrated that the 
viability of a number of representative organisms was maintained to at least 6 months 
by using stool blended with normal saline and glycerol under anaerobic conditions. The 
three previously published FMT studies in UC used aerobic stool processing methods; 
therefore, potentially therapeutic organisms might have been lost by the time the stool 
was administered to patients in these studies. It is possible that the therapeutic effect 
seen in Chapter 5 (23% gain of donor FMT over placebo) was similar to that in previous 
positive trials despite a shorter duration and lower intensity of treatment because of the 
enhanced potency of anaerobically prepared stool. 
7.1.3 Short-duration and low-intensity faecal microbiota transplantation is 
effective at inducing remission in mild to moderately active ulcerative colitis and is 
acceptable to patients 
The study in Chapter 5 demonstrated that a three-dose, 1-week induction course of 
donor FMT was more likely to induce clinical and endoscopic remission in participants 
with active UC at week 8 than autologous FMT. The study also showed a significant 
difference in favour of donor FMT for the secondary end points of clinical remission 
and clinical response. 
This study used a rigorous composite primary end point of corticosteroid-free clinical 
and endoscopic remission and achieved a 23% gain of donor FMT over placebo. The 
meta-analysis in Chapter 6 demonstrated a 19% gain of donor FMT over placebo across 
all four RCTs. These results compare favourably with the most effective therapies 
currently available for UC. In the ACT-1 study, the gain for infliximab (combined 
5mg/kg and 10mg/kg groups) over placebo was 20%.3 In the Ultra 2 study, the gain for 
adalimumab over placebo was 7%4; in the PURSUIT study, the gain for golimumab 
over placebo was 11%5, and in the GENIMI 1 study, the gain for vedolizumab over 
placebo was 12%.6 All of these biologic agents are expensive and the anti-TNF 
therapies have potential side effects of serious infection or malignancy, which limit their 




Moayyedi et al. demonstrated efficacy of donor FMT over placebo with weekly enemas 
for 6 weeks7 and Paramsothy et al. demonstrated efficacy of donor FMT over placebo 
with an intensive regime that involved enemas 5 days per week for 8 weeks.8 This is a 
relatively high treatment burden that may limit its applicability in routine practice. The 
short induction regime of a single FMT delivered via colonoscopy followed by two 
FMT enemas over 1 week using anaerobically prepared stool suspension is likely to be 
more acceptable in “real-world” practice. 
7.1.4 Patients believe faecal microbiota transplantation to be an acceptable 
therapy for ulcerative colitis 
Patient acceptance of any new therapy is crucial to its effectiveness in the clinical 
setting. This was explored in Chapter 5 and supplement. Prior to undergoing FMT 
therapy, 96% of patients believed that FMT as carried out in this study would be 
acceptable to people with UC. Importantly, 95% of surveyed patients who received the 
short induction course in the study in Chapter 5 found it to be an acceptable therapy. 
The majority (92%) had no concerns about discussing their FMT treatment with friends 
and family, and 98% had no cultural or religious concerns with FMT. Moreover, 62% of 
patients believed that FMT helped their symptoms and 80% of patients considered it 
likely to be safe, with 20% of patients unsure of its safety. This patient feedback 
indicates that the overall patient experience of FMT therapy was favourable. 
7.1.5 Induction faecal microbiota transplantation therapy is not sufficient to 
maintain remission in the majority of ulcerative colitis patients 
The study in Chapter 5 was the first to assess efficacy and safety out to 1 year following 
donor FMT. These 12-month data have a number of limitations. First, they were “open-
label” and are without a control group. Second, some patients had changes in therapy 
during the period of follow-up. Despite these limitations, some patients appeared to 
achieve sustained remission following donor FMT without additional medical therapy. 
Of the 12 patients who achieved clinical and endoscopic remission in the donor FMT 
arm, 5 (42%) were in clinical and endoscopic remission at 12 months and 3/12 reported 
no symptoms in the intervening 12-month period. At 12 months, 21 of 49 (49%) 
patients who underwent colonoscopy were in clinical and endoscopic remission; 9 of 
these 21 (43%) patients reported no symptoms since receiving donor FMT. At 12 
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months, 27 of 49 (55%) of patients were in clinical remission and 8 of 43 (19%) were in 
endoscopic remission. 
7.1.6 No short-term safety signal for faecal microbiota transplantation for 
ulcerative colitis; larger studies with longer follow-up required 
There were very few side effects noted during the induction phase of the study in 
Chapter 5. There were three serious adverse events in the dFMT group (worsening 
colitis, CDI requiring colectomy and pneumonia) and two in the aFMT group (both 
worsening colitis), and none were obviously attributable to FMT. Similarly, the 
induction phases of the other three RCTs analysed in Chapter 6 showed low rates of 
adverse effects. A recent Cochrane review meta-analysis addressed serious adverse 
events in the induction phase of these studies (7–12 weeks) and found no significant 
difference between the donor FMT and control groups; 10/140 (7%) in the FMT group, 
compared with 7/137 (5%) in the control group (RR 1.40, 95% CI 0.55–3.58, I² = 0%).9 
The study of FMT in UC in this thesis was the first to assess adverse effects at 12 
months. Of the 61 patients who completed the 12-month adverse effects questionnaire, 
31 (51%) reported at least one adverse event. Many of these adverse events would be 
expected in the usual course of UC, such as 13 patients reporting worsening colitis. 
Nine patients underwent colectomy during the 12-month follow-up (including one 
patient within 8 weeks of donor FMT). Colectomy was an expected outcome for many 
patients in this study because they often had disease refractory to available medical 
therapy. Of note, maintenance therapy with biological agents was not available to many 
of the patients in this study as they were only funded by the PBS for this indication in 
2015. There were eight reported infections, and these appeared to be unrelated to FMT; 
however, there were two cases of CDI, one of which resulted in colectomy 7 weeks 
following donor FMT. UC is a risk factor for CDI; however, CDI in this context is 
notable given the high efficacy of FMT in treating CDI in patients with IBD.10 
There were five immune-related diseases (two new cases of psoriatic arthritis and one 
each of enteropathic arthritis, Crohn’s disease and allergy to infliximab) that developed 
in the 12-month follow-up period. Enteropathic arthritis occurs in up to 14% of 
individuals with UC11; thus, the development of this condition in this cohort is not 
unexpected with or without FMT. It is not uncommon for cases of putative UC to be 
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subsequently diagnosed as Crohn’s disease, and it is unclear whether the patient who 
developed Crohn’s disease had an incorrect diagnosis entering the study or whether he 
developed new Crohn’s disease following donor FMT. 
There were two cases of psoriatic arthritis that developed in the 12 months of follow-up. 
Psoriatic arthritis is a T cell-mediated disease in which pathogenic T cells produce IL-
17 in response to IL-23.12 Patients with psoriatic arthritis have been noted to have 
dysbiosis with low levels of Akkermansia mucinophilia species and Ruminococcus 
genera, compared with controls.13 In a mouse model, segmented filamentous bacteria 
induced autoimmune arthritis through the ability to specifically promote differentiation 
of the Th17 subset14. The gut microbiota can influence local and systemic immune 
responses via alterations in intestinal permeability, molecular mimicry and activation of 
effector immune cells.15 It is therefore possible that alterations in the gut microbiome 
may contribute to the direction of differentiation of naïve T cells into specific effector T 
cells that drive the pathogenesis of psoriatic arthritis. 
During the 12 months of follow-up, 13 patients reported weight gain, 8 weight loss and 
40 unchanged weight (Supplementary Table S5.14). There is evidence from studies in 
mice that an obese phenotype can be transmitted by FMT from an obese individual to a 
germ-free mouse, resulting in weight gain in that animal.16 There is a single case report 
of obesity occurring in a human recipient of donor FMT for CDI; however, it was not 
clear from this case report that donor FMT was responsible for the weight gain 
observed.17 In the study in chapter 5, donors all had a normal BMI (18–25); therefore, 
any change in weight post FMT was unlikely due to acquiring the phenotype from an 
individual with an abnormal BMI. 
The 8-week adverse events data did not demonstrate any safety signal for donor FMT; 
however, the study was not powered to assess this secondary end point. In addition, 8 
weeks’ follow-up is not sufficient time to manifest many potential adverse events. The 
12-month safety data give a longer view but have the limitation of being “open-label”. 
Without a control group, it is not possible to assign causality from donor FMT to any 
adverse effects as UC patients are at risk of developing many of the observed conditions 
irrespective of therapy. 
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7.1.7 Lamina propria mononuclear cell populations correlate with disease severity 
but not with donor faecal microbiota transplantation effect 
The immunological changes that occur in UC in humans are not well characterised or 
well understood. UC is known to be associated with damage to the mucosal barrier, 
allowing the luminal microbiota to trigger a sustained inflammatory response. Previous 
studies have suggested that UC is associated with a possible atypical type 2 helper T 
cell immune response driven by NK T cells (potentially linked with a loss of immune 
tolerance) with an altered profile of regulatory T cells and microbial sensors on 
dendritic cells.18-21 However, these data have many limitations in that they derive from 
animal models or from small or poorly characterised cohorts of human subjects.  
This was the first study to assess mucosal and blood immune cell populations prior to 
and following donor FMT for UC. As far as we are aware, this was also the first study 
to assess mucosal and blood mononuclear cell populations in relation to disease activity 
(total Mayo score) in UC. Previous studies have compared UC patients with healthy 
controls only. The exploratory studies from Chapter 5 demonstrate an association of a 
number of mucosal immune cell populations and total Mayo score. Lamina propria B 
cell (β = 0.46 [95% CI 0.06 to -0.87]; P = 0.03) and dendritic cell (β = 0.43 [95% CI 
0.04 to -0.82]; P = 0.03) populations were positively associated with total Mayo score at 
baseline. Conversely, lamina propria NK cells (β = -0.50 [95% CI -0.91 to -0.09]; P = 
0.02) were negatively associated with total Mayo score at baseline. Lamina propria B 
cell (β = 0.67 [95% CI 0.13 to -1.2]; P = 0.03) and T regulatory cell (β = 1.1 [95% CI 
0.27 to -2.0]; P = 0.03) populations were positively associated with change in total 
Mayo score from baseline to week 8. Conversely, helper T cells (β = -0.8 [95% CI, -1.4 
to -0.19]; P = 0.03) were negatively associated with change in total Mayo score from 
baseline to week 8. The association between disease severity at baseline and LPMC 
populations as well as change in disease severity and LPMC populations are novel 
findings. 
Fuss et al. previously compared samples from 15 patients with severe UC with six 
controls without colitis by using Student t tests without adjustment for patient-related 
factors. They found increased numbers of nonclassical NK T cells (i.e., NK T cells that 
do not bear an invariant T cell receptor) that produce markedly increased amounts of 
IL-13.20 In Chapter 5 of this thesis, there was no association between the entire NK T 
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cell population or the nonclassical NK T cells and total Mayo score at baseline. The 
analyses in this thesis included 10 LPMC populations and two peripheral blood 
mononuclear cell populations that were compared with disease severity (total Mayo 
score). Samples were taken from a greater number of patients (67) than previous 
studies20,22, and statistical modelling that adjusted for multiple potential biases (e.g.,  
patient age and steroid use) was used, making the data here more robust. 
There is evidence for a loss of immunoregulation to luminal antigens in UC. Peripheral 
blood lymphocytes and LPMCs respond vigorously to antigens from sonicated 
autologous bacteria but not bacteria from healthy stool donors.23 There is also evidence 
that regulatory T cells (CD4+CD25+FOXP3+) may not adequately counteract the 
inflammatory response in UC.24 In previous studies, CD4+LAP+ T cells have been 
noted to be increased in UC relative to controls; however, FOXP3+ regulatory T cells 
were not increased.22 We therefore hypothesised that donor FMT may induce a 
therapeutic response by stimulating T regulatory cell activity. However, donor FMT 
was not significantly associated with change in regulatory T cell numbers or any other 
lamina propria cell populations at week 8. Similarly, donor FMT adjusted for total 
Mayo score was not significantly associated with change in any lamina propria cell 
populations at week 8. If the therapeutic effect of donor FMT was primarily driven via 
stimulating a particular immune population, then a correlation with donor FMT and/or 
donor FMT adjusted for total Mayo score would be expected. The pattern that we have 
observed of correlations between various cell populations and both baseline total Mayo 
score and change in total Mayo score from baseline but not FMT treatment effect 
(adjusted and unadjusted for total Mayo score) suggests that the immune populations 
studied are not the primary driver of the donor FMT effect. However, the 
immunological analyses in this study were exploratory and had limitations of analysing 
the proportions of mononuclear cells in the lamina propria without assessing their 
behaviour. It is therefore possible that changes in the activity of mononuclear cells may 




7.1.8 Butyrate levels were not associated with disease severity or donor faecal 
microbiota transplantation effect 
Another exploratory hypothesis in this thesis was that donor FMT may have a 
therapeutic effect by increasing colonic butyrate levels. Butyrate, a product of colonic 
bacterial fermentation of dietary fibre, is the primary energy source of colonocytes.25 
Further, butyrate is essential for the maintenance of the colonic mucosal barrier and 
inhibits colonic inflammation, carcinogenesis and oxidative stress.26 Despite the known 
beneficial effects of butyrate on colonocyte health, butyrate delivered via enema has 
failed to demonstrate therapeutic efficacy27-29 or improve inflammatory and oxidative 
stress parameters in human subjects with UC.30,31 In Chapter 5, we did not find any 
association between butyrate or other SCFA levels in stool, and UC disease activity or 
donor FMT therapy. Similarly, butyrate-producing species and genera such as 
Faecalibacterium prausnitzii, Rosburia spp. and Anaerostipes spp. did not increase 
following donor FMT. These exploratory data suggest that the therapeutic effect of 
donor FMT is not mediated via increasing butyrate production by the microbiome. It is 
possible, however, that butyrate production did increase following donor FMT but did 
not result in an increased butyrate concentration being measured as it was used at an 
increased rate by healing enterocytes with recovery of their metabolic capacity. 
7.2 Future Research Directions 
Based on the work performed in this thesis, future research directions regarding FMT as 
a therapy for UC are presented below. 
There are two major issues that need to be resolved before FMT can become a realistic 
treatment option for patients with UC in Australia. The first is evidence of efficacy and 
safety of FMT as a maintenance therapy and the second is regulatory change to allow 




7.2.1 Maintenance faecal microbiota transplantation for ulcerative colitis and 
further safety data are required 
There are currently no published trials examining FMT maintenance therapy in UC. 
However, there is a single trial published in abstract form for which limited details are 
available. In this single-blind randomised placebo-controlled trial, 78 Indian patients 
underwent induction therapy with multi-session FMT (0, 2, 6, 10, 14, 18 and 22 weeks). 
Forty-three of 78 patients treated with induction FMT achieved clinical remission; 22 of 
these were randomly assigned to receive FMT and 21 received placebo 
colonoscopically every 8 weeks. The primary outcome was achieved in 19 of 22 
(86.4%) participants allocated to FMT versus 14 of 21 (66.7%) patients allocated to 
placebo (P = 0.126). The secondary end point of histological remission [12 of 22 
(54.5%) with FMT versus 3 of 21 (14.3%) with placebo; P = 0.006] was achieved in a 
significantly higher number of patients with donor FMT than placebo. The results from 
this abstract are encouraging and the full-trial publication is awaited. 
Further trials of maintenance therapy are required to establish efficacy and safety of 
FMT as maintenance therapy. In the published abstract, FMT was delivered via 
colonoscopy every 8 weeks; this demonstrates proof of concept but is not deliverable in 
real-world practice. Therefore, an important question to answer with regard to 
maintenance therapy is the optimal delivery method.  In the outpatient setting, a therapy 
would need to be delivered via capsule or enema to be feasible for patients. Other 
important questions to answer are dose and dose interval of both induction and 
maintenance therapy. Dose-finding maintenance trials of FMT for UC will be important 
to determine dosing interval and quantity. They may also shed light on the mechanisms 
responsible for the therapeutic effect of FMT. These trials will be better placed than 
induction studies to monitor a number of elements (such as bacterial strains or their 
products) that may be driving the therapeutic response and correlate their levels with 
disease activity. Repeated sampling over time with associated meta-data would give 
more power to potentially elucidate complex interactions that may be at play. 
In addition to maintenance data, further studies with larger patient numbers and long 
follow-up periods are required to assess the long-term safety of FMT for UC. In future, 
if FMT is prescribed for the treatment of UC outside of the clinical trial setting, then a 
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dedicated registry, such as has been established in the United States of America for 
FMT for CDI32, should be established and would provide additional safety data. 
7.2.2 Regulatory change and funding of faecal microbiota transplantation are 
required 
Delivering FMT for UC in clinical practice in Australia would require nationwide 
access to screened stool aliquots. This would require both regulatory change, Australian 
Register of Therapeutic Goods, and funding from the Medicare benefits schedule or 
other government agencies to ensure equity of access. 
Frozen stool banking facilities that provide timely, safe and effective access to FMT are 
highly desirable. OpenBiome in the United States of America is a good model.33 At 
present, there is both under- and over-regulation of FMT in Australia. On one hand, 
FMT may be delivered in the local care setting without being subject to agreed 
standards for screening and manufacturing practice. Medical practitioners are able to 
compound and administer an unregistered therapeutic product to a patient under their 
care with appropriate consent. Conversely, supply of FMT aliquots from stool banks 
that adhere to rigorous production standards is not currently permissible. Current 
legislation prohibits the wider distribution of therapeutic products that are not certified 
according to Good Manufacturing Practice (GMP) protocols. The need for GMP 
certification, as currently interpreted, represents a significant barrier to the distribution 
of screened stool aliquots from stool banks. Beyond stringent screening for potentially 
transmissible conditions, a GMP requirement for standardisation of donor faecal 
product is not achievable as stool composition varies widely. As a consequence, access 
to safe and screened FMT therapy for CDI in Australia is inequitable. Developing a 
regulatory framework that focuses on achievable screening and safe manufacturing 
practice without product standardisation would facilitate this. 
Unlike most pharmaceutical therapies, FMT is not currently funded by most third-party 
payers, and this presents problems with equity of access to this therapy. Given the 
strong evidence for FMT as a treatment of rCDI, funding should be provided within 
government health budgets. As indications for FMT in other diseases such as UC 




7.2.3 Does faecal microbiota transplantation act via altering the metabolic capacity 
of the recipient microbiota? 
The observation of no association of donor FMT treatment effect with colonic lamina 
propria immune populations or luminal butyrate levels suggests that FMT may be 
reducing inflammation via an alternative mechanism. One possible explanation is that 
FMT has a therapeutic effect in UC by resolving a metabolic deficit within the colonic 
microbiota. 
There is evidence that there is a failure of butyrate oxidation in the colonocytes of 
patients with UC.34-36 This leads to an energy deficiency state within the colonocyte 
with an associated loss of critical functions such as maintenance of the mucosal barrier 
by mucus and tight-junction production. Butyrate oxidation in human colonocytes has 
been demonstrated to be inhibited by high levels of nitric oxide.36 Nitric oxide is 
produced by bacterial reduction of  dietary nitrate (potentiated by sulphide) as well as 
by inflammatory immune cells.37 
It is plausible that the treatment effect of donor FMT results from the acquisition of 
metabolic functional capacity from donor microorganisms. A number of organisms that 
increased following donor FMT (table S5.8) have been demonstrated to be involved in 
nitrogen, sulphur and hydrogen metabolism in vitro. Nitric oxide, a product of bacterial 
reduction of nitrate as well as lamina propria inflammatory cells, has been proposed as 
an important injurious agent in UC pathogenesis. High levels of nitric oxide can inhibit 
the ability of enterocytes to utilise butyrate38, and sulphides in the colon are able to 
inhibit the reduction of nitric oxide.39,40 Peptococcus niger, Acidaminococcus intestini 
and Odoribacter splanchnicus can all reduce nitric oxide to nitrous oxide and nitrogen. 
M. smithii has an important role reducing sulphide in the colon. M. smithii and the 
reductive acetogenic bacteria species, Clostridium methylpentosum, also utilise 
hydrogen and carbon dioxide and may  optimise colonic fermentation.41 
The two organisms most strongly associated with donor FMT treatment effect (table 
S5.9), Anaerofilum pentosovorans and Bacteroides coprophilus, do not reduce sulphate 
to the injurious sulphide; however, their ability to reduce nitric oxide (theoretically 
beneficial) is not known.42,43 
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The major limitation of the microbiome analysis in Chapter 5 is that 16S rRNA 
sequencing was used to identify candidate organisms associated with donor FMT effect. 
16S rRNA sequencing can characterise bacteria phylogenetically in terms of their 
genera and can assign species grouping for some organisms. However, 16S rRNA 
sequencing does not have the resolution to accurately identify strains. It is therefore 
difficult to make inferences about the metabolic potential of organisms identified using 
this technique. Two different strains from the same species can have different metabolic 
potential and therefore disease potentiating or ameliorating potential. Metagenomic 
sequencing was prohibitively expensive when this study was designed. However, the 
cost of metagenomic sequencing has fallen dramatically in the last few years and, as a 
result, it is far more accessible to researchers. 
Future studies should use a combination of metagenomic sequencing and culture based 
techniques to identify candidate metabolic pathways and corresponding organisms that 
may be involved in the disease process or the FMT treatment effect. This data could 
then be used to select candidates for rationally designed microbial therapeutics that 
could replace donor FMT. In addition to using metagenomics to survey the changing 
metabolic potential of the microbiome post FMT, more extensive metabolomics would 
also be informative. In this study, there was no association with SCFA levels and the 
donor FMT effect; however, other metabolites may be important. Given the proposed 
role that sulphites and nitrite/nitric oxide may play in UC pathogenesis37, measuring 
these metabolic products would be informative in terms of supporting or refuting the 
evidence from the colonocyte culture models as to the role these pathways play in UC 
pathogenesis. It may also be helpful in exploring the therapeutic benefit of donor FMT. 
7.2.4 Faecal microbiota transplantation as a tool to discover disease mechanism 
and microbial therapy 
Uncovering the mechanism of action of donor FMT would pave the way for the 
development of rationally designed microbial therapeutics. It seems likely that the 
demonstrated effect of donor FMT is mediated by microbes or microbial products and 
that these elements could be refined and delivered in a standardised therapy. This would 
have a number of advantages over donor FMT. First, a standardised product is likely to 
provide a more predictable therapeutic and safety profile than donor FMT and would be 
more easily evaluated by regulatory agencies. Second, reducing the therapy to include 
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only the necessary active constituents would enhance safety by reducing the risk of 
disease transmission due to failed screening of a donor. It is known from blood donor 
safety analysis that screening failures do rarely occur for known diseases and 
historically occurred for hepatitis C before the virus was characterised.44,45 These 
infectious risks are present for FMT but would be absent for defined microbial consortia 
derived from pure isolates. Third, defined strains or consortia of organisms with known 
metabolic potential would potentially allow tailoring of therapy to the specific microbial 
“deficit” identified in a prospective patient’s gut microbiota. Theoretically, these 
advantages of rationally designed microbial therapy should lead to gains in both 
efficacy and safety. 
There are currently efforts underway to develop microbial therapies for UC. Data from 
this thesis have been licensed by the University of Adelaide to the UK company 
Microbiotica for the purpose of developing a rationally designed microbial therapy. 
Seres Therapeutics presented data of a phase 1b study on a consortia of spore-forming 
gram-positive bacteria (SER-287) in abstract form in 2018. The trial included 58 adults 
with mild to moderate UC assigned to one of three treatment arms or placebo. The 
treatment arms included 6 days of vancomycin pre-treatment followed by 8 weeks of 
SER-287, either daily or weekly, and placebo pre-treatment followed by weekly SER-
287. Remission was defined as a total modified Mayo score ≤2 and endoscopic subscore 
≤1. Microbiome engraftment was also assessed. Remission occurred in 6/15 (40%) 
receiving vancomycin pre-treatment followed by SER-287 daily, 2/15 (13%) receiving 
placebo pre-treatment followed by SER-287 daily, 3/17 (17%) receiving vancomycin 
pre-treatment followed by SER-287 weekly and 0/11 (0%) receiving placebo. 
Engraftment of SER-287 bacteria was greatest in the vancomycin pre-treatment groups 
followed by the SER-287 treatment group, compared with other SER-287 treatment or 
placebo groups. This trial had small numbers and participants were divided into four 
study populations. Therefore, it was not adequately powered to assess efficacy or safety; 
however, the results are interesting and larger phase III studies are awaited. 
An interesting finding from this study was the possible greater efficacy of the 
vancomycin pre-treatment arm than the placebo pre-treatment arm. It appeared that by 
reducing luminal gram-positive populations with vancomycin, both the therapeutic 
effect and the engraftment of the bacterial treatment were enhanced. None of the four 
RCTs of FMT for UC assessed in Chapter 6 used antibiotic pre-treatment. However, all 
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of the studies other than Moayyedi et al. used bowel preparation with polyethylene 
glycol, which would have the effect of reducing the colonic bacterial load prior to FMT. 
The systematic review conducted in Chapter 6 included 14 cohort studies of FMT for 
UC, five of which used antibiotic pre-treatment. The rate of clinical remission with 
FMT was 19/57 (33%) in the studies using antibiotic pre-treatment, compared with 
20/111 (18%) without antibiotic pre-treatment. Antibiotic pre-treatment perhaps offered 
some advantage despite heterogeneity in study design between the groups. Donor FMT 
contains a large number of phages, which may provide a similar effect to antibiotic pre-
treatment by reducing recipient colonic microbial populations. Phages may not be 
present or be present in far smaller numbers in defined microbial consortia such as 
SER-287, and therefore antibiotic pre-treatment may provide a greater benefit in this 
setting than in the setting of donor FMT. 
7.2.5 Other indications for faecal microbiota transplantation 
This thesis has demonstrated the utility of using FMT as a therapy, a tool to learn about 
disease pathogenesis and a means to develop new microbial therapies. In these respects, 
FMT offers huge potential. There are recent trials of FMT published in irritable bowel 
syndrome46,47, hepatic encephalopathy48 and autism49, and a number are underway in a 
variety of other conditions. 
There are theoretical reasons why FMT may be of benefit to patients with diseases 
where there is a metabolic “lesion” or deficiency within the gut microbiome. Traditional 
medical therapies have consisted of molecules that knock out certain unwanted 
physiological processes such as a bacterial enzyme or inflammatory cytokines. Almost 
all current medications from antibiotics to new anti-TNF biological drugs operate in this 
way. This model is highly successful where there is a single pathogen or isolated 
pathway that can be targeted. However, many common chronic diseases are associated 
with reduction in diversity and metabolic function within the microbiome.50 If loss of 
these functions performed by the microbiome results in disease, then replenishing these 
metabolic pathways would be a logical solution. Knocking out downstream 
physiological pathways with drugs in this context should only be expected to yield 
modest results. FMT and microbial therapies offer the possibility of ecological 
restoration and replenishment of lost metabolic function and, in this respect, involve a 




This thesis has demonstrated that FMT is an effective therapy for the indication of 
remission of active UC. This opens up the possibility for rationally designed microbial 
therapeutics as novel therapies for the disease. New therapies for UC are needed 
because those currently available are limited by incomplete efficacy and adverse effects 
including serious infections and malignancy. Further trials of FMT in UC assessing its 
role in maintenance therapy and its long-term safety are needed before FMT can 
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Appendix 1: Fecal Microbiota Transplant for Clostridium 
difficile Colitis-Induced Toxic Megacolon 
Background 
Toxic megacolon is a severe and potentially fatal complication of Clostridium difficile 
(CD) induced colitis that occurs in up to 5% of cases. It results in acute colonic 
distension and is accompanied by major systemic disturbance, including shock. The 
standard treatment for toxic megacolon is subtotal colectomy. This manuscript describes 
the first case of faecal microbiota transplantation (FMT) as an effective treatment for 
toxic megacolon without surgery reported in the literature. This case demonstrates the 
life-saving potential of having access to pre-screened donor stool, frozen and available 
on demand. 
Presented in this chapter is the manuscript published in the American Journal of 
Gastroenterology 2015; 110 (5): 775-7 
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To the editor: 
Toxic megacolon (TMC) is a severe and potentially fatal complication of colonic 
inflammation in which acute colonic distension >6 cm is accompanied by major 
systemic disturbance(1). It occurs as a complication in up to 5% of cases of Clostridium 
difficile (CD) induced colitis(2-4). The standard  treatment for TMC is subtotal 
colectomy(5). Here we report the first case of fecal microbiota transplant (FMT) as an 
effective treatment for TMC without surgery. 
A 69-year-old woman was transferred to our institution from a renal dialysis centre with 
fever, abdominal pain and 4 days of profuse watery diarrhoea. Three weeks prior she 
had received oral vancomycin for a severe episode of CD colitis following a course of 
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oral flucloxacillin for cellulitis. Her past medical history included haemodialysis for 
end-stage renal failure secondary to polycystic kidney disease, polymyalgia rheumatica, 
cardiomyopathy, hypertension and post-polio syndrome. 
On admission she was febrile and tachycardic. Her abdomen was soft with bowel 
sounds present but there was diffuse tenderness over the lower abdomen without 
guarding. CT abdomen showed marked wall thickening throughout the colon without 
dilatation. Flexible sigmoidoscopy showed pseudomembranous colitis of the rectum and 
sigmoid colon (image 1). CD toxin was positive by PCR. Despite oral vancomycin 
(250mg 6 hourly) her condition deteriorated over the following 3 days with ongoing 
fever, frequent diarrhea and diffuse abdominal pain. On day 4 her bowels did not open 
and she developed shock (blood pressure 76/30 mmHg, pulse 110 bpm). She was 
transferred to the intensive care unit for fluid resuscitation and intravenous 
metronidazole was commenced in addition to oral vancomycin. 
Following extensive discussion with medical and surgical staff she declined subtotal 
colectomy. An abdominal x-ray the following morning demonstrated dilatation of the 
cecum and ascending colon to 9 cm consistent with TMC (image 2). She remained 
febrile and became drowsy. The patient and her relatives consented to FMT 
understanding that the procedure would be investigational and not standard therapy for 
TMC. Then, 160mL of thawed fecal suspension was administered via a push 
enteroscope positioned in the jejunum, as colonic delivery was thought to be too high 
risk. The donor stool had been collected 5 months earlier and stored at -112°F in a 10% 
glycerol suspension. The material was thawed 3 hours prior to the procedure. 
Following FMT, the patient became afebrile within 24 hours. Her abdominal pain 
resolved and inflammatory markers improved. On day 7 post FMT, the patient 
developed left lower lobe pneumonia that was treated successfully with 12 days of 
antibiotic therapy. She was discharged from hospital and subsequently had no further 
reported CD colitis within 12 months of follow-up. 
To our knowledge this is the first case report of successful treatment of TMC due to CD 
with FMT and antibiotics without surgery. Although a previous case was reported(6), 
the patient received FMT following decompression surgery and it is possible the 
improvement partially reflected mechanical factors. Our patient declined surgery and 
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FMT was conducted as a “last ditch” measure. The prompt and durable response to 
FMT at 12 months suggests that in some cases FMT can reverse even severe disruption 
to colonic physiology associated with TMC in CD colitis. However, FMT cannot be 
recommended until further data are available and should be currently considered only 
where surgery is declined or unavailable. 
For patients who develop recurrent, antibiotic refractory CD colitis, FMT has been 
shown to offer the best chance of cure with success in 81–94% of cases(7, 8). As such it 
is becoming standard treatment for recurrent CD colitis(9). However FMT remains an 
investigational therapy and should be considered within the framework of relevant 
policies such as those set out by the FDA. Although FMT should not replace surgery in 
the majority of patients with TMC, the outcome reported here suggests that the role of 
FMT in CD colitis may expand to encompass later stage disease particularly for patients 
who decline surgery or have unacceptable surgical risk. 
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1. Objectives of Study 
Primary 
• To determine whether faecal microbiota transplantation (FMT) improves clinical 
and inflammatory outcomes in patients with active ulcerative colitis (UC). 
Secondary 
• To determine whether any clinical change is accompanied by an alteration in the 
faecal- and/or mucosa-associated microbiome of UC patients prior to and 
following FMT. 
• Assessment of alteration and durability of change in the recipient microbiota 
after FMT in UC patients. 
• To examine the mucosal immune changes induced by FMT and to examine 
whether they are influenced by changes in microbiome and/or disease activity. 
• To examine the durability of clinical response/improvement after initial response 
to FMT in subjects with active UC. 
• To establish patient satisfaction with FMT as a therapy for UC. 
2. Background and Significance 
UC is a chronic inflammatory bowel disease (IBD) that is characterised by recurring 
episodes of inflammation primarily involving the mucosal layer and occasionally the 
submucosa of the colon. Inflammation usually originates in the rectum and progresses 
in a contiguous fashion proximally. Although the aetiology of UC remains unclear, 
several factors are believed to play a role in its development and progression, including 
host genotype, immune disequilibrium and the composition of microbial communities 
resident in the gastrointestinal tract. 
There is strong evidence for the involvement of microbes in the development of UC. 
IBD is associated with changes in the diversity of the gut microbiota, and although 
alterations in the abundance of specific bacterial species have often been identified, 
there remains no specific organism that is reliably associated with the condition1. There 
also appear to be changes in the functional activity of the microbiome, with changes in 
gene expression as well as protein production in the microbes of patients with IBD1. It 
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is unclear whether the altered microbiota is a result of, or initiates, the inflammatory 
process in humans. There is some evidence, however, that an altered microbiota 
develops prior to the onset of colitis in an animal model of interleukin (IL)-10 knockout 
mice2. 
Intestinal flora and their metabolic products play a critical role in maintaining the health 
of the colon. Patients who undergo ileostomy and have subsequent diversion of the 
luminal contents from the colon often develop a “diversion” colitis. The distal 
colonocytes in this instance are deprived of short-chain fatty acids (SCFAs) such as 
butyrate, a product of anaerobic bacterial fermentation of undigested dietary 
carbohydrates3. Yet, animal models of IBD also require bacteria within the colon for 
inflammation to develop4. It has been observed that altering the bacterial and nutrient 
colonic milieu by diverting the faecal stream using ileostomy reduces the recurrence of 
Crohn’s disease in the colon5. Further supporting the notion that bacterial antigens 
contribute to, or drive, the autoimmune injury to the bowel, is evidence that antibiotics 
have some therapeutic efficacy in UC. In a recent systematic review, antibiotic therapy 
for UC was significantly associated with remission6. Antibiotic therapy gave a 
statistically significant relative risk reduction for active disease of 0.64 (CI 0.43–0.96). 
However, while bacteria are necessary to develop IBD, with germ-free animals unable 
to be induced to develop IBD, bacterial absence (or change in abundance/mix) can also 
lead to inflammation. 
Probiotics have as yet demonstrated only limited therapeutic efficacy in UC7. In vitro 
studies have demonstrated that probiotic bacteria are able to modulate gut immune 
cells8,9, while in vivo in a German study, E.coli Nissle 1917 was equivalent in efficacy 
to mesalamine for maintenance of remission of UC10. Additionally, a randomised trial 
of 77 patients with UC found that VSL#3, a cocktail of eight different bacteria, was 
more effective than placebo in improving symptoms and inducing remission at 12 
weeks11. For patients with pouchitis, trials with VSL#3 have shown both therapeutic 
and prophylactic efficacy12. The outcomes in probiotic studies, however, have often 
been inconsistent and modest. This may be due to the variable actions of the different 
bacterial species that have been tested as well as the general limitations of most 
probiotic preparations. These probiotics provide a comparatively low number and 
diversity of bacterial species in comparison with the vast human gut microbiota. For this 
reason, some probiotic bacterial strains may not be able to compete effectively against 
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the complex interactions of an established and adapted indigenous gut microbial 
community13. 
FMT has been described as “the ultimate probiotic” as it provides an entire microbiome 
to the recipient. This therapy delivers a much greater number and diversity of bacteria 
than any current commercially available preparation. FMT was first reported in humans 
by Eiseman et al. in 1958 in the treatment of four patients with pseudomembranous 
colitis14. Three of the four patients were described as terminally or critically ill requiring 
vasopressor support and all were successfully cured. Over the subsequent years, there 
have been case reports and case series describing FMT predominantly for Clostridium 
difficile colitis but also for treating IBD, irritable bowel syndrome and 
constipation13,15,16. In the past decade, there has been a heightened interest in the use of 
this therapy, predominantly driven by increasing rates of recurrent C. difficile infection. 
During this time C. difficile has become more frequent, more severe and more refractory 
to standard treatment as well as more likely to relapse17. Standard treatment with 
metronidazole or vancomycin alters the normal gut flora that would usually provide 
colonisation resistance against C. difficile infection. For this reason, after successful 
initial therapy, up to 35% of patients will experience a symptomatic recurrence after 
ceasing antibiotics18. A subset of patients will have multiple recurrences and subsequent 
relapses occur in 45–65% of patients who have relapsed one or more times19,20. For 
patients with recurrent C. difficile colitis, FMT offers the greatest chance of cure of any 
therapy, with success in 87–100% of cases13,21-25. This impressive success rate is 
presumably due to the ability of the transplanted bacteria to recolonise/occupy the 
missing components/niches of the normal intestinal microbiota, thus removing the 
microbial niche that C. difficile would otherwise exploit. 
FMT for UC was first reported in the literature by a gastroenterologist, Dr Justin D 
Bennet, from Kansas City, who described the results of a faecal transplant he received 
for his own disease26. Dr Bennet had continuous active, severe UC for 7 years, 
confirmed endoscopically and histologically, that was refractory to standard therapy. Dr 
Bennet described receiving antibiotics to “sterilise” his bowel prior to retention stool 
enemas. At the time of publication in 1989, he had been symptom and medication free 
for the first time in 11 years, at 6 months post FMT. 
 
227 
Borody et al. described case reports of six patients (three men and three women aged 
25–53 years) with UC for at least 5 years who were treated with FMT16. All patients had 
suffered severe, recurrent symptoms and UC had been confirmed on colonoscopy and 
histological examination. Faecal flora donors were healthy adults who were extensively 
screened for parasites and bacterial pathogens. Patients were prepared with oral 
antibiotics and oral polyethylene glycol lavage. 
Faecal suspensions were administered as retention enemas and the process repeated 
daily for 5 days. By 1 week post FMT, some symptoms of UC had improved. Complete 
reversal of symptoms was achieved in all patients by 4 months post FMT, by which 
time all other UC medications had been ceased. At 1 to 13 years post FMT, and without 
any UC medication, there was no clinical, colonoscopic or histologic evidence of UC in 
any patient. The authors concluded that colonic infusion of donor human intestinal flora 
can reverse UC in selected patients, and that these results support the concept of 
abnormal bowel flora or even a specific, albeit unidentified, bacterial pathogen causing 
UC. However, caution is needed when interpreting their data as this centre is known to 
have undertaken a large number of these treatments and it is uncertain why only six are 
reported. There is no comment in this paper as to the number of patients at their facility 
in whom this technique was attempted and if there were any patients in whom the 
treatment failed; moreover, this is open-label treatment, which is now an insufficient 
standard of proof when evaluating novel therapies. Hence, randomised placebo-
controlled trials are needed to rigorously examine the efficacy of this proposed 
“alternative” therapy. 
An anticipated concern in the medical community regarding FMT has been patient 
acceptance. This has been an assumption based on little evidence. To look at this 
question of patient willingness to undergo FMT, Kahn et al. performed a qualitative 
study to explore the attitudes and concerns of patients and parents of children with UC 
regarding FMT as a potential treatment27. They conducted six focus groups at a clinic in 
Chicago, Illinois and participants were asked about their perceptions of and interest in 
FMT as a treatment for UC. Sessions were recorded, transcribed and reviewed to 
identify domains, themes and major concepts. The focus groups included 15 adult 
patients and seven parents of children with colitis. The study identified five major 
domains pertaining to FMT: impressions of treatment, benefits, risks, potential 
mechanisms and social concerns. All but one participant expressed interest in FMT and 
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several wished it were already available. Participants compared FMT to probiotics, felt 
it was “natural”, was easier than current therapies and would be safe with donor 
screening. Although initial distaste and the “yuck factor” were uniformly mentioned, 
these concerns were outweighed by perceived benefits. The study concluded that given 
adequate supporting research, donor selection and screening, adult patients and parents 
of children with UC will consider FMT and are eager for it to become available. 
FMT for UC is currently undertaken at a private gastroenterology clinic in Sydney and 
case reports of success from this clinic are reported in the literature16. There is also 
evidence from UC online forums that patients are conducting FMT for UC outside of 
the health care setting28,29. This is occurring in an unregulated fashion, with only very 
limited evidence of efficacy from seven case reports in the literature. These occurrences 
underline the need for more robust scientific evidence in this area and a randomised 
controlled study of efficacy. 
2.1 Standard of care for ulcerative colitis 
The management of UC involves both maintenance medication and medication used to 
control flares of the disease. The goal of maintenance therapy in UC is to maintain 
steroid-free remission, clinically and endoscopically. This requires regular clinical 
assessment including history, physical examination and at times colonoscopic 
examination. Other tools of assessment include blood (e.g., C-reactive protein [CRP], 
WCC) and stool (calprotectin) testing for inflammatory markers and imaging including 
MRI, CT or ultrasound. 
The choice of maintenance treatment in UC is determined by disease extent, disease 
course (frequency of flares), failure of previous maintenance treatment, severity of the 
most recent flare, treatment used for inducing remission during the most recent flare, 
safety of maintenance treatment and cancer prevention. The mainstay of maintenance 
medication is the 5-aminosalicylic acid (5-ASA) compounds such as mesalazine and 
sulphasalazine30,31. These compounds are commonly taken orally in formulations that 
predominantly deliver the active 5-ASA component to the colon. Alternatively, or in 
addition, mesalazine preparations can be delivered topically via enema or suppository if 
the disease only involves the left side of the colon (although it is only PBS funded for 
topical therapy during a flare and not for maintenance of remission—even though it also 
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works in this setting). The majority of patients can be managed with maintenance 5-
ASA compounds most of the time. For patients who have repeated flares of disease on 
5-ASA maintenance therapy (one or more flares in a year needing steroids), thiopurine 
medication such as azathioprine or 6-mercapropurine should be used32. These 
medications induce systemic immunosuppression, and reduce the incidence and severity 
of flares of colitis, but also slightly increase the risk of some infections and malignancy. 
Anti-TNF agents such as infliximab and adalimumab have been shown to have benefit 
in maintaining remission in UC33 (and are licensed for this indication by the TGA); 
however, these agents are very expensive and not funded by the pharmaceutical benefits 
scheme in Australia, and so are not readily available. The anti-TNF agents also give an 
increased risk of infection, particularly latent TB reactivation. 
Mild flares of UC can be managed with higher doses of oral 5-ASA compounds or the 
addition of topical 5-ASAs given via enema or suppository. More severe flares are 
usually managed with a course of systemic corticosteroid. These can be given 
intravenously in acute, severe disease or orally in less severe flares. The steroids should 
then be tapered over time and discontinued. There is no indication for long-term steroid 
use in UC, and prolonged steroid use is associated with a number of complications 
including infection, osteoporosis, obesity, diabetes, poor wound healing, thinning skin, 
mood changes and insomnia. Severe flares of UC not responsive to steroids may 
respond to rescue therapy with the addition of either cyclosporin or anti-TNF therapy. 
Patients in whom colonic inflammation cannot be controlled adequately frequently 
undergo total colectomy. This may be done electively (for refractory disease) or 
emergently in acute fulminant colitis. Colectomy entails surgical risk that is higher in 
the emergent setting; this risk includes infection, wound breakdown and mortality. 
Colectomy is considered “curative” for UC especially if an ileostomy stoma is created; 
however, it frequently also leads to complications both short- and long-term. In 
addition, in patients in whom an ileal–anal pouch is fashioned, up to 50% will 
subsequently develop pouchitis at 4 years post surgery34. 
3. Specific Safety Considerations 
A recent review article assessed all cases of FMT in the literature prior to 201113. A 
total of 239 patients had undergone FMT. The authors did not find any serious adverse 
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events related to the procedure. Some studies reported patient deaths due to the 
underlying disease, where the patient has not responded to the FMT. In one study, in 
which donor faeces were instilled via a nasogastric tube, a patient died of peritonitis. 
This patient was undergoing peritoneal dialysis for end-stage renal failure at the time 
and was septic with severe C. difficile colitis. Her condition remained unchanged 
immediately post transplantation; however, on the third day, she developed peritonitis. 
Although considered more likely the result of peritoneal dialysis, the nasogastric tube 
insertion could not be discounted to have been contributory35. One patient in a study by 
Silverman et al. developed irritable bowel symptoms following FMT25. 
Following this literature review in 2011, there have been four further cohort studies in 
the literature of patients who have undergone faecal transplant for C. difficile 
colitis21,22,36,37. A total of 216 patients who underwent FMT via colonoscopy were 
included in these four studies with no immediate adverse effects from FMT noted. 
There is a potential to transmit infection via contaminated donor stool. The donor stool 
will therefore undergo microscopy and culture for potential bacterial pathogens, and 
microscopy for ova, cysts and parasites, as well as viral studies and C. difficile toxin 
analysis. 
Blood testing to exclude HIV, hepatitis B and C, and syphilis will be undertaken. 
Changes in faecal microbiota have been found in patients with a number of 
gastrointestinal and extra-intestinal diseases. Changes in the microbiome of patients 
with IBD and irritable bowel syndrome are well documented in the literature. There 
have also been associations between various bowel flora and obesity and the metabolic 
syndrome38. The association has not been documented as causal and it appears probably 
related to the diet consumed by these subjects. It would, however, be prudent to exclude 
donors with the metabolic syndrome from the study. 
In an audit of 16,318 colonoscopies performed in Northern California from 1994 to 
2002, Levin et al. found serious complications occurred in 5.0 of 1000 procedures39. 
The major risk of colonoscopy, bowel perforation, occurred in 0.09% of colonoscopies 
in that study. Other risks include dehydration from bowel preparation, over-sedation, 
aspiration, bleeding and splenic laceration. This patient group will however be 
undergoing regular colonoscopies for their UC and will be familiar with these risks. 
 
231 
Risks from standard therapies they may be offered for active disease (e.g., steroids, 
immunomodulators and colectomy) are also substantial, thus risks from colonoscopy for 
FMT are relative. 
4. Ethical Considerations 
UC is a chronic, debilitating disease with a near-normal life expectancy40. Current 
therapies are inadequate and the disease continues to have an unacceptably high rate of 
chronic relapsing symptoms. This is underlined by evidence that up to 30% of patients 
will require colectomy after 25 years of disease41. For this reason, it is important for the 
medical community to rigorously examine potential new therapies that may benefit this 
group of patients. 
A small number of case reports of successful treatment of UC with FMT have been 
reported in the literature16,26. However, the findings of these case reports have never 
been tested in a randomised controlled trial (RCT). Despite this very limited evidence, 
there is a clinic in Australia offering UC patients FMT as a therapy16. There is also 
evidence from online forums that patients are undertaking this therapy without medical 
supervision28,29. Despite the minimal evidence in the literature, there is a willingness 
among sufferers of UC to try this potential therapy27. We believe an RCT in this area is 
necessary to gather evidence for or against the effectiveness of FMT as a treatment for 
UC. A positive result will avail UC sufferers of a new therapy and a negative one will 
help discourage the use of an unproven, invasive therapy. Stool analysis of faecal 
transplant success may also fast-track development of tailored probiotic medicines. 
Donors will be anonymous and so will not be known to the recipient. This avoids any 
apportion of blame towards a known donor should a complication or treatment failure 
arise during the trial. 
Colonoscopy will be used to deliver the initial stool transplantation and to assess the 
colon during follow-up. This is an invasive procedure that carries some risk. Most of the 
recent studies of FMT for C. difficile have used colonoscopic delivery13,22,23 as it allows 
assessment of the underlying disease and allows the donor bacteria to contact the entire 
colon. Patients with symptomatic UC ordinarily undergo examination with colonoscopy 
as part of the assessment of disease activity to help guide treatment. The initial 
colonoscopy in this trial will therefore not be an additional procedure. However, the 
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colonoscopic examinations at week 8 and at 12 months may be additional procedures 
depending on the state of the patient’s disease and symptoms. 
The colonoscopic examinations will involve biopsy of the mucosa for analysis of 
microbiota as well as immune function and histopathology. The majority of these 
biopsies will be additional to that which the patient would ordinarily receive outside of 
the trial. These biopsies will be critical to detect any changes in the mucosal-associated 
microbiota or immune changes associated with the FMT. The risk of biopsy of the 
mucosa is small with the major risk being bleeding. Biopsies can be safely performed 
on a single antiplatelet agent42. Patients on duel antiplatelet therapy or anticoagulant 
medication (e.g., warfarin or heparin) will be excluded from the study. 
As FMT has only been performed in large numbers in the past decade, there may be 
unknown long-term risks. However, there have been no reports of major complications 
of faecal transplant in the literature to date. 
Taking blood may cause short-term pain or discomfort and patients will be informed 
about this before entering the trial. The volume of blood taken is not extreme and will 
not cause side effects. If patients are of the view that blood sampling is too painful, they 
may withdraw from the study at any time. Blood tests as well as answering 
questionnaires will involve an increased time burden and patients will be informed 
about this before the trial begins. It is not anticipated that the FMT procedure will cause 
any adverse reactions, but participants will be provided with information about supports 
they can contact should they experience any distress in relation to the study. 
Before taking part in the study, informed written consent will be obtained from patients. 
The researchers will ensure that the patient is given full and adequate verbal and written 
information about the nature, purpose, possible risk and benefit of the trial. They will be 
given sufficient time to consider the information, to ask questions and to seek advice 
prior to being asked whether they wish to participate in the study. Participants will also 
be assured their participation in the trial is absolutely voluntary. All treatment decisions 
are at the discretion of the usual treating physician, and will not be altered by the trial. 
The participation is strictly confidential, and the identity of subjects will not be 
disclosed to other medical or research staff unless subjects agree. 
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Once subjects have been enrolled in this study, they will be given a study participant 
code, and only study investigators will have access to their name and personal details. 
We intend to summarise the results in a manuscript and to submit it for publication in a 
peer reviewed journal. Therefore, all information gathered from this study will be 
published in a form that does not allow patient identification. We will not provide any 
feedback with regard to individual microbiota composition or immunologic function. 
Our proposed study has the support of the director of the Royal Adelaide Hospital 
Department of Gastroenterology and Hepatology, Richard Holloway, as well as the 
head of Endoscopic Services, Mark Schoeman. The head of the IBD Service, Jane 
Andrews, will be the lead supervisor of the study. The Royal Adelaide Hospital has a 
large cohort of approximately 800 patients with IBD and a strong record of successful 
clinical research. The proposed study also has the support of the head of 
gastroenterology at the Queen Elizabeth Hospital, Ian Roberts-Thomson. The Queen 
Elizabeth Hospital has a cohort of approximately 300 patients with IBD. The study 
supervisors all have extensive experience in medical research as well as experience in 
supervising PhD students. 
The Commonwealth Scientific and Industrial Research Organisation (CSIRO) in 
Adelaide has broad experience in human gut flora and microbial analysis. This is an 
area of focus for its recent research. The Nerve Gut Research Laboratory at the Royal 
Adelaide Hospital is a leader in the field of research into the neuro-immunological and 
neuro-endocrine processes of the human gut. 
5. Study Design 
This study is an 8-week randomised placebo-controlled trial with a 44-week open-label 
extension. 
Randomisation 
Patients will be randomly allocated into the following groups: 
• Group 1: Patients receive previously frozen pooled donor stool via colonoscopic 
insertion into the right colon. 
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• Group 2: Patients receive previously frozen own stool via colonoscopic insertion 
into the right colon. 
Open-label therapy from 8 weeks 
Patients who are randomly assigned to the placebo group who do not have a clinically 
relevant response (achieving remission, having a drop in Mayo score by ≥3 or achieving 
an endoscopic subscore of 0–1) by week 8 will then cross over to receive active donor 
FMT at the 8 week colonoscopy. The FMT will be conducted in an identical manner to 
Group 1 with FMT followed by two enemas on day 3 or 4 and one on day 6 or 7. 
5.1 Recruitment 
Patients will be recruited from IBD clinics at the Royal Adelaide and Queen Elizabeth 
Hospitals. Patients on the mailing list for the Royal Adelaide Hospital will be contacted 
about the trial through the quarterly newsletter. Gastroenterologists in Adelaide will be 
informed about the trial though a presentation at the South Australian Gut Club and an 
email to the South Australian Gut Club members. The trial will be listed on the 
Australian and New Zealand clinical trials registry as well as the Gastroenterology 
Society of Australia website. 
We will enrol 70 patients with 35 patients in each arm of the trial. 
5.2 Inclusion criteria 
Patients with the following characteristics will be included: 
1. mild to moderate active UC (total Mayo score 3 to 10) 
2. endoscopic subscore of 2 or greater (to ensure symptoms are due to UC, not 
post-inflammatory irritable bowel syndrome) 
3. patients aged 18 to 75 years with established diagnosis of UC. 
5.3 Exclusion criteria 
Patients with any of the following characteristics will be excluded: 
1. severe UC (Mayo score 11–12 or Truelove and Witts criteria) 
2. more than 25mg of prednisolone per day (or equivalent steroid) 
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3. previous colonic surgery 
4. active gastrointestinal infection 
5. pregnancy 
6. anticoagulant therapy or duel antiplatelet therapy (e.g., aspirin and clopidogrel) 
7. current use of antibiotics 
8. anti-TNF therapy. 
Activity of disease will be defined by the Mayo score. This scoring system has 3 points 
each for stool frequency, rectal bleeding, endoscopic findings and physician’s global 
assessment, giving a total score out of 12. 
A score of: 
• 0, 1 or 2 indicates inactive disease and exclusion from the trial 
• 3 to 10 allows inclusion in the trial. Subjects will need an endoscopic subscore 
of at least 2 for inclusion to prove active disease (0 = normal mucosa and 1 = 
erythema only; most studies start with 2) 
• 11–12 indicates severe disease and these patients will be excluded from the trial. 
Similarly, any patient who fulfils Truelove and Witts criteria for severe colitis will be 
excluded while they meet these criteria. Truelove and Witts is defined as >6 bloody 
bowel motions per day plus one or more of the following: haemoglobin <10.5g/dL, ESR 
>30mm/hr, pulse rate >90 beats per minute and temperature over 37.5°C. 
5.4 Medication prior to enrolment 
Stable dosing of UC maintenance therapy is required prior to enrolment: 
1. 5-ASA stable dosing for at least 4 weeks 
2. thiopurines and methotrexate stable dosing for at least 6 weeks 
3. biological agents stable dosing for at least 8 weeks 
4. option to enrol on an oral dose of prednisolone ≤25mg, with a mandatory taper 
of 5mg per week. 
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6. Outcome Measures 
6.1 Primary outcome 
The primary outcome will be steroid-free remission of UC at week 8 defined as: 
1. total Mayo score of ≤2 AND 
2. Mayo endoscopic score of ≤1. 
6.2 Secondary outcomes 
Secondary outcomes will comprise: 
1. clinical response (≥3 point reduction in total Mayo score at week 8 and 1 year) 
2. clinical remission (Simple Clinical Colitis Activity Index (SCCAI) ≤2 at week 8 
and 1 year)43 
3. endoscopic remission (Mayo <1 at week 8 and 1 year) 
4. safety (assessed at week 8 and 1 year) 
5. changes in mucosal- and faecal-associated microbiota following FMT assessed 
by 16S ribosomal RNA sequencing, stratified by: 
i. change in total Mayo score following FMT 
ii. randomisation 
iii. durability of engraftment of donor microbiome following FMT 
iv. changes in peripheral blood and colonic lamina propria mononuclear cell 
populations (assessed by FACS) following FMT 
v. patient perception and palatability. 
Disease activity measures of symptoms score (SCCAI), and endoscopic and histologic 
gradings, as well as records of hospitalisation, corticosteroid requirement, periods of 
symptom flares and colectomy rate will be recorded at the 1-year mark as part of the 
open-label observation period from 8 weeks to 1 year. 
7. Patient Participation 
7.1 Recruitment 
Participants will be recruited from: 
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• Royal Adelaide Hospital (RAH) and The Queen Elizabeth Hospital (TQEH) 
gastroenterology IBD databases and newsletters 
• gastroenterology in- or out-patient encounter(s) at the RAH and TQEH (and 
Flinders Medical Centre after relevant approvals) by referral from their 
clinicians and by searching OPD letters. 
Patients on clinical databases who have previously consented to being contacted 
regarding research studies will receive information about the study in the RAH IBD 
Service regular newsletter and may also be contacted by telephone, and if no answer is 
obtained a letter will be sent. All other patients will be contacted via a letter or by their 
treating clinician in whichever way the clinician feels is most appropriate to the 
particular patient. 
Regarding the use of letters for contact, subjects who have already consented to be 
contacted regarding research (on database) will receive a letter signed by A/Prof 
Andrews (at RAH) or Prof Roberts-Thomson (at TQEH) on behalf of the study 
investigators. 
The initial invitation letter will include an opt-out slip for subjects not wishing to be 
contacted further. Subjects not opting out or responding within 4 weeks after invitation 
will be contacted up to a further three times by two different methods (phone, SMS, 
email or letter) to ascertain whether they wish to participate or not. Demographic details 
of non-responders will be recorded to enable a full description of the sources of possible 
bias. All who agree to participate will be subsequently screened to ensure they fulfil 
inclusion criteria. 
Donors will be recruited with a flyer advertisement on notice boards at the RAH and 
TQEH as well as the Adelaide University Medical School and Adelaide University 
campus. 
7.2 Withdrawal criteria 
Patients may withdraw from the study at any time. We will ask for their reasons for 
statistical purposes; however, they will not be obliged to provide this information. 
Withdrawal from the study will not affect ongoing standard medical care in any way. 
Their clinicians will be informed of their participation in the study. We will ask patients 
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to notify us of any changes in their treatment during the course of the study and, if 
necessary, we will seek their permission to verify this with their treating clinician. 
8. Ulcerative Colitis Patient Assessment 
8.1 The week prior to enrolment 
1. The patient should have the opportunity to read the patient information sheet, 
discuss the trial with family or friends and ask questions of the investigators prior to 
signing trial consent. 
2. Patient questionnaire regarding perception and expectation of faecal transplant 
prior to procedure. 
3. Detailed history of UC: 
• date of diagnosis 
• extent of disease 
• medication use—current and prior 
• previous surgery 
• previous hospitalisation 
• comorbid disease  
• current symptoms 
• extra-articular manifestations. 
4. Stool collected for: 
• infection screen: microscopy culture + sensitivity, Clostridium difficile toxin 
(5g) 
• possible re-administration for placebo arm subjects (50g) 
• microbiome analysis: 6 × 0.25g stool in Eppendorf tubes, 2 × 5g stool in larger 
brown stool pots. 
For collection and processing methods see section 10. 
5. Disease activity assessment: 
• faecal calprotectin 
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• CRP, ESR, FBC, U+E, LFTs 
• symptom severity (SCCAI ) at screening and one day prior to FMT 
• flexible sigmoidoscopy: 
i. total Mayo score 
ii. disease extent (≥10cm of disease required) 
iii. biopsy for light microscopy and histopathology to exclude CMV 
inclusions. 
8.2 Randomisation 
Randomisation will be conducted once the patient satisfies the inclusion and exclusion 
criteria and has consented to enter the study. This should occur within 1–7 days prior to 
the first faecal transplant, which will be delivered via colonoscopy. 
Prior to randomisation, three aliquots of pooled donor stool suspension from a single 
batch and three aliquots of the donor’s own stool suspension will each be placed in clear 
plastic bags in the -80°C freezer at the endoscopy unit. All stool aliquots will be in 
identical yellow-topped 250mL cryo-safe containers. These will include 1 × 200mL 
suspension for colonoscopic delivery and 2 × 100mL suspensions for enema delivery. 
Donor stool pots will be labelled on the lid with: 
1. batch number 
2. date of manufacture of batch. 
Patient’s own stool will be labelled on the lid with: 
1. patient ID consisting of initials and study number (e.g., AB-1) 
2. date of patient stool donation. 
Randomisation to be conducted by hospital clinical trial nursing staff using 
www.random.org. 
1. Cardboard circular caps with patient ID and either “Transplant” or “Save” and 
either “Colon” or “Enema” are then placed on the pots containing donor or 
patient’s own stool depending on randomisation. 
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2. “Transplant” caps are placed on the pots to be given at and in the week 
following the first colonoscopy. 
3. “Save” pots will be saved and the cap removed following the 8 week 
colonoscopy. If these contain donor stool, they will be given to the patient at the 
8 week colonoscopy and in the subsequent week.  
4. “Colon” pots will be delivered at colonoscopy and the “Enema” pots delivered 
via enema in the following week. 





Faecal transplant for active ulcerative colitis trial 
Protocol for randomisation of FMT 
1–7 days prior to faecal transplant use the random number generator 
http://www.random.org/ 
Into the “true random number generator” box on the right of the screen set the minimum 
to 1 and maximum to 2 
Select: Generate 
1 = Donor faecal transplant 
2 = Placebo faecal transplant (patient’s own stool) 
 
Go to the -80°C Freezer. 
1. For Donor Faecal transplant stick the “Transplant” disks on the top of the donor 
stool yellow pots and the “Save” disks on the placebo pots. Record the batch 
number in the transplant record book. 
2. For Placebo Faecal transplant stick the “Save” disks on the donor stool yellow 
pots and the “Save” disks on the donor pots. The donor stool will then be saved 
to transplant at 8 weeks at the open-label crossover. 
The donor stool pots are labelled with a Batch number and date (e.g., Batch 3, 2/7/13). 
The patient’s own stool (placebo) is labelled with patient study number.  
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8.3 Week 1 of trial 
8.3.1 Day prior to colonoscopy 
1. Patient to take a light breakfast and then to fast from solids. 
2. Maintain high fluid intake throughout the day. 
3. Take three sachets of Colonlytely bowel preparation (polyethylene glycol) in 3L 
of water. 
8.3.2 Morning of colonoscopy 
1. Randomised faecal aliquot labelled “Transplant” and “Colon” to be removed 
from the -80°C freezer and thawed at room temperature for 3.5 hours prior to 
delivery. 
2. Patient to receive loperamide 2mg orally prior to colonoscopy. 
3. SCCAI score diary to be collected. 
4. Mayo symptom scores to be taken (endoscopic score to be added at 
colonoscopy). 
5. Biopsy posts should be pre-labelled with the site and number of biopsies 
required. 
6. Consent should be obtained for this procedure on a standard CALHN consent 
form in addition to the study consent form that has previously been signed. 
7. While inserting cannula, take 60mL of blood: 
i. 50mL into 6 × heparin tubes (green and black top) for peripheral blood 
mononuclear cell flow cytometry (to be taken to Dr Hughes at Nerve Gut 
Laboratory) 
ii. 5mL into a small EDTA (purple tube) (to be sent to clinical laboratory) 
iii. 5mL into a GEL (white top) for electrolytes and liver function, C-
reactive protein (to be sent to SA pathology laboratory). 
8.3.3 At colonoscopy 
1. Assess disease severity (using endoscopic Mayo score at point of maximum 
inflammation) and disease extent. 
2. Biopsies should be taken on colonoscope insertion*: 
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i. left-sided biopsies: 11 total; 6 in RPMI media, 2 into RNA later 
(microbiome), 1 RNA later (PCR), 1 formalin (histopath), 1 PFA (IHC) 
ii. right-sided biopsies: 9 biopsies; 6 in RPMI media, 2 into RNA later 
(microbiome), 1 formalin (histopath). 
3. An attempt should be made to remove any residual fluid or faecal material 
during colonoscope insertion with suction and washing if required. 
4. Once at caecum patient should be rolled onto the right lateral position and 
randomised faecal suspension delivered into the right colon. If caecum cannot be 
reached then delivery of faecal suspension into the right colon beyond the 
hepatic flexure is acceptable. 
5. Patient should then remain on their right side for 1 hour following procedure. 
6. Following 1 hour the patient should be assessed for any adverse effects and if 
well sat up and offered food and drink prior to discharge. 
*Biopsies at each colonoscopy in more detail: 
• 2 biopsies will be taken from both the recto-sigmoid region and ascending 
colon-caecal region of the colon for microbiota analysis. Each in 2.5mL RNA 
later. 
• 1 biopsy from each region will be taken for histopathology analysis into 
formalin.  
• 1 biopsy from left colon for immunohistochemistry (formalin) and 1 from the 
left colon for PCR (cytokines, transcription factors) (RNA later). 
• 4 biopsies will be taken from the left and 4 from the right colon for flow 
cytometry (FACS) analysis (RPMI complete media), processed the same day as 
colonoscopy. 
• 2 biopsies from the left colon and 2 from the right for supernatant release for 
cytokines/mast cell mediators (RPMI complete media). 
• This will amount to 9 biopsies in the right colon and 11 in the left colon. 
8.3.4 Enemas 
Two enemas of 100mL faecal suspension will be delivered by a gastroenterologist at the 




1. take 2mg of loperamide prior to enema 
2. lay on left lateral position for enema insertion 
3. roll from the left lateral to prone position then right lateral and then back to left 
lateral position following enema insertion. This is to encourage proximal 
distribution of the enema 
4. attempt to hold the enema for 1 hour. 
8.4 Week 4 assessment 
1. Stool collection for faecal calprotectin level and microbiome analysis. 
2. Stool to be collected in sterile blue bags that are placed over the toilet. 
3. Patient to zip tie blue bag closed and place blue bag in clear zip-lock bag. 
4. Deliver to CSIRO laboratory within 1 hour. 
5. Bag to be opened and stool processed under anaerobic conditions in anaerobic 
chamber: 
i. microbiome analysis: 6 × 0.25g stool in Eppendorf tubes; 2 × 5g stool in 
larger brown stool pots. 
8.5 Week 8 assessment 
8.5.1 Two days prior to colonoscopy 
1. Stool collection for faecal calprotectin level and microbiome analysis. 
2. Stool to be collected in sterile blue bags that are placed over the toilet. 
3. Patient to zip tie blue bag closed and place blue bag in clear zip-lock bag. 
4. Deliver to CSIRO laboratory within 1 hour. 
5. Bag to be opened and stool processed under anaerobic conditions in anaerobic 
chamber: 
i. microbiome analysis: 6 × 0.25g stool in Eppendorf tubes; 2 × 5g stool in 
larger brown stool pots. 
8.5.2 One day prior to colonoscopy 
1. Patient to take a light breakfast and then to fast from solids. 
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2. Maintain high fluid intake throughout the day. 
3. Take three sachets of Colonlytely bowel preparation (polyethylene glycol) in 3L 
of water. 
8.5.3 Morning of colonoscopy 
1. Randomised faecal aliquot labelled “Save” and “Colon” to be removed from the 
-80°C freezer and thawed at room temperature for 3.5 hours prior to delivery. 
2. Patient to receive loperamide 2mg orally prior to colonoscopy. 
3. SCCAI score diary to be collected. 
4. Mayo symptom scores to be taken (endoscopic score to be added at 
colonoscopy). 
5. Adverse events since randomisation recorded. 
6. Biopsy pots should be pre-labelled with the site and number of biopsies 
required. 
7. Consent should be obtained for this procedure on a standard CALHN consent 
form in addition to the study consent form that has previously been signed. 
8. While inserting cannula, take 60mL of blood: 
i. 50 mL into 6 × heparin tubes (green and black top) for peripheral blood 
mononuclear cell flow cytometry (to be taken to Dr Hughes at Nerve Gut 
Laboratory) 
ii. 5mL into a small EDTA (purple tube) (to be sent to clinical laboratory) 
iii. 5mL into a GEL (white top) for electrolytes and liver function, C-
reactive protein (to be sent to clinical laboratory). 
8.5.4 At colonoscopy 
1. Assess disease severity using endoscopic Mayo score at point of maximum 
inflammation and disease extent. 
2. Biopsies should be taken on colonoscope insertion*. 
3. Left-sided biopsies: 11 total; 6 in RPMI media, 2 into RNA later (microbiome), 
1 RNA later (PCR), 1 formalin (histopath), 1 PFA (IHC). 
4. Right-sided biopsies: 9 biopsies; 6 in RPMI media, 2 into RNA later 
(microbiome), 1 formalin (histopath). 
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5. An attempt should be made to remove any residual fluid or faecal material 
during colonoscope insertion with suction and washing if required. 
6. Once at caecum (and disease severity has been assessed and recorded), the 
cardboard “Save” cap should be removed from the pot to reveal the contents of 
the faecal pot: 
i. If this is labelled as the patient’s own stool it should be discarded and the 
colonoscope withdrawn. 
ii. If this is labelled as donor stool then the patient should be rolled onto the 
right lateral position and the un-blinded faecal suspension delivered into 
the right colon. 
7. If caecum cannot be reached then delivery of faecal suspension into the right 
colon beyond the hepatic flexure is acceptable. 
8. Patient should then remain on their right side for 1 hour following procedure. 
9. Following 1 hour the patient should be assessed for any adverse effects and 
offered food and drink prior to discharge. 
10. Patient to be informed about randomisation. If they were initially randomised to 
placebo/autologous FMT then they will require two further donor FMTs via 
enema. 
*Biopsies at each colonoscopy in more detail: 
• 2 biopsies will be taken from both the recto-sigmoid region and ascending 
colon-caecal region of the colon for microbiota analysis. Each in 2.5mL RNA 
later. 
• 1 biopsy from each region will be taken for histopathology analysis into 
formalin. 
• 1 biopsy from left colon for immunohistochemistry (formalin) and 1 from the 
left colon for PCR (cytokines, transcription factors) (RNA later). 
• 4 biopsies will be taken from the left and 4 from the right colon for flow 
cytometry (FACS) analysis (RPMI complete media), processed the day of 
colonoscopy. 
• 2 biopsies from the left colon and 2 from the right for supernatant release for 
cytokines / mast cell mediators (RPMI complete media). 
• This will amount to 9 biopsies in the right colon and 11 in the left colon. 
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8.5.5 Enemas (patients randomised to placebo/autologous FMT) 
Two enemas of 100mL faecal suspension will be delivered by a medical practitioner at 
the clinic in the week following colonoscopy (days 2–4, days 5–7). 
1. Patient to take 2mg of loperamide prior to enema. 
2. Lay on left lateral position for enema insertion. 
3. Roll into prone positions, right lateral and then back to left lateral position 
following enema insertion. 
4. Patient should attempt to hold the enema for 1 hour. 
8.6 One-year assessment 
Patient will be posted or emailed: 
1. SCCAI symptoms score 
2. patient questionnaire regarding experience of faecal transplant prior to procedure 
and adverse events 
3. invitation to undergo disease activity assessment. 
Patients who do not return forms within 2 weeks will be contacted via telephone. 
8.6.1 Two days prior to flexible sigmoidoscopy 
1. Stool collection for faecal calprotectin level and microbiome analysis. 
2. Stool to be collected in sterile blue bags that are placed over the toilet. 
3. Patient to zip tie blue bag closed and place blue bag in clear zip-lock bag. 
4. Deliver to CSIRO laboratory within 1 hour. 
5. Bag to be opened and stool processed under anaerobic conditions in anaerobic 
chamber: 
i. microbiome analysis: 6 × 0.25g stool in Eppindorf tubes; 2 × 5g stool in 
larger brown stool pots 
ii. faecal calprotectin. 
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8.6.2 Flexible sigmoidoscopy 
1. Mayo symptom scores to be taken (endoscopic score to be added at 
colonoscopy). 
2. Adverse events since randomisation recorded. 
3. Biopsy pots should be pre-labelled with the site and number of biopsies 
required. 
4. Consent should be obtained for this procedure on a standard consent form in 
addition to the study consent form that has previously been signed. 
5. While inserting cannula, take 60mL of blood: 
i. 50mL into 6 × heparin tubes (green and black top) for peripheral blood 
mononuclear cell flow cytometry (to be taken to Dr Hughes at Nerve Gut 
Laboratory) 
ii. 5mL into a small EDTA (purple tube) (to be sent to clinical laboratory) 
iii. 5mL into a GEL (white top) for electrolytes and liver function, C-
reactive protein (to be sent to clinical laboratory). 
6. Assess disease severity using endoscopic Mayo score at point of maximum 
inflammation. 
7. Biopsies should be taken on the left side only. 
8. Left-sided biopsies: 11 total; 6 in RPMI media, 2 into RNA later (microbiome), 
1 RNA later (PCR), 1 formalin (histopath), 1 PFA (IHC). 
9. Following 1 hour the patient should be assessed for any adverse effects and 
offered food and drink prior to discharge. 
8.6.3 Care during the follow-up period 
During the trial, subjects will be treated to the standard of care for UC. This involves a 
fixed maintenance medication as prescribed/advised by their own physician. Patients 
will enter this trial because of a flare, and all therapy they are on at entry will be 
continued except for the steroid taper as described. 
A subject who experiences a flare of their disease during the study will be treated with 
standard therapy as if they were not in the study. This will include increasing their oral 
5-ASA and/or adding a topical enema or suppository therapy. Systemic steroid therapy 
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may also be used. Steroid use will be quantified during the study and steroid 
requirement over the 12 month period will be another secondary endpoint. Once 
patients are commenced on steroid it will be tapered as explained above. 
If a subject deteriorates on steroid therapy, they may require escalation of their medical 
therapy or surgery. Escalation of medical therapy may involve increasing the steroid 
dose temporarily. Patients who are naïve to thiopurine therapy may benefit from the 
addition of a thiopurine. Thiopurines can take up to 12 weeks to reach their therapeutic 
effect and so “rescue therapy” may be needed in the intervening period. Rescue therapy 
involves the addition of cyclosporine or an anti-TNF agent such as infliximab (if 
available through compassionate access) in the short term. Rescue therapy will be 
continued for 6 to 12 weeks to allow the thiopurine medication to reach its full effect. 
Patients who have a severe flare of UC that does not respond to intravenous steroid 
medication within 3 to 5 days are unlikely to improve and should be assessed for 
surgical colectomy44, as would be the case in routine care. 
9. Stool Donor Recruitment and Screening 
9.1 Donor recruitment 
Posters will be placed on noticeboards on the University of Adelaide campus. These 
will detail that we are recruiting stool donors and the posters will have the contact 
details of Dr Costello and Dr Andrews. 
9.2 Donor screening 
Potential donors will be sent the donor information sheet via email or post. 
Donors who consent will undergo a four-stage screening process with medical history, 
physical examination, blood testing and stool testing with the aim of reducing the risk 
of disease transmission from donor to recipient. 
9.2.1 Medical history 
Inclusion of patients who: 
1. are 18 to 65 years of age 
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2. have not received antibiotic therapy for the past 6 months 
3. have not had unprotected sexual intercourse in the last 1 month outside of a 
long-term monogamous relationship 
4. have not travelled outside of Australia for past 1 month. 
Inclusion of patients who have no active medical problems or a history of: 
1. inflammatory bowel disease  
2. irritable bowel syndrome 
3. colonic polyps 
4. bowel cancer 
5. any other gastrointestinal disorder 
6. obesity 
7. high blood pressure 
8. diabetes 
9. heart disease 
10. stroke 
11. major depression 
12. infection with hepatitis B or C, HIV or syphilis 
13. autoimmune disease (e.g., rheumatoid arthritis, SLE). 
9.2.2 Physical examination 
Cardiovascular and gastrointestinal examination. 
Height and weight: BMI <18 and >30 is an exclusion. 
9.2.3 Blood testing 
• full blood count (anaemia, WCC >12.5 are exclusions) 
• electrolytes, urea and creatinine (renal impairment eGFR <60 is an exclusion) 
• liver function tests (abnormal LFTs are exclusions) 
• human T cell lymphotropic virus 1 and 2 serology (positive serology is an 
exclusion) 
• Epstein Barr virus IgM and IgG (positive IgM is exclusion) 
• cytomegalovirus IgM and IgG (positive IgM is exclusion) 
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• syphilis (positive rapid plasma regain is an exclusion) 
• Strongyloides stercoralis, Entamoeba histolytica (positive serology is an 
exclusion) 
• toxoplasma serology (positive serology is an exclusion) 
• hepatitis A virus IgM (positive serology is an exclusion) 
• hepatitis B PCR (positive PCR is an exclusion) 
• hepatitis C PCR (positive PCR is an exclusion) 
• HIV PCR (positive PCR is an exclusion) 
• fasting lipids and blood sugar level (total cholesterol >4.0mmol/L, LDL >2.5 
mmol/L, triglycerides >2.0mmol/L, HDL <1.0mmol/L are exclusions) 
• C-reactive protein (>8 exclusion) 
9.2.4 Stool testing 
• microscopy and culture 
• Clostridium difficle toxin PCR 
• egg, cysts and parasites (including Cryptosporidium spp., Giardia spp. and 
Entamoeba histolytica PCR) 
10. Stool Collection and Processing 
Once donors have passed all the screening requirements they are eligible to donate for 1 
month. To donate stool beyond this time will require repeat screening. 
10.1 Stool collection 
1. Stool collected in sterile blue bags that are placed over the toilet. 
2. Stool donor to zip tie blue bag closed and place blue bag in clear zip-lock bag. 
3. Stool donor to produce stool at CSIRO or deliver to CSIRO laboratory in esky 
within 1 hour of defecation. 
4. 4–6 stool donors will be asked to provide stool on each collection day. 
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10.2 Stool processing 
10.2.1 Donor stool processing 
Setting up 
Ensure anaerobic chamber is primed with gas and is anaerobic. 
See instructions on setting up anaerobic chamber. 
Set-up 
Blender case as well as spatulas, glass beaker and glass measuring cylinder to be 
autoclaved within 24 hours of commencing stool processing (ideally the night prior): 
1. weigh stool (empty clear and blue bag weight = 47g)  
2. saline (mL) = 2.6 × total stool weight (g). 
3. glycerol (mL) = 0.4 × total stool weight (g). 
4. sterile 200mL yellow pots (number) = total stool weight/50 (rounded up) 
5. transfer these minimum amounts into the anaerobic chamber. 
Equipment 
Blender (cylinder and base) 
Stainless steel spatulas (autoclaved) 
Glass beaker (autoclaved) 
Glass measuring cylinder (autoclaved) 
8 × Eppendorf tubes labelled: 
• donor number 
• date 
• tube number 
• F = fresh.  G = Glycerol 
Note pad, pen and scissors 
Scientific weigh scales 
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Prior to blending 
1. Add 0.25g of stool to each of 6 × labelled, capped Eppendorf tubes. 
2. Add 5g of stool to 2 × larger brown pots. 
3. Record weight of stool in note pad. 
Blending process 
1. Stool from four donors will be pooled and blended with normal saline and sterile 
pharmaceutical grade glycerol (in the ratio 25% stool, 65% saline, 10% 
glycerol). 
2. The number of donors to be pooled will be limited to four to reduce the risk of 
transmissible disease from a single donor. 
3. Blend on low power for 20 seconds and then high power for a further 20 
seconds. 
4. Aliquot the stool suspension into the sterile yellow pots (Colonoscopy, 200mL; 
Enema, 100mL) and label with batch number and date. 
5. Each batch consists of 1 × 200mL pot and 2 × 100mL pot. 
6. Each recipient will receive the same batch (same blend of donor stool from 
single day donation) for each of their three faecal transplants. 
7. Multiple such batches can be produced from each donor stool blend. 
8. Half fill a further 2 × Eppendorf tubes with blended stool mix. 
9. Transfer the stool suspensions and tubes directly into -80 degree freezer. 
10.2.2 Documentation and tracing of donors 
1. Each stool donor will be recorded in the secure and confidential study “stool 
donor register” document. This will include: 
i. donor name 
ii. date of birth 
iii. address and contact details 
iv. result of screening history, physical examination and blood and stool 
tests. 
2. Each stool donor will be assigned a donor number. 
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3. Each stool aliquot will be numbered and recorded in the secure and confidential 
faecal transplant aliquot document that will list the four stool donors who 
contributed to each aliquot. In this way any possible transmission of infection 
can be traced. 
4. A small amount of each individual donation will be set aside and frozen 
individually. This will allow repeat testing and tracing of each individual 
donation in the future in the event of possible transmission of infection. 
10.2.3 Ulcerative colitis patient stool processing 
1. Each subject potentially suitable for the study, will also be asked to donate a 
stool sample of their own.  
2. A small portion of the stool will be set aside to undergo faecal-associated 
microbiota analysis. 
3. 50g of the remainder will be mixed with 20mL sterile pharmaceutical grade 
glycerol and 130mL saline and placed into frozen storage at -80°C. This stool 
will then be used to transplant those subjects randomised to receive “placebo” 
with their own stool. In this way the FMT will remain blinded to both the 
subject and colonoscopist. 
10.2.4 Cleaning equipment 
Blender case, stainless steel implements and glassware should all be cleaned following 
stool processing in the order listed below: 
1. rinsed with water in the sink 
2. washed with detergent and water 
3. rinsed with water 
4. washed with enzymatic wash 
5. rinsed with water 
6. autoclaved. 
11. Analysis and Reporting of Results 




Analysis of stool microbiota and microbiota metabolites will mainly be conducted at 
CSIRO Animal, Food and Health research laboratories in Adelaide under the guidance 
of Dr Michael Conlon. Some analyses may be outsourced to other laboratories, but 
under the broad direction of Dr Conlon in consultation with Dr Costello and other 
collaborators. The abundance and/or activities of faecal and mucosal (biopsy)-
associated microbes will be analysed using molecular methods. This is expected to 
include the use of QPCR for a range of bacterial targets but may also include deep 
sequencing of microbial DNA for an in-depth analysis of microbial population changes. 
Isolation (culture) of bacteria from stool samples may be considered to further 
understanding of metabolic changes occurring in bacteria of IBD patients compared 
with healthy controls. Stool will be analysed for SCFAs, ammonia, phenols, cresols and 
bile acids using a range of methods established at CSIRO where sufficient material is 
available. Other metabolites may also be measured. 
Gut mucosal immunological analysis with be performed with Dr Patrick Hughes at the 
Nerve Gut Research Laboratory. 
Blood sampling 
A total of 60mL will be taken at each time point and will be used for further 
experiments outlined below. 
Isolation of PBMC and LPMC cells 
Peripheral blood mononuclear cells (PBMCs) are isolated from whole blood via density 
gradient centrifugation. Lamina propria mononuclear cells (LPMCs) are isolated from 
colonic biopsies via collagenase digestion and density gradient centrifugation. Cells will 
be stored under liquid nitrogen until further analysed. 
PBMCs and biopsy tissue will be used for flow cytometry and cell sorting. 
PBMCs and LPMCs are surface stained using monoclonal antibodies against specific 
immune cell subsets (e.g., T memory cells CD45(RO); T helper cells (CD4); cytoxic T 
cells (CD8); B cells (CD19); natural killer cells (6B11), monocytes (CD14); and the 
integrins a4, b7 and CCR9). PBMCs and LPMCs will be surface stained, permeabilised 
and stained with anti-cytokine or opioid antibodies to detect intracellular cytokine 
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content/opioid content (e.g., TNF-a, IL-1b, b-endorphin), as well as transcription factor 
content (e.g., FOXP3). 
12. Statistical Analysis 
Patient information will be de-identified and the results of microbiota, immune analysis 
and clinical scores will be recorded in an Excel spread sheet. This data will then be 
imported into the R program for statistical analysis. Statistical analysis will be 
conducted in collaboration with the University of Adelaide department of statistics.  
12.1 Primary outcome power analysis 
The study is powered to detect a significant difference in the primary outcome of 
inducing remission at 8 weeks post FMT with 32 patients in each arm. This was 
calculated using a Z test with pooled variance for the difference of two independent 
proportions. The significance level was set at 5% and the power at 80%. The estimated 
remission rate in the placebo group was 26.4% and the minimum clinically relevant 
remission rate we are powered to detect is 60%. 
Comparisons between treatment groups of the primary and secondary dichotomous 
outcomes will be assessed using Fisher’s exact tests with an intention to treat analysis. 
The placebo remission rate is difficult to predict because of the heterogeneous nature of 
previous studies that investigated induction of remission in UC. Our placebo remission 
rate was derived from the active UC trials 1 and 245 (ACT-1 and ACT-2). The ACT-1 
and ACT-2 trials were randomised, double-blind, placebo-controlled studies that 
evaluated the efficacy of IV infliximab 5 or 10mg/kg IV infusion for induction and 
maintenance treatment in adults with UC. The clinical response rate in those patients in 
the ACT-2 trial who were not steroid dependent was 26.4%. These patients had 
moderate to severe colitis with a Mayo score of 6 to 12 on enrolment and so had more 
severe disease on average than our patients. Response was defined as at least a 3-point 
reduction and 30% reduction in the Mayo score to determine clinical response at week 
8. Another trial of patients with mild to moderate ulcerative colitis46 found a remission 
rate at 8 weeks with oral mesalamine 2.4g daily of 22%. Many of our patients will be 
taking an oral aminosalicilate compound and some a concomitant steroid. The remission 




The analysis of serious adverse effects at week 8 will be by Fischer’s exact test. 
Assessment of treatment on the change in serum creatinine, ALT, ALP, bilirubin and 
haemoglobin will be assessed using linear mixed effects regression with week 8 values 
as the outcome. Adverse effects at 1 year will be recorded; however, there will not be a 
comparator group. 
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1. Objectives of Study 
Primary 
• To determine whether faecal microbiota transplantation (FMT) improves clinical 
and inflammatory outcomes in patients with active ulcerative colitis (UC). 
Secondary 
• To determine whether any clinical change is accompanied by an alteration in the 
faecal- and/or mucosal-associated microbiome of UC patients prior to and 
following FMT. 
• Assessment of alteration and durability of change in the recipient microbiota 
after FMT in UC patients. 
• To examine the mucosal immune changes induced by FMT and to examine 
whether they are influenced by changes in microbiome and/or disease activity. 
• To examine the durability of clinical response/improvement after initial response 
to FMT in subjects with active UC. 
• To establish patient satisfaction with FMT as a therapy for UC. 
2. Background and Significance 
UC is a chronic inflammatory bowel disease (IBD) that is characterised by recurring 
episodes of inflammation primarily involving the mucosal layer and occasionally the 
submucosa of the colon. Inflammation usually originates in the rectum and progresses 
in a contiguous fashion proximally. Although the aetiology of UC remains unclear, 
several factors are believed to play a role in its development and progression, including 
host genotype, immune disequilibrium and the composition of microbial communities 
resident in the gastrointestinal tract. 
There is strong evidence for the involvement of microbes in the development of UC. 
IBD is associated with changes in the diversity of the gut microbiota, and although 
alterations in the abundance of specific bacterial species have often been identified, 
there remains no specific organism that is reliably associated with the condition1. There 
also appear to be changes in the functional activity of the microbiome, with changes in 
gene expression as well as protein production in the microbes of patients with IBD1. It 
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is unclear whether the altered microbiota is a result of, or initiates, the inflammatory 
process in humans. There is some evidence, however, that an altered microbiota 
develops prior to the onset of colitis in an animal model of interleukin (IL)-10 knockout 
mice2. 
Intestinal flora and their metabolic products play a critical role in maintaining the health 
of the colon. Patients who undergo ileostomy and have subsequent diversion of the 
luminal contents from the colon often develop a “diversion” colitis. The distal 
colonocytes in this instance are deprived of short-chain fatty acids (SCFAs) such as 
butyrate, a product of anaerobic bacterial fermentation of undigested dietary 
carbohydrates3. Yet, animal models of IBD also require bacteria within the colon for 
inflammation to develop4. It has been observed that altering the bacterial and nutrient 
colonic milieu by diverting the faecal stream using ileostomy reduces the recurrence of 
Crohn’s disease in the colon5. Further supporting the notion that bacterial antigens 
contribute to, or drive, the autoimmune injury to the bowel, is evidence that antibiotics 
have some therapeutic efficacy in UC. In a recent systematic review, antibiotic therapy 
for UC was significantly associated with remission6. Antibiotic therapy gave a 
statistically significant relative risk reduction for active disease of 0.64 (CI 0.43–0.96). 
However, while bacteria are necessary to develop IBD, with germ-free animals unable 
to be induced to develop IBD, bacterial absence (or change in abundance/mix) can also 
lead to inflammation. 
Probiotics have as yet demonstrated only limited therapeutic efficacy in UC7. In vitro 
studies have demonstrated that probiotic bacteria are able to modulate gut immune 
cells8,9, while in vivo in a German study, E. coli Nissle 1917 was equivalent in efficacy 
to mesalamine for maintenance of remission of UC10. Additionally, a randomised trial 
of 77 patients with UC found that VSL#3, a cocktail of eight different bacteria, was 
more effective than placebo in improving symptoms and inducing remission at 12 
weeks11. For patients with pouchitis, trials with VSL#3 have shown both therapeutic 
and prophylactic efficacy12. The outcomes in probiotic studies, however, have often 
been inconsistent and modest. This may be due to the variable actions of the different 
bacterial species that have been tested as well as the general limitations of most 
probiotic preparations. These probiotics provide a comparatively low number and 
diversity of bacterial species in comparison with the vast human gut microbiota. For this 
reason, some probiotic bacterial strains may not be able to compete effectively against 
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the complex interactions of an established and adapted indigenous gut microbial 
community13. 
FMT has been described as “the ultimate probiotic” as it provides an entire microbiome 
to the recipient. This therapy delivers a much greater number and diversity of bacteria 
than any current commercially available preparation. FMT was first reported in humans 
by Eiseman et al. in 1958 in the treatment of four patients with pseudomembranous 
colitis14. Three of the four patients were described as terminally or critically ill requiring 
vasopressor support and all were successfully cured. Over the subsequent years, there 
have been case reports and case series describing FMT predominantly for Clostridium 
difficile colitis but also for treating IBD, irritable bowel syndrome and 
constipation13,15,16. In the past decade, there has been a heightened interest in the use of 
this therapy, predominantly driven by increasing rates of recurrent C. difficile infection. 
During this time, C. difficile has become more frequent, more severe and more 
refractory to standard treatment as well as more likely to relapse17. Standard treatment 
with metronidazole or vancomycin alters the normal gut flora that would usually 
provide colonisation resistance against C. difficile infection. For this reason, after 
successful initial therapy, up to 35% of patients will experience a symptomatic 
recurrence after ceasing antibiotics18. A subset of patients will have multiple 
recurrences, and subsequent relapses occur in 45–65% of patients who have relapsed 
one or more times19,20. For patients with recurrent C. difficile colitis, FMT offers the 
greatest chance of cure of any therapy, with success in 87–100% of cases13,21-25. This 
impressive success rate is presumably due to the ability of the transplanted bacteria to 
recolonise/occupy the missing components/niches of the normal intestinal microbiota, 
thus removing the microbial niche that C. difficile would otherwise exploit. 
FMT for UC was first reported in the literature by a gastroenterologist, Dr Justin D 
Bennet, from Kansas City, who described the results of a faecal transplant he received 
for his own disease26. Dr Bennet had continuous active, severe UC for 7 years, 
confirmed endoscopically and histologically, that was refractory to standard therapy. Dr 
Bennet described receiving antibiotics to “sterilise” his bowel prior to retention stool 
enemas. At the time of publication in 1989, he had been symptom and medication free 
for the first time in 11 years, at 6 months post FMT. 
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Borody et al. described case reports of six patients (three men and three women aged 
25–53 years) with UC for at least 5 years who were treated with FMT16. All patients had 
suffered severe, recurrent symptoms and UC had been confirmed on colonoscopy and 
histological examination. Faecal flora donors were healthy adults who were extensively 
screened for parasites and bacterial pathogens. Patients were prepared with oral 
antibiotics and oral polyethylene glycol lavage. 
Faecal suspensions were administered as retention enemas and the process repeated 
daily for 5 days. By 1 week post FMT, some symptoms of UC had improved. Complete 
reversal of symptoms was achieved in all patients by 4 months post FMT, by which 
time all other UC medications had been ceased. At 1 to 13 years post FMT, and without 
any UC medication, there was no clinical, colonoscopic or histologic evidence of UC in 
any patient. The authors concluded that colonic infusion of donor human intestinal flora 
can reverse UC in selected patients, and that these results support the concept of 
abnormal bowel flora or even a specific, albeit unidentified, bacterial pathogen causing 
UC. However, caution is needed when interpreting their data as this centre is known to 
have undertaken a large number of these treatments and it is uncertain why only six are 
reported. There is no comment in this paper as to the number of patients at their facility 
in whom this technique was attempted and if there were any patients in whom the 
treatment failed; moreover, this is open-label treatment, which is now an insufficient 
standard of proof when evaluating novel therapies. Hence, randomised placebo-
controlled trials are needed to rigorously examine the efficacy of this proposed 
“alternative” therapy. 
An anticipated concern in the medical community regarding FMT has been patient 
acceptance. This has been an assumption based on little evidence. To look at this 
question of patient willingness to undergo FMT, Kahn et al. performed a qualitative 
study to explore the attitudes and concerns of patients and parents of children with UC 
regarding FMT as a potential treatment27. They conducted six focus groups at a clinic in 
Chicago, Illinois and participants were asked about their perceptions of and interest in 
FMT as a treatment for UC. Sessions were recorded, transcribed and reviewed to 
identify domains, themes and major concepts. The focus groups included 15 adult 
patients and seven parents of children with colitis. The study identified five major 
domains pertaining to FMT: impressions of treatment, benefits, risks, potential 
mechanisms and social concerns. All but one participant expressed interest in FMT and 
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several wished it were already available. Participants compared FMT to probiotics, felt 
it was “natural”, was easier than current therapies and would be safe with donor 
screening. Although initial distaste and the “yuck factor” were uniformly mentioned, 
these concerns were outweighed by perceived benefits. The study concluded that given 
adequate supporting research, donor selection and screening, adult patients and parents 
of children with UC will consider FMT and are eager for it to become available. 
FMT for UC is currently undertaken at a private gastroenterology clinic in Sydney and 
case reports of success from this clinic are reported in the literature16. There is also 
evidence from UC online forums that patients are conducting FMT for UC outside of 
the health care setting28,29. This is occurring in an unregulated fashion, with only very 
limited evidence of efficacy from seven case reports in the literature. These occurrences 
underline the need for more robust scientific evidence in this area and a randomised 
controlled study of efficacy. 
2.1 Standard of care for ulcerative colitis 
The management of UC involves both maintenance medication and medication used to 
control flares of the disease. The goal of maintenance therapy in UC is to maintain 
steroid-free remission, clinically and endoscopically. This requires regular clinical 
assessment including history, physical examination and at times colonoscopic 
examination. Other tools of assessment include blood (e.g., C-reactive protein [CRP] 
and WCC) and stool (calprotectin) testing for inflammatory markers, and imaging 
including MRI, CT or ultrasound. 
The choice of maintenance treatment in UC is determined by disease extent, disease 
course (frequency of flares), failure of previous maintenance treatment, severity of the 
most recent flare, treatment used for inducing remission during the most recent flare, 
safety of maintenance treatment and cancer prevention. The mainstay of maintenance 
medication is the 5-aminosalicylic acid (5-ASA) compounds such as mesalazine and 
sulphasalazine30,31. These compounds are commonly taken orally in formulations that 
predominantly deliver the active 5-ASA component to the colon. Alternatively, or in 
addition, mesalazine preparations can be delivered topically via enema or suppository if 
the disease only involves the left side of the colon (although it is only PBS funded for 
topical therapy during a flare and not for maintenance of remission—even though it also 
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works in this setting). The majority of patients can be managed with maintenance 5-
ASA compounds most of the time. For patients who have repeated flares of disease on 
5-ASA maintenance therapy (one or more flares in a year needing steroids), thiopurine 
medication such as azathioprine or 6-mercapropurine should be used32. These 
medications induce systemic immunosuppression, and reduce the incidence and severity 
of flares of colitis, but also slightly increase the risk of some infections and malignancy. 
Anti-TNF agents such as infliximab and adalimumab have been shown to have benefit 
in maintaining remission in UC33 (and are licensed for this indication by the TGA); 
however, these agents are very expensive. The anti-TNF agents also give an increased 
risk of infection, particularly latent TB reactivation. 
Mild flares of UC can be managed with higher doses of oral 5-ASA compounds or the 
addition of topical 5-ASAs given via enema or suppository. More severe flares are 
usually managed with a course of systemic corticosteroid. These can be given 
intravenously in acute, severe disease or orally in less severe flares. The steroids should 
then be tapered over time and discontinued. There is no indication for long-term steroid 
use in UC, and prolonged steroid use is associated with a number of complications 
including infection, osteoporosis, obesity, diabetes, poor wound healing, thinning skin, 
mood changes and insomnia. Severe flares of UC not responsive to steroids may 
respond to rescue therapy with the addition of either cyclosporin or anti-TNF therapy. 
Patients in whom colonic inflammation cannot be controlled adequately frequently 
undergo total colectomy. This may be done electively (for refractory disease) or 
emergently in acute fulminant colitis. Colectomy entails surgical risk that is higher in 
the emergent setting; this risk includes infection, wound breakdown and mortality. 
Colectomy is considered “curative” for UC especially if an ileostomy stoma is created; 
however, it frequently also leads to complications both short- and long-term. In 
addition, in patients in whom an ileal–anal pouch is fashioned, up to 50% will 
subsequently develop pouchitis at 4 years post surgery34. 
3. Specific Safety Considerations 
A recent review article assessed all cases of FMT in the literature prior to 201113. A 
total of 239 patients had undergone FMT. The authors did not find any serious adverse 
events related to the procedure. Some studies reported patient deaths due to the 
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underlying disease, where the patient has not responded to the FMT. In one study, in 
which donor faeces were instilled via a nasogastric tube, a patient died of peritonitis. 
This patient was undergoing peritoneal dialysis for end-stage renal failure at the time 
and was septic with severe C. difficile colitis. Her condition remained unchanged 
immediately post transplantation; however, on the third day, she developed peritonitis. 
Although considered more likely the result of peritoneal dialysis, the nasogastric tube 
insertion could not be discounted to have been contributory35. One patient in a study by 
Silverman et al. developed irritable bowel symptoms following FMT25. 
Following this literature review in 2011, there have been four further cohort studies in 
the literature of patients who have undergone faecal transplant for C. difficile 
colitis21,22,36,37. A total of 216 patients who underwent FMT via colonoscopy were 
included in these four studies with no immediate adverse effects from FMT noted. 
There is a potential to transmit infection via contaminated donor stool. The donor stool 
will therefore undergo microscopy and culture for potential bacterial pathogens, and 
microscopy for ova, cysts and parasites, as well as viral studies and C. difficile toxin 
analysis. 
Blood testing to exclude HIV, hepatitis B and C, and syphilis will be undertaken. 
Changes in faecal microbiota have been found in patients with a number of 
gastrointestinal and extra-intestinal diseases. Changes in the microbiome of patients 
with IBD and irritable bowel syndrome are well documented in the literature. There 
have also been associations between various bowel flora and obesity and the metabolic 
syndrome38. The association has not been documented as causal and it appears probably 
related to the diet consumed by these subjects. It would, however, be prudent to exclude 
donors with the metabolic syndrome from the study. 
In an audit of 16,318 colonoscopies performed in Northern California from 1994 to 
2002, Levin et al. found serious complications occurred in 5.0 of 1000 procedures39. 
The major risk of colonoscopy, bowel perforation, occurred in 0.09% of colonoscopies 
in that study. Other risks include dehydration from bowel preparation, over-sedation, 
aspiration, bleeding and splenic laceration. This patient group will however be 
undergoing regular colonoscopies for their UC and will be familiar with these risks. 
Risks from standard therapies they may be offered for active disease (e.g., steroids, 
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immunomodulators and colectomy) are also substantial, thus risks from colonoscopy for 
FMT are relative. 
4. Ethical Considerations 
UC is a chronic, debilitating disease with a near-normal life expectancy40. Current 
therapies are inadequate and the disease continues to have an unacceptably high rate of 
chronic relapsing symptoms. This is underlined by evidence that up to 30% of patients 
will require colectomy after 25 years of disease41. For this reason, it is important for the 
medical community to rigorously examine potential new therapies that may benefit this 
group of patients. 
A small number of case reports of successful treatment of UC with FMT have been 
reported in the literature16,26. However, the findings of these case reports have never 
been tested in a randomised controlled trial (RCT). Despite this very limited evidence, 
there is a clinic in Australia offering UC patients FMT as a therapy16. There is also 
evidence from online forums that patients are undertaking this therapy without medical 
supervision28,29. Despite the minimal evidence in the literature, there is a willingness 
among sufferers of UC to try this potential therapy27. We believe an RCT in this area is 
necessary to gather evidence for or against the effectiveness of FMT as a treatment for 
UC. A positive result will avail UC sufferers of a new therapy and a negative one will 
help discourage the use of an unproven, invasive therapy. Stool analysis of faecal 
transplant success may also fast-track development of tailored probiotic medicines. 
Donors will be anonymous and so will not be known to the recipient. This avoids any 
apportion of blame towards a known donor should a complication or treatment failure 
arise during the trial. 
Colonoscopy will be used to deliver the initial stool transplantation and to assess the 
colon during follow-up. This is an invasive procedure that carries some risk. Most of the 
recent studies of FMT for C. difficile have used colonoscopic delivery13,22,23 as it allows 
assessment of the underlying disease and allows the donor bacteria to contact the entire 
colon. Patients with symptomatic UC ordinarily undergo examination with colonoscopy 
as part of the assessment of disease activity to help guide treatment. The initial 
colonoscopy in this trial will therefore not be an additional procedure. However, 
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colonoscopic examinations at week 8 and at 12 months may be additional procedures 
depending on the state of the patient’s disease and symptoms. 
The colonoscopic examinations will involve biopsy of the mucosa for analysis of 
microbiota as well as immune function and histopathology. The majority of these 
biopsies will be additional to that which the patient would ordinarily receive outside of 
the trial. These biopsies will be critical to detect any changes in the mucosal-associated 
microbiota or immune changes associated with the FMT. The risk of biopsy of the 
mucosa is small with the major risk being bleeding. Biopsies can be safely performed 
on a single antiplatelet agent42. Patients on duel antiplatelet therapy or anticoagulant 
medication (e.g., warfarin or heparin) will be excluded from the study. 
As FMT has only been performed in large numbers in the past decade, there may be 
unknown long-term risks. However, there have been no reports of major complications 
of faecal transplant in the literature to date. 
Taking blood may cause short-term pain or discomfort and patients will be informed 
about this before entering the trial. The volume of blood taken is not extreme and will 
not cause side effects. If patients are of the view that blood sampling is too painful they 
may withdraw from the study at any time. Blood tests as well as answering 
questionnaires will involve an increased time burden and patients will be informed 
about this before the trial begins. It is not anticipated that the FMT procedure will cause 
any adverse reactions, but participants will be provided with information about supports 
they can contact should they experience any distress in relation to the study. 
Before taking part in the study, informed written consent will be obtained from patients. 
The researchers will ensure that the patient is given full and adequate verbal and written 
information about the nature, purpose, possible risk and benefit of the trial. They will be 
given sufficient time to consider the information, to ask questions and to seek advice 
prior to being asked whether they wish to participate in the study. Participants will also 
be assured their participation in the trial is absolutely voluntary. All treatment decisions 
are at the discretion of the usual treating physician, and will not be altered by the trial. 
The participation is strictly confidential, and the identity of subjects will not be 
disclosed to other medical or research staff unless subjects agree. 
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Once subjects have been enrolled in this study, they will be given a study participant 
code, and only study investigators will have access to their name and personal details. 
We intend to summarise the results in a manuscript and to submit it for publication in a 
peer reviewed journal. Therefore, all information gathered from this study will be 
published in a form that does not allow patient identification. We will not provide any 
feedback with regard to individual microbiota composition or immunologic function. 
Our proposed study has the support of the director of the Royal Adelaide Hospital 
Department of Gastroenterology and Hepatology, Richard Holloway, as well as the 
head of Endoscopic Services, Mark Schoeman. The head of the IBD Service, Jane 
Andrews, will be the lead supervisor of the study. The Royal Adelaide Hospital has a 
large cohort of approximately 800 patients with IBD and a strong record of successful 
clinical research. The proposed study also has the support of the head of 
gastroenterology at the Queen Elizabeth Hospital, Ian Roberts-Thomson. The Queen 
Elizabeth Hospital has a cohort of approximately 300 patients with IBD. The study 
supervisors all have extensive experience in medical research as well as experience in 
supervising PhD students. 
The Commonwealth Scientific and Industrial Research Organisation (CSIRO) in 
Adelaide has broad experience in human gut flora and microbial analysis. This is an 
area of focus for its recent research. The Nerve Gut Research Laboratory at the Royal 
Adelaide Hospital is a leader in the field of research into the neuro-immunological and 
neuro-endocrine processes of the human gut. 
5. Study Design 
This study is an 8-week randomised placebo-controlled trial with a 44-week open-label 
extension. 
Randomisation 
Patients will be randomly allocated into the following groups: 
• Group 1: Patients receive previously frozen pooled donor stool via colonoscopic 
insertion into the right colon. 
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• Group 2: Patients receive previously frozen own stool via colonoscopic insertion 
into the right colon. 
Open-label therapy from 8 weeks 
Patients who are randomly assigned to the placebo group by week 8 will then be offered 
active donor FMT at the week 8 colonoscopy. The FMT will be conducted in an 
identical manner to Group 1 with FMT followed by two enemas on day 3 or 4 and one 
on day 6 or 7. 
5.1 Recruitment 
Patients will be recruited from IBD clinics at the Royal Adelaide and Queen Elizabeth 
Hospitals. Patients on the mailing list for the Royal Adelaide Hospital will be contacted 
about the trial through the quarterly newsletter. Gastroenterologists in Adelaide will be 
informed about the trial though a presentation at the South Australian Gut Club and an 
email to the South Australian Gut Club members. The trial will be listed on the 
Australian and New Zealand clinical trials registry as well as the Gastroenterology 
Society of Australia website. 
We will enrol 70 patients with 35 patients in each arm of the trial. 
5.2 Inclusion criteria 
Patients with the following characteristics will be included: 
1. mild to moderate active UC (total Mayo score 3 to 10) 
2. endoscopic subscore of 2 or greater (to ensure symptoms are due to UC, not 
post-inflammatory irritable bowel syndrome) 
3. patients aged 18 to 75 years with established diagnosis of UC. 
5.3 Exclusion criteria 
Patients with any of the following characteristics will be excluded: 
1. severe UC (Mayo score 11–12 or Truelove and Witts criteria) 
2. more than 25mg of prednisolone per day (or equivalent steroid) 
3. previous colonic surgery 
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4. active gastrointestinal infection 
5. pregnancy 
6. anticoagulant therapy or duel antiplatelet therapy (e.g., aspirin and clopidogrel) 
7. current use of antibiotics. 
Activity of disease will be defined by the Mayo score. This scoring system has 3 points 
each for stool frequency, rectal bleeding, endoscopic findings and physician’s global 
assessment, giving a total score out of 12. 
A score of: 
• 0, 1 or 2 indicates inactive disease and exclusion from the trial 
• 3 to 10 allows inclusion in the trial. Subjects will need an endoscopic subscore 
of at least 2 for inclusion to prove active disease. (0 = normal mucosa and 1 = 
erythema only—most studies start with 2) 
• 11–12 indicates severe disease and these patients will be excluded from the trial. 
Similarly, any patient who fulfils Truelove and Witts criteria for severe colitis will be 
excluded while they meet these criteria. Truelove and Witts is defined as >6 bloody 
bowel motions per day plus one or more of the following: haemoglobin <10.5g/dL, ESR 
>30mm/hr, pulse rate >90 beats per minute and temperature over 37.5°C. 
5.4 Medication prior to enrolment 
Stable dosing of UC maintenance therapy is required prior to enrolment: 
1. 5-ASA stable dosing for at least 4 weeks 
2. thiopurines and methotrexate stable dosing for at least 6 weeks 
3. biological agents stable dosing for at least 8 weeks 
4. option to enrol on an oral dose of prednisolone ≤25mg, with a mandatory taper 
of 5mg per week. 
6. Outcome Measures 
6.1 Primary outcome 
The primary outcome will be steroid-free remission of UC at week 8 defined as: 
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1. total Mayo score of ≤2 AND 
2. Mayo endoscopic score of ≤1. 
6.2 Secondary outcomes 
Secondary outcomes will comprise: 
1. clinical response (≥3 point reduction in total Mayo score at week 8 and 1 year) 
2. clinical remission (Simple Clinical Colitis Activity Index (SCCAI) ≤2 at week 8 
and 1 year)43 
3. endoscopic remission (Mayo <1 at week 8 and 1 year) 
4. safety (assessed at week 8 and 1 year) 
5. changes in mucosal- and faecal-associated microbiota following FMT assessed 
by 16S ribosomal RNA sequencing, stratified by: 
i. change in total Mayo score following FMT 
ii. randomisation 
iii. durability of engraftment of donor microbiome following FMT 
iv. changes in peripheral blood and colonic lamina propria mononuclear cell 
populations (assessed by FACS) following FMT 
v. patient perception and palatability. 
Disease activity measures of symptoms score (SCCAI), endoscopic and histologic 
grading, and records of hospitalisation, corticosteroid requirement, periods of symptom 
flares and colectomy rate will be recorded at the 1-year mark as part of the open-label 
observation period from 8 weeks to 1 year. 
7. Patient Participation 
7.1 Recruitment 
Participants will be recruited from: 
• Royal Adelaide Hospital (RAH), The Queen Elizabeth Hospital (TQEH) and 
Fiona Stanley Hosptial (FSH) Gastroenterology IBD databases and newsletters 
• gastroenterology in- or out-patient encounter(s) at the RAH, TQEH and FSH by 
referral from their clinicians and by searching OPD letters. 
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Patients on clinical databases who have previously consented to being contacted 
regarding research studies will receive information about the study in the RAH IBD 
Service regular newsletter and may also be contacted by telephone, and if no answer is 
obtained a letter will be sent. All other patients will be contacted via a letter or by their 
treating clinician in whichever way the clinician feels is most appropriate to the 
particular patient. 
Regarding the use of letters for contact, subjects who have already consented to be 
contacted regarding research (on database) will receive a letter signed by A/Prof 
Andrews (at RAH), Prof Roberts-Thomson (at TQEH) or Dr Waters (at FSH) on behalf 
of the study investigators. 
The initial invitation letter will include an opt-out slip for subjects not wishing to be 
contacted further. Subjects not opting out or responding within 4 weeks after invitation 
will be contacted up to a further three times by two different methods (phone, SMS, 
email or letter) to ascertain whether they wish to participate or not. Demographic details 
of non-responders will be recorded to enable a full description of the sources of possible 
bias. All who agree to participate will be subsequently screened to ensure they fulfil 
inclusion criteria. 
Donors will be recruited with a flyer advertisement on notice boards at Adelaide 
University Medical School and Adelaide University campus. 
7.2 Withdrawal criteria 
Patients may withdraw from the study at any time. We will ask for their reasons for 
statistical purposes; however, they will not be obliged to provide this information. 
Withdrawal from the study will not affect ongoing standard medical care in any way. 
Their clinicians will be informed of their participation in the study. We will ask patients 
to notify us of any changes in their treatment during the course of the study and, if 
necessary, we will seek their permission to verify this with their treating clinician. 
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8. Ulcerative Colitis Patient Assessment 
8.1 The week prior to enrolment 
1. The patient should have the opportunity to read the patient information sheet, 
discuss the trial with family or friends and ask questions of the investigators prior to 
signing trial consent. 
2. Patient questionnaire regarding perception and expectation of faecal transplant 
prior to procedure. 
3. Detailed history of UC: 
• date of diagnosis 
• extent of disease 
• medication use—current and prior 
• previous surgery 
• previous hospitalisation 
• comorbid disease 
• current symptoms 
• extra-articular manifestations. 
4. Stool collected for: 
• infection screen: microscopy culture + sensitivity, Clostridium difficile toxin 
(5g) 
• possible re-administration for placebo arm subjects (50g) 
• microbiome analysis: 6 × 0.25g stool in Eppendorf tubes, 2 × 5g stool in larger 
brown stool pots. 
For collection and processing methods see section 10. 
5. Disease activity assessment: 
• faecal calprotectin 
• CRP, ESR, FBC, U+E, LFTs 
• symptom severity (SCCAI ) at screening and one day prior to FMT 
 
281 
• flexible sigmoidoscopy: 
i. total Mayo score 
ii. disease extent (≥10cm of disease required) 
iii. biopsy for light microscopy and histopathology to exclude CMV 
inclusions. 
8.2 Randomisation 
Randomisation will be conducted once the patient satisfies the inclusion and exclusion 
criteria and has consented to enter the study. This should occur within 1–7 days prior to 
the first faecal transplant, which will be delivered via colonoscopy. 
Prior to randomisation, three aliquots of pooled donor stool suspension from a single 
batch and three aliquots of the donor’s own stool suspension will each be placed in clear 
plastic bags in the -80°C freezer at the endoscopy unit. All stool aliquots will be in 
identical yellow-topped 250mL cryo-safe containers. These will include 1 × 200mL 
suspension for colonoscopic delivery and 2 × 100mL suspensions for enema delivery. 
Donor stool pots will be labelled on the lid with: 
1. batch number 
2. date of manufacture of batch. 
Patient’s own stool will be labelled on the lid with: 
1. patient ID consisting of initials and study number (e.g., AB-1) 
2. date of patient stool donation. 
Randomisation to be conducted by hospital clinical trial nursing staff using 
www.random.org. 
1. Cardboard circular caps with patient ID and either “Transplant” or “Save” and 
either “Colon” or “Enema” are then placed on the pots containing donor or 
patient’s own stool depending on randomisation. 
2. “Transplant” caps are placed on the pots to be given at and in the week 
following the first colonoscopy. 
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3. “Save” pots will be saved and the cap removed following the 8 week 
colonoscopy. If these contain donor stool, they will be given to the patient at the 
8 week colonoscopy and in the subsequent week. 
4. “Colon” pots will be delivered at colonoscopy and the “Enema” pots delivered 
via enema in the following week. 





Faecal transplant for active ulcerative colitis trial 
Protocol for randomisation of FMT 
1–7 days prior to faecal transplant use the random number generator 
http://www.random.org/ 
Into the “true random number generator” box on the right of the screen set the minimum 
to 1 and maximum to 2 
Select: Generate 
1 = Donor faecal transplant 
2 = Placebo faecal transplant (patient’s own stool) 
 
 
Go to the -80°C Freezer. 
1. For Donor Faecal transplant stick the “Transplant” disks on the top of the donor 
stool yellow pots and the “Save” disks on the placebo pots. Record the batch 
number in the transplant record book. 
2. For Placebo Faecal transplant stick the “Save” disks on the donor stool yellow 
pots and the “Save” disks on the donor pots. The donor stool will then be saved 
to transplant at 8 weeks at the open-label crossover. 
The donor stool pots are labelled with a Batch number and date (e.g., Batch 3, 2/7/13). 
The patient’s own stool (placebo) is labelled with patient study number.  
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8.3 Week 1 of trial 
8.3.1 Day prior to colonoscopy 
1. Patient to take a light breakfast and then to fast from solids. 
2. Maintain high fluid intake throughout the day. 
3. Take three sachets of Colonlytely bowel preparation (polyethylene glycol) in 3L 
of water. 
8.3.2 Morning of colonoscopy 
1. Randomised faecal aliquot labelled “Transplant” and “Colon” to be removed 
from the -80°C freezer and thawed at room temperature for 3.5 hours prior to 
delivery. 
2. Patient to receive loperamide 2mg orally prior to colonoscopy. 
3. SCCAI score diary to be collected. 
4. Mayo symptom scores to be taken (endoscopic score to be added at 
colonoscopy). 
5. Biopsy posts should be pre-labelled with the site and number of biopsies 
required. 
6. Consent should be obtained for this procedure on a standard CALHN consent 
form in addition to the study consent form that has previously been signed. 
7. While inserting cannula, take 60mL of blood: 
i. 50mL into 6 × heparin tubes (green and black top) for peripheral blood 
mononuclear cell flow cytometry (to be taken to Dr Hughes at Nerve Gut 
Laboratory) 
ii. 5mL into a small EDTA (purple tube) (to be sent to clinical laboratory) 
iii. 5mL into a GEL (white top) for electrolytes and liver function, C-
reactive protein (to be sent to SA pathology laboratory). 
8.3.3 At colonoscopy 
1. Assess disease severity (using endoscopic Mayo score at point of maximum 
inflammation) and disease extent. 
2. Biopsies should be taken on colonoscope insertion*: 
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i. left-sided biopsies: 11 total; 6 in RPMI media, 2 into RNA later 
(microbiome), 1 RNA later (PCR), 1 formalin (histopath), 1 PFA (IHC). 
ii. right-sided biopsies: 9 biopsies; 6 in RPMI media, 2 into RNA later 
(microbiome), 1 formalin (histopath). 
3. An attempt should be made to remove any residual fluid or faecal material 
during colonoscope insertion with suction and washing if required. 
4. Once at caecum, patient should be rolled onto the right lateral position and 
randomised faecal suspension delivered into the right colon. If caecum cannot be 
reached, then delivery of faecal suspension into the right colon beyond the 
hepatic flexure is acceptable. 
5. Patient should then remain on their right side for 1 hour following procedure. 
6. Following 1 hour, the patient should be assessed for any adverse effects and if 
well sat up and offered food and drink prior to discharge. 
*Biopsies at each colonoscopy in more detail: 
• 2 biopsies will be taken from both the recto-sigmoid region and ascending 
colon-caecal region of the colon for microbiota analysis. Each in 2.5mL RNA 
later. 
• 1 biopsy from each region will be taken for histopathology analysis into 
formalin. 
• 1 biopsy from left colon for immunohistochemistry (formalin) and 1 from the 
left colon for PCR (cytokines, transcription factors) (RNA later). 
• 4 biopsies will be taken from the left and 4 from the right colon for flow 
cytometry (FACS) analysis (RPMI complete media), processed the same day as 
colonoscopy. 
• 2 biopsies from the left colon and 2 from the right for supernatant release for 
cytokines/mast cell mediators (RPMI complete media). 
• This will amount to 9 biopsies in the right colon and 11 in the left colon. 
8.3.4 Enemas 
Two enemas of 100mL faecal suspension will be delivered by a gastroenterologist at the 




1. take 2mg of loperamide prior to enema 
2. lay on left lateral position for enema insertion 
3. roll from the left lateral to prone position then right lateral and then back to left 
lateral position following enema insertion. This is to encourage proximal 
distribution of the enema 
4. attempt to hold the enema for 1 hour. 
8.4 Week 4 assessment 
1. Stool collection for faecal calprotectin level and microbiome analysis. 
2. Stool to be collected in sterile blue bags that are placed over the toilet. 
3. Patient to zip tie blue bag closed and place blue bag in clear zip-lock bag. 
4. Deliver to CSIRO laboratory within 1 hour. 
5. Bag to be opened and stool processed under anaerobic conditions in anaerobic 
chamber: 
i. microbiome analysis: 6 × 0.25g stool in Eppendorf tubes, 2 × 5g stool in 
larger brown stool pots. 
8.5 Week 8 assessment 
8.5.1 Two days prior to colonoscopy 
1. Stool collection for faecal calprotectin level and microbiome analysis. 
2. Stool to be collected in sterile blue bags that are placed over the toilet. 
3. Patient to zip tie blue bag closed and place blue bag in clear zip-lock bag. 
4. Deliver to CSIRO laboratory within 1 hour. 
5. Bag to be opened and stool processed under anaerobic conditions in anaerobic 
chamber: 
i. microbiome analysis: 6 × 0.25g stool in Eppendorf tubes, 2 × 5g stool in 
larger brown stool pots. 
8.5.2 One day prior to colonoscopy 
1. Patient to take a light breakfast and then to fast from solids. 
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2. Maintain high fluid intake throughout the day. 
3. Take three sachets of Colonlytely bowel preparation (polyethylene glycol) in 3L 
of water. 
8.5.3 Morning of colonoscopy 
1. Randomised faecal aliquot labelled “Save” and “Colon” to be removed from the 
-80°C freezer and thawed at room temperature for 3.5 hours prior to delivery. 
2. Patient to receive loperamide 2mg orally prior to colonoscopy. 
3. SCCAI score diary to be collected. 
4. Mayo symptom scores to be taken (endoscopic score to be added at 
colonoscopy). 
5. Adverse events since randomisation recorded. 
6. Biopsy pots should be pre-labelled with the site and number of biopsies 
required. 
7. Consent should be obtained for this procedure on a standard CALHN consent 
form in addition to the study consent form that has previously been signed. 
8. While inserting cannula, take 60mL of blood: 
i. 50mL into 6 × heparin tubes (green and black top) for peripheral blood 
mononuclear cell flow cytometry (to be taken to Dr Hughes at Nerve Gut 
Laboratory) 
ii. 5mL into a small EDTA (purple tube) (to be sent to clinical laboratory) 
iii. 5mL into a GEL (white top) for electrolytes and liver function, C-
reactive protein (to be sent to clinical laboratory). 
8.5.4 At colonoscopy 
1. Assess disease severity using endoscopic Mayo score at point of maximum 
inflammation and disease extent. 
2. Biopsies should be taken on colonoscope insertion*. 
3. Left-sided biopsies: 11 total; 6 in RPMI media, 2 into RNA later (microbiome), 
1 RNA later (PCR), 1 formalin (histopath), 1 PFA (IHC). 
4. Right-sided biopsies: 9 biopsies; 6 in RPMI media, 2 into RNA later 
(microbiome), 1 formalin (histopath). 
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5. An attempt should be made to remove any residual fluid or faecal material 
during colonoscope insertion with suction and washing if required. 
6. Once at caecum (and disease severity has been assessed and recorded), the 
cardboard “Save” cap should be removed from the pot to reveal the contents of 
the faecal pot: 
i. If this is labelled as the patient’s own stool, it should be discarded and 
the colonoscope withdrawn. 
ii. If this is labelled as donor stool, then the patient should be rolled onto 
the right lateral position and the un-blinded faecal suspension delivered 
into the right colon. 
7. If caecum cannot be reached then delivery of faecal suspension into the right 
colon beyond the hepatic flexure is acceptable. 
8. Patient should then remain on their right side for 1 hour following procedure. 
9. Following 1 hour the patient should be assessed for any adverse effects and 
offered food and drink prior to discharge. 
10. Patient to be informed about randomisation. If they were initially randomised to 
placebo/autologous FMT then they will require two further donor FMTs via 
enema. 
*Biopsies at each colonoscopy in more detail: 
• 2 biopsies will be taken from both the recto-sigmoid region and ascending 
colon-caecal region of the colon for microbiota analysis. Each in 2.5mL RNA 
later. 
• 1 biopsy from each region will be taken for histopathology analysis into 
formalin. 
• 1 biopsy from left colon for immunohistochemistry (formalin) and 1 from the 
left colon for PCR (cytokines, transcription factors) (RNA later). 
• 4 biopsies will be taken from the left and 4 from the right colon for flow 
cytometry (FACS) analysis (RPMI complete media), processed the day of 
colonoscopy. 
• 2 biopsies from the left colon and 2 from the right for supernatant release for 
cytokines/mast cell mediators (RPMI complete media). 
• This will amount to 9 biopsies in the right colon and 11 in the left colon. 
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8.5.5 Enemas (patients randomised to placebo/autologous FMT) 
Two enemas of 100mL faecal suspension will be delivered by a medical practitioner at 
the clinic in the week following colonoscopy (days 2–4, days 5–7). 
1. Patient to take 2mg of loperamide prior to enema. 
2. Lay on left lateral position for enema insertion. 
3. Roll into prone positions, right lateral and then back to left lateral position 
following enema insertion. 
4. Patient should attempt to hold the enema for 1 hour. 
8.6 One-year assessment 
Patient will be posted or emailed: 
1. SCCAI symptoms score 
2. patient questionnaire regarding experience of faecal transplant prior to procedure 
and adverse events 
3. invitation to undergo disease activity assessment. 
Patients who do not return forms within 2 weeks will be contacted via telephone. 
8.6.1 Two days prior to flexible sigmoidoscopy 
1. Stool collection for faecal calprotectin level and microbiome analysis. 
2. Stool to be collected in sterile blue bags that are placed over the toilet. 
3. Patient to zip tie blue bag closed and place blue bag in clear zip-lock bag. 
4. Deliver to CSIRO laboratory within 1 hour. 
5. Bag to be opened and stool processed under anaerobic conditions in anaerobic 
chamber: 
i. microbiome analysis: 6 × 0.25g stool in Eppindorf tubes; 2 × 5g stool in 
larger brown stool pots 
ii. faecal calprotectin. 
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8.6.2 Flexible sigmoidoscopy 
1. Mayo symptom scores to be taken (endoscopic score to be added at 
colonoscopy). 
2. Adverse events since randomisation recorded. 
3. Biopsy pots should be pre-labelled with the site and number of biopsies 
required. 
4. Consent should be obtained for this procedure on a standard consent form in 
addition to the study consent form that has previously been signed. 
5. While inserting cannula, take 60mL of blood: 
i. 50 mL into 6 × heparin tubes (green and black top) for peripheral blood 
mononuclear cell flow cytometry (to be taken to Dr Hughes at Nerve Gut 
Laboratory) 
ii. 5mL into a small EDTA (purple tube) (to be sent to clinical laboratory) 
iii. 5mL into a GEL (white top) for electrolytes and liver function, C-
reactive protein (to be sent to clinical laboratory). 
6. Assess disease severity using endoscopic Mayo score at point of maximum 
inflammation. 
7. Biopsies should be taken on the left side only. 
8. Left-sided biopsies: 11 total; 6 in RPMI media, 2 into RNA later (microbiome), 
1 RNA later (PCR), 1 formalin (histopath), 1 PFA (IHC). 
9. Following 1 hour the patient should be assessed for any adverse effects and 
offered food and drink prior to discharge. 
8.6.3 Care during the follow-up period 
During the trial, subjects will be treated to the standard of care for UC. This involves a 
fixed maintenance medication as prescribed/advised by their own physician. Patients 
will enter this trial because of a flare, and all therapy they are on at entry will be 
continued except for the steroid taper as described. 
A subject who experiences a flare of their disease during the study will be treated with 
standard therapy as if they were not in the study. This will include increasing their oral 
5-ASA and/or adding a topical enema or suppository therapy. Systemic steroid therapy 
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may also be used. Steroid use will be quantified during the study and steroid 
requirement over the 12-month period will be another secondary endpoint. Once 
patients are commenced on steroid, it will be tapered as explained above. 
If a subject deteriorates on steroid therapy, they may require escalation of their medical 
therapy or surgery. Escalation of medical therapy may involve increasing the steroid 
dose temporarily. Patients who are naïve to thiopurine therapy may benefit from the 
addition of a thiopurine. Thiopurines can take up to 12 weeks to reach their therapeutic 
effect and so “rescue therapy” may be needed in the intervening period. Rescue therapy 
involves the addition of cyclosporine or an anti-TNF agent such as infliximab (if 
available through compassionate access) in the short term. Rescue therapy will be 
continued for 6 to 12 weeks to allow the thiopurine medication to reach its full effect. 
Patients who have a severe flare of UC that does not respond to intravenous steroid 
medication within 3 to 5 days are unlikely to improve and should be assessed for 
surgical colectomy44, as would be the case in routine care. 
9. Stool Donor Recruitment and Screening 
9.1 Donor recruitment 
Posters will be placed on noticeboards on the University of Adelaide campus. These 
will detail that we are recruiting stool donors and the posters will have the contact 
details of Dr Costello and Dr Andrews. 
9.2 Donor screening 
Potential donors will be sent the donor information sheet via email or post. 
Donors who consent will undergo a four-stage screening process with medical history, 
physical examination, blood testing and stool testing with the aim of reducing the risk 
of disease transmission from donor to recipient. 
9.2.1 Medical history 
Exclusion of patients with: 
• age: <18 or >65 
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• antimicrobial therapy or probiotics in the past 3 months 
• active medical illness or symptoms 
• any medications (other than oral contraceptive pill) 
• international travel in last 6 months to areas at high risk of traveller’s diarrhoea 
• high-risk sexual activity (unprotected sex in last 1 month outside of a 
monogamous relationship, men who have sex with men, sex for drugs or money) 
• illicit drug use 
• tattoo or body piercing within 6 months 
• known HIV or viral hepatitis exposure in the last 12 months 
• incarceration or a history of incarceration 
• family history of colorectal carcinoma involving two or more first-degree 
relatives 
• household members with active gastrointestinal infection. 
Inclusion of patients who have no active medical problems or a history of: 
• inflammatory bowel disease 
• irritable bowel syndrome 
• colonic polyps 
• bowel cancer 
• any other gastrointestinal disorder 
• obesity 
• high blood pressure 
• diabetes 
• heart disease 
• stroke 
• major depression 
• infection with hepatitis B or C, HIV or syphilis 
• autoimmune disease (e.g., rheumatoid arthritis, SLE). 
9.2.2 Physical examination 
Cardiovascular and gastrointestinal examination. 
Height and weight: BMI <18 and >30 is an exclusion. 
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9.2.3 Blood testing 
• full blood count (anaemia, WCC >12.5 are exclusions) 
• electrolytes, urea and creatinine (renal impairment eGFR <60 is an exclusion) 
• liver function tests (abnormal LFTs are exclusions) 
• human T cell lymphotropic virus 1 and 2 serology (positive serology is an 
exclusion) 
• Epstein Barr virus IgM and IgG (positive IgM is exclusion) 
• cytomegalovirus IgM and IgG (positive IgM is exclusion) 
• syphilis (positive rapid plasma regain is an exclusion) 
• Strongyloides stercoralis, Entamoeba histolytica (positive serology is an 
exclusion) 
• toxoplasma serology (positive serology is an exclusion) 
• hepatitis A virus IgM (positive serology is an exclusion) 
• hepatitis B PCR (positive PCR is an exclusion) 
• hepatitis C PCR (positive PCR is an exclusion) 
• HIV PCR (positive PCR is an exclusion) 
• fasting lipids and blood sugar level (total cholesterol >4.0mmol/L, LDL >2.5 
mmol/L, triglycerides >2.0mmol/L, HDL <1.0mmol/L are exclusions) 
• C-reactive protein (>8 exclusion) 
• ANA (>1/160 is an exclusion) 
• helicobacter serology (positive serology is an exclusion) 
9.2.4 Stool testing 
• microscopy and culture 
• Clostridium difficle toxin PCR 
• egg, cysts and parasites (including Cryptosporidium spp., Giardia spp. and 
Entamoeba histolytica PCR) 
• rotavirus, norovirus and adenovirus PCR 
10. Stool Collection and Processing 
Once donors have passed all the screening requirements they are eligible to donate for 1 
month. To donate stool beyond this time will require repeat screening. 
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10.1 Stool collection 
1. Stool collected in sterile blue bags that are placed over the toilet. 
2. Stool donor to zip tie blue bag closed and place blue bag in clear zip-lock bag. 
3. Stool donor to produce stool at CSIRO or deliver to CSIRO laboratory in esky 
within 1 hour of defecation. 
4. 4–6 stool donors will be asked to provide stool on each collection day. 
10.2 Stool processing 
10.2.1 Donor stool processing 
Setting up 
Ensure anaerobic chamber is primed with gas and is anaerobic. 
See instructions on setting up anaerobic chamber. 
Set-up 
Blender case as well as spatulas, glass beaker and glass measuring cylinder to be 
autoclaved within 24 hours of commencing stool processing (ideally the night prior): 
1. weigh stool (empty clear and blue bag weight = 47g) 
2. saline (mL) = 2.6 × total stool weight (g) 
3. glycerol (mL) = 0.4 × total stool weight (g) 
4. sterile 200mL yellow pots (number) = total stool weight/50 (rounded up) 
5. transfer these minimum amounts into the anaerobic chamber. 
Equipment 
Blender (cylinder and base) 
Stainless steel spatulas (autoclaved) 
Glass beaker (autoclaved) 
Glass measuring cylinder (autoclaved) 
8 × Eppendorf tubes labelled: 




• tube number 
• F = fresh. G = Glycerol 
Note pad, pen and scissors 
Scientific weigh scales 
Prior to blending 
1. Add 0.25g of stool to each of 6 labelled, capped Eppendorf tubes. 
2. Add 5g of stool to 2 × larger brown pots. 
3. Record weight of stool in note pad. 
Blending process 
1. Stool from four donors will be pooled and blended with normal saline and sterile 
pharmaceutical grade glycerol (in the ratio 25% stool, 65% saline, 10% 
glycerol). 
2. The number of donors to be pooled will be limited to four to reduce the risk of 
transmissible disease from a single donor. 
3. Blend on low power for 20 seconds and then high power for a further 20 
seconds. 
4. Aliquot the stool suspension into the sterile yellow pots (Colonoscopy, 200mL; 
Enema, 100mL) and label with batch number and date. 
5. Each batch consists of 1 × 200mL pot and 2 × 100mL pot. 
6. Each recipient will receive the same batch (same blend of donor stool from 
single day donation) for each of their three faecal transplants. 
7. Multiple such batches can be produced from each donor stool blend. 
8. Half fill a further 2 × Eppendorf tubes with blended stool mix. 
9. Transfer the stool suspensions and tubes directly into -80 degree freezer. 
10.2.2 Documentation and tracing of donors 
1. Each stool donor will be recorded in the secure and confidential study “stool 
donor register” document. This will include: 
i. donor’s name 
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ii. date of birth 
iii. address and contact details 
iv. result of screening history, physical examination, and blood and stool 
tests. 
2. Each stool donor will be assigned a donor number. 
3. Each stool aliquot will be numbered and recorded in the secure and confidential 
faecal transplant aliquot document that will list the four stool donors who 
contributed to each aliquot. In this way any possible transmission of infection 
can be traced. 
4. A small amount of each individual donation will be set aside and frozen 
individually. This will allow repeat testing and tracing of each individual 
donation in the future in the event of possible transmission of infection. 
10.2.3 Ulcerative colitis patient stool processing 
1. Each subject potentially suitable for the study will also be asked to donate a 
stool sample of their own. 
2. A small portion of the stool will be set aside to undergo faecal-associated 
microbiota analysis. 
3. 50g of the remainder will be mixed with 20mL sterile pharmaceutical grade 
glycerol and 130mL saline and placed into frozen storage at -80°C. This stool 
will then be used to transplant those subjects randomised to receive “placebo” 
with their own stool. In this way the FMT will remain blinded to both the 
subject and colonoscopist. 
10.2.4 Cleaning equipment 
Blender case, stainless steel implements and glassware should all be cleaned following 
stool processing in the order listed below: 
1. rinsed with water in the sink 
2. washed with detergent and water 
3. rinsed with water 
4. washed with enzymatic wash 




11. Analysis and Reporting of Results 
All of the outlined techniques are well established and have been used in previous 
studies. 
Analysis of stool microbiota and microbiota metabolites will mainly be conducted at 
CSIRO Animal, Food and Health research laboratories in Adelaide under the guidance 
of Dr Michael Conlon. Some analyses may be outsourced to other laboratories, but 
under the broad direction of Dr Conlon in consultation with Dr Costello and other 
collaborators. The abundance and/or activities of faecal and mucosal (biopsy)-
associated microbes will be analysed using molecular methods. This will include the use 
of 16S ribosomal RNA sequencing. Isolation (culture) of bacteria from stool samples 
may be considered to further understanding of metabolic changes occurring in bacteria 
of IBD patients compared with healthy controls. Stool will be analysed for SCFAs using 
a range of methods established at CSIRO, where sufficient material is available. Other 
metabolites may also be measured. 
11.1 Bacterial analysis 
Bacterial DNA will be extracted from the samples using the MoBio PowerMag 
Microbial DNA Isolation kit (MoBio Laboratories, Carlsbad, CA, USA) following the 
manufacturer’s protocol. All stool samples will be extracted and processed in duplicate. 
Amplicon library preparation will be performed using a modified dual-index PCR 
approach. The V4-V5 hypervariable region of the 16S rRNA gene will be amplified 
using first-step primers (515F, 806R), modified by the inclusion of a phaser, and the 
indexed barcodes added to the second set (i5, i7) enable multiplexing of the large 
number of samples45. The library will be pooled at equi-molar concentrations and run 
on an Illumina HiSeq2500 Rapid instrument using 2 × 250 base pair paired-end 
chemistry (Ramaciotti Centre for Genomics, University of New South Wales). 
11.2 Bioinformatics 
Raw sequencing data will be processed using a combination of both in-house and open-
source software. The bioinformatic pipeline will utilise USEARCH algorithms46, which 
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include merging, quality-filtering, partitioning/de-replicating and clustering into 
operational taxonomic units (OTUs) at 97% similarity. Representative sequences from 
each OTU will be classified in two ways: via the RDP Naïve Bayesian Classifier and by 
finding the closest match in a set of curated reference sequences (RDP 16S Training Set 
+ RefSeq 16S)47. The use of two independent classification techniques improves 
confidence in the taxonomic assignments. 
11.3 Immunological analysis via flow cytometry 
Gut mucosal immunological analysis with be performed with Dr Patrick Hughes at the 
Nerve Gut Research Laboratory. 
Blood sampling 
A total of 60mL will be taken at each time point, and will be used for further 
experiments outlined below. 
Isolation of PBMC and LPMC cells 
Peripheral blood mononuclear cells (PBMCs) are isolated from whole blood via density 
gradient centrifugation. Lamina propria mononuclear cells (LPMCs) are isolated from 
colonic biopsies via collagenase digestion and density gradient centrifugation. Cells will 
be stored under liquid nitrogen until further analysed. 
PBMC cells and biopsy tissue will be used for the following. 
LPMC isolation: Colonic mucosal biopsies will be incubated twice in Hepes buffered 
HBSS supplemented with 1mM EDTA and 1mM DTT (Sigma) for 10min at 37°C 
under slow rotation, with the suspension strained (100µM) between incubations. 
Residual tissue will be incubated in Hepes buffered Ca2+/Mg2+ free HBSS for 10min at 
37°C under slow rotation and strained (100µM). Residual tissue will be minced and 
incubated in complete media (RPMI 1640 [Gibco, Germany] supplemented with foetal 
calf serum, glutamax and penicillin/streptomycin, Collagenase D [1mg/mL; Roche, 
NSW, Australia], DNAse1 [0.5mg/mL; Sigma] and Dispase [3mg/mL; Roche]) for 
20min twice, with supernatant removal from centrifugation (300g, 5min) after each 
incubation. Residual suspensions will be sequentially strained (100µM followed by 
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40µM), with the supernatant centrifuged (300g, 5min), resuspended and stained with 
trypan blue to determine viability and cell number as previously described48-50. 
Cell staining: 0.5 × 106 Fc blocked (BD Biosciences, NSW, Australia) cells will be 
stained for viability (FVD eFlour450, eBioscience) and the following anti-human 
monoclonal antibody panels (BD Bioscience unless otherwise stated): (a) HLADR-
APC, CD11C-FITC, Lin (CD3, CD14, CD16, CD19, CD34, CD56 all APC-Cy7, 
CD33-PerCP Cy5.5); (b) CD3-APC, CD45RO-PerCP Cy5.5, CD19-APC Cy7, CD20-
APC Cy7, CD16-PE, CD56-PE, Vα24jα-FITC (eBioscience), c) CD3-APC, CD8-FITC, 
CD45RO-PerCP Cy5.5, γδT-PE (eBioscience). For TREG, cells will be stained with 
CD4-APC Cy7, CD8-PE, CD45RO PerCP Cy5.5, CD25 PE Cy7, β7-FITC, followed by 
fixation and permeabilisation (Transcription buffer staining set, eBioscience) and 
staining with FOXP3-APC (eBioscience). The following gating strategy will be used to 
identify cell populations: macrophages (lin-ve/HLADR/CD33+ve), dendritic cells (lin –
ve HLADR+/CD33+/CD11c+), THELPER (CD4+ CD8-), TCYTOTOXIC (CD8+ CD4-), 
TREGULATORY (CD4+/CD8-/CD25+/FOXP3+), B (CD3-, CD19+ CD20+), natural killer 
(CD3-/CD16+/CD56+/CD45RO-), natural killer T (CD3+/NKT+), γδ T (CD3+/γδT+) 
in LPMCs; and gut-homing THELPER (CD4+/CD8-/CD45RO+/β7+) and gut-homing 
TREGULATORY (CD4+/CD8-/CD45RO+/β7+/CD25+/FOXP3+) in PBMCs. 
12. Statistical Analysis 
Patient information will be de-identified and the results of microbiota, immune analysis 
and clinical scores will be recorded in an Excel spread sheet. This data will then be 
imported into the R program for statistical analysis. Statistical analysis will be 
conducted in collaboration with the University of Adelaide department of statistics. 
12.1 Primary outcome power analysis 
The study is powered to detect a significant difference in the primary outcome of 
inducing remission at 8 weeks post FMT with 32 patients in each arm. This was 
calculated using a Z test with pooled variance for the difference of two independent 
proportions. The significance level was set at 5% and the power at 80%. The estimated 
remission rate in the placebo group was 26.4% and the minimum clinically relevant 
remission rate we are powered to detect is 60%. 
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The placebo remission rate is difficult to predict because of the heterogeneous nature of 
previous studies that investigated induction of remission in UC. Our placebo remission 
rate was derived from the active UC trials 1 and 251 (ACT-1 and ACT-2). The ACT-1 
and ACT-2 trials were randomised, double-blind placebo-controlled studies that 
evaluated the efficacy of IV infliximab 5 or 10mg/kg IV infusion for induction and 
maintenance treatment in adults with UC. The clinical response rate in those patients in 
the ACT-2 trial who were not steroid dependent was 26.4%. These patients had 
moderate to severe colitis with a Mayo score of 6 to 12 on enrolment and so had more 
severe disease on average than our patients. Response was defined as at least a 3-point 
reduction and 30% reduction in the Mayo score to determine clinical response at week 
8. Another trial of patients with mild to moderate UC52 found a remission rate at 8 
weeks with oral mesalamine 2.4g daily of 22%. Many of our patients will be taking an 
oral aminosalicilate compound and some a concomitant steroid. The remission rate in 
this case would be expected to be higher than 22%. 
12.2 Clinical outcomes 
Comparisons between treatment groups of the primary and secondary dichotomous 
outcomes will be assessed using Fisher’s exact tests, with individuals analysed in the 
group to which they are allocated (intention to treat). Assessment of treatment on the 
change in total Mayo score will be assessed using linear mixed effects regression with 
week 8 total Mayo score as outcome and adjusting for baseline total Mayo score and 
steroid use at either time point. A random intercept will be included for each group of 
individuals receiving the same donor mix. Associations between baseline factors and 
change in total Mayo score will be assessed in a similar manner, with treatment group 
also adjusted for as a fixed effect covariate. To assess the effect of oral steroid use at 
either time point, a mixed effects regression will be constructed with total Mayo score 
(at either assessment) as outcome with oral steroid use, assessment time and the 
treatment–assessment time pairwise interaction as fixed effects. Two non-nested 
random intercepts will be included, one for correlations due to treatment batch effects, 
the other to account for observations within the same patient. The random effects will 




As with the clinical outcomes, the comparison between treatment groups and 
occurrence of SAEs will be assessed using a Fischer’s exact test. Assessment of 
treatment on the change in serum creatinine, ALT, ALP, bilirubin and haemoglobin will 
be assessed using linear mixed effects regressions with week 8 values as outcome. 
Fixed effects covariates include treatment group and baseline values with a random 
intercept to account for within-batch correlations. 
12.4. Inflammatory markers 
The models used to assess the differences due to treatment in white blood cell count, 
neutrophil count and C-reactive protein will be the same as those used to assess the 
safety blood markers (see above). The exception being calprotectin, which has an extra 
assessment at week 4. This model extends the mixed effects regressions with 
assessment time (week 4 v week 8) and the pairwise interaction with treatment as 
additional fixed effects. As before, random effect intercepts will be included for each 
individual and each treatment batch, with individual effects nested with batch. After 
inspection of the residual distribution, these analyses will be performed on the change in 
log transformed calprotectin, with results being converted back to the original scale. 
12.5 Microbiome: Diversity 
Diversity will be defined as the fraction of unique species present at an assessment out 
of all species present at any analysis in any sample. Therefore, logistic mixed effects 
regressions will be used to compare between treatment groups with donor stool and 
stool mix samples. Outcome will be the presence of a species in a particular sample. 
Fixed effects will include sample origin (donor v mix v treated patient v untreated 
patient) and total sample count (log transformed). Three non-nested random effects will 
be included: patient identifier, donor batch and the microbiome species identifier. To 
assess the effect of treatment, a separate model will be contrasted with only post 
baseline samples included as outcome. This model will be identical to the previous, 
except that the fixed effects will be baseline prevalence (logit transformed), treatment 
allocation, assessment time (week 4 v week 8), the pairwise treatment–assessment time 
interaction and total sample count (log transformed). Associations between both 
baseline diversity and change in diversity, and change in total Mayo score will be 
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assessed as before (re Clinical outcomes). A two-stage approach will be taken. First, the 
mean diversity will be estimated using the logistic mixed effects models previously 
described in this section. These diversity estimates will then be included in the models 
of total Mayo score as fixed effects. 
12.6 Microbiome: Abundance v total Mayo score 
Associations between changes in biome species abundance with change in total Mayo 
score will be modelled in a similar manner. For each sample, the mean proportion of 
total counts will be calculated, and subsequently for individuals, with samples at both 
week 4 and 8 averaged to estimate baseline and post randomisation prevalence 
estimates. The change in prevalence will then be included in linear mixed effects 
models of total Mayo score (re Clinical outcomes). A false discovery rate (FDR) 
analysis will be performed to provide evidence of associations beyond what would be 
expected because of multiple testing, with the FDR being compared with the same 
analysis repeated, but with outcome (total Mayo score) permuted between individuals. 
12.7 Microbiome: Abundance v treatment 
The change in prevalence by treatment group and assessment time will be assessed 
using a negative binomial mixed effects regression for each microbiome species. Fixed 
effects include treatment allocation, assessment time (baseline, week 4, week 8 and 12 
months) and their pairwise interaction. Nested random intercepts per patient and 
assessment will be included in the model, with total sample count (log transformed) 
included as an offset. 
12.8 Metabolome 
Baseline levels of butyrate and dietary fibre will be compared between donors and UC 
patients using non-parametric Mann-Whitney-Wilcox tests. The effect of treatment on 
these and other SCFAs will be assessed using linear mixed effects regressions. Fixed 
effects include assessment time (week 4 v 8), treatment group and baseline SCFA 
abundance, with two nested random intercepts at the donor batch and patient levels. 
After examination of residual distributions, all SFCA variables will be log transformed 
and results reported as percentages of baseline scores. Associations between baseline 
total Mayo scores and SCFAs will be assessed using linear regressions, adjusting for 
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oral steroid use, with baseline SCFA levels log transformed. Associations between 
change in total Mayo scores and change in SCFAs will be performed in the same two-
stage approach. SCFA change levels will be estimated per individual using linear mixed 
effects regressions, adjusting for baseline levels and treatment, with individual random 
effects nested within batch. Patient level estimates of SCFA change will be entered into 
linear mixed effects regressions of total Mayo score as a fixed effect using the same 
methodology described above (re Clinical outcomes). 
12.9 Immune system 
The models used to assess associations between immunological measures and total 
Mayo score both at baseline and for post-treatment change will be the same as those 
used for SCFAs (see Metabolome above). With baseline and week 8 assessments for the 
immunological data, the difference in log transformed values will be included in the 
mixed effects regression of total Mayo score. 
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Appendix 2C: Summary of Changes 
Page numbers apply to the final protocol: 
1. Title page. Oliver Waters added as investigator at Fiona Stanley Hospital in 
Western Australia. Fiona Stanley Hospital was added as a third site for the trial 
in 2015. 
2. Pages 271. Under “Standard of care”. Deleted “Anti TNF agents not funded by 
the pharmaceutical benefits scheme in Australia and so, are not readily 
available”. Funding became available for anti-TNF agents in 2014 (after 
commencement of the study). 
3. Page 276. Under “Open-label therapy”. Changed such that all who are randomly 
assigned to the placebo group by week 8 will then be offered active donor FMT 
at the 8 week colonoscopy. Previously only those who do not have a clinically 
relevant response (achieving remission, having a drop in Mayo score by ≥3 or 
achieving a endoscopic subscore of 0–1) would be offered donor FMT. This 
change was made as patient 4 was enrolled and as such all patients in the 
placebo arm were offered donor FMT at week 8. 
4. Page 276. Under “Exclusion criteria”. Anti-TNF therapy removed as exclusion 
criteria. This therapy became funded for ulcerative colitis in 2014 and at this 
time we allowed patients on this medication to enter the trial. 
5. Page 276. Under “Recruitment”. Fiona Stanley Hospital in Western Australia 
added as a study site in 2015 and Dr Oliver Waters added as an investigator at 
that site. 
6. Page 276. Under “Recruitment”. Donor recruitment flyers were not placed on 
the hospital grounds and only the university. The university population were 
considered more suitable to be stool donors. 
7. Page 277. Under “Medication prior to enrolment”. Biological agents dosing 
stable for at least 8 weeks. This change was made when biological agents were 
no longer an exclusion. 
8. Page 292. Under “Medical history”. Exclusion criteria broadened in 2015 to 




9. Page 293. Under “Blood testing”. ANA and helicobacter serology added in 
2015. 
10. Page 293. Under “Stool testing”. Viral studies added in 2015. 
11. Page 297. Under “11. Analysis and Reporting of Results”. More detailed plan 
for bacterial and immunological analysis added. 
12. Page 300. Under “12.2 Clinical outcomes”. The statistical plan for clinical 
outcomes is expanded beyond using Fischer’s exact test alone to test the primary 
and secondary clinical endpoints. Factors affecting remission will be analysed 
using linear mixed effects regression. 
13. Page 301. Under “12.4 Inflammatory markers”. Statistical plan for analysis of 
inflammatory markers included with linear mixed effects regression. 
14. Page 301. Under “12.5-12.7 Microbiome”. Statistical plan for the analysis of 
diversity, abundance v total Mayo score and abundance v treatment added. 
15. Page 302. Under “12.8 Metabolome”. Statistical analysis of stool short-chain 
fatty acids and dietary fibre intake. Again, linear mixed effects regression 
analysis was proposed. 
16. Page 303. Under “12.9 Immune system”. Statistical analysis of immune cell 
populations was added. Again linear mixed effects regression analysis was 
proposed to compare immune populations to total Mayo score. 
